Antiviral compounds and methods of making and using same
By providing the compounds of formula I and their salts, the problem of difficulty in effectively treating or preventing viral infections such as Paramyxoviridae in the prior art is solved, and effective treatment and prevention of these viral infections are achieved.
Patent Information
- Application Number
- CN202380024316.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-03
- Filing Date
- 2023-03-01
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to effectively treat or prevent viral infections caused by Paramyxoviridae, Pneumoviridae, Pseudoviridae, Flaviviridae, Fibroviridae and Orthomyxoviridae.
A compound, a compound of formula I and a pharmaceutically acceptable salt thereof, is provided for the preparation of a drug for the treatment or prevention of these viral infections, including administering to a subject the compound or its salt to the treatment or prevention of viral infections. .
By direct administration, the compound or its salt can effectively treat or prevent the above-mentioned viral infections, providing a new pharmaceutical use to deal with diseases caused by these viruses.
Smart Images

Figure CN118900839A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 316,231, filed on March 3, 2022, which is incorporated herein in its entirety for all purposes.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which is submitted electronically in an .XML file format and is hereby incorporated by reference in its entirety. This .XML copy was created on February 9, 2023, is named 1429-WO-PCT.xml, and is 3,491 bytes in size. Background Art
[0005] There is a need for compounds, pharmaceutical compositions, and methods for treating viral infections, such as those of the Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, and Orthomyxovirus families. Embodiments of the present disclosure may address these and other needs. Summary of the Invention
[0006] Disclosed herein are, among other things, compounds of formula I:
[0007]
[0008] or a pharmaceutically acceptable salt thereof, wherein:
[0009] R 1 OH, OC(O)R 4 or OC(O)OR 4 ;
[0010] R 2 OH, OC(O)R 5 or OC(O)OR 5 ;or
[0011] R 1 and R 2 Combined to form -OC(O)O- or -OCHR 6 O-, where
[0012] R 6 is H, C1-C6 alkyl, C1-C6 alkoxy or C6-C 10 aryl;
[0013] R 3is H or C(O)OR 7 ,or
[0014] R 1 and R 3 together to form -OC(O)-;
[0015] R 4 、R 5 and R 7 Each is independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 carbocyclyl, C6-C 10 aryl, a 4- to 6-membered heterocyclyl containing 1, 2 or 3 O atoms, or a 5- to 6-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O and S;
[0016] where R 4 、R 5 and R 7 Each independently optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, -N3, -OR 8 、C1-C8 alkyl、-NR 9 R 10 , C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl; and
[0017] Each R 8 are independently H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; each R 9 are independently H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; each R 10 are independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl;
[0018] and
[0019] The base is in
[0020] R 11 Is -OP(O)(OH)2 or -OC(O)R 12 Substituted C1-C6 alkyl;
[0021] R 12 is C1-C8 alkyl or O-C1-C8 alkyl; and
[0022] R 13 Is -OP(O)(OH)2 or -OC(O)R 12 Substituted C1-C6 alkyl;
[0023] wherein the compound is not
[0024] Also disclosed herein are compounds of subformulae of Formula I, such as Formula II, and pharmaceutically acceptable salts thereof.
[0025] Disclosed herein are pharmaceutical compositions comprising a pharmaceutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
[0026] Also disclosed herein are methods of treating or preventing a viral infection in a subject in need thereof, wherein the method comprises administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt thereof.
[0027] The present disclosure also provides methods of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
[0028] The present disclosure provides a method for preparing a medicament for treating or preventing a viral infection in a subject in need thereof, characterized by using a compound disclosed herein or a pharmaceutically acceptable salt thereof.
[0029] The present disclosure provides a method for preparing a medicament for treating or preventing a viral infection in a human in need thereof, characterized by using a compound disclosed herein or a pharmaceutically acceptable salt thereof.
[0030] The present disclosure provides the use of a compound disclosed herein or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing a viral infection in a human in need thereof.
[0031] The present disclosure provides the use of a compound disclosed herein or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing a viral infection in a human in need thereof. DETAILED DESCRIPTION
[0032] I. Overview
[0033] The present disclosure generally relates to methods and compounds for treating or preventing viral infections, such as those caused by Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, and Orthomyxoviridae. The following description sets forth exemplary methods, parameters, and the like. However, it should be understood that such description is not intended to limit the scope of the present disclosure but is provided as a description of exemplary embodiments.
[0034] II. Definitions
[0035] As used in this specification, the following words, phrases, and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.
[0036] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment of a substituent. For example, -CONH2 is attached through a carbon atom. Dashes at the beginning or end of a chemical group are for convenience; a chemical group can be depicted without one or more dashes without losing its ordinary meaning. A wavy line drawn through a line in a structure indicates the point of attachment of a group. Unless required by chemistry or structure, directionality is not indicated or implied by the order in which chemical groups are written or named.
[0037] For example, the wavy lines on the chemical groups shown below The point of attachment is indicated, ie, it shows the broken bond through which the group is connected to another described group.
[0038] As used herein, "compounds of the present disclosure" may refer to compounds of any one of Formula I to Formula II or pharmaceutically acceptable salts thereof. Similarly, the phrase "compound of Formula (number)" means compounds of the formula and pharmaceutically acceptable salts thereof.
[0039] The prefix "C u- C v " indicates that the following group has u to v carbon atoms. For example, "C 1- "C8 alkyl" indicates that the alkyl group has 1 to 8 carbon atoms.
[0040] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. For example, an alkyl group can have 1 to 20 carbon atoms (i.e., C1-C 20Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH), ethyl (Et, -CHCH), 1-propyl (n-Pr, n-propyl, -CHCHCH), 2-propyl (i-Pr, isopropyl, -CH(CH)), 1-butyl (n-Bu, n-butyl, -CHCHCHCH), 2-methyl-1-propyl (i-Bu, isobutyl, -CHCH(CH)), 2-butyl (s-Bu, sec-butyl, -C H(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, tert-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1 -butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (- )2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), and 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3). Other alkyl groups include, but are not limited to, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, pentadecyl, hexadecyl, heptadecyl, and octadecyl.
[0041] "Alkenyl" refers to a straight or branched hydrocarbon chain containing at least two carbon atoms and at least one carbon-carbon double bond. As used herein, an alkenyl group can have from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl) or 2 to 4 carbon atoms (ie, C 2-4Alkenyl). Alkenyl may include any number of carbon atoms, such as C2, C3, C4, C5, C6, C7, C8, C9, C 10 、C 11 、C 12 、C 13 、C 14 、C 15 、C 16 、C 17 、C 18 、C 19 、C 20 Or any range therein. The alkenyl group may have any suitable number of double bonds, including but not limited to 1, 2, 3, 4, 5 or more. Examples of alkenyl groups include but are not limited to vinyl (vinyl / ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl or 1,3,5-hexatrienyl.
[0042] "Alkoxy" means an alkyl group having the formula -O-, wherein the alkyl group as defined above is attached to the parent molecule via an oxygen atom. The alkyl portion of the alkoxy group may have from 1 to 20 carbon atoms (i.e., C1-C 20 alkoxy), 1 to 12 carbon atoms (i.e., C1-C 12 Suitable alkoxy groups include, but are not limited to, methoxy (-O-CH or -OMe), ethoxy (-OCHCH or -OEt), isopropoxy (-O-CH(CH)), tert-butoxy (-OC(CH) or -OtBu), and the like. Other examples of suitable alkoxy groups include, but are not limited to, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.
[0043] "Alkynyl" refers to an unbranched or branched hydrocarbon chain containing at least one carbon-carbon triple bond. For example, an alkynyl group can have 2 to 20 carbon atoms (i.e., C 2-20 Alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 Alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl) or 2 to 4 carbon atoms (ie, C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond. 2-6Examples of alkynyl groups include, but are not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-4-ynyl, and pent-1,4-diynyl.
[0044] "Aryl" means an aromatic hydrocarbon radical derived by removing one hydrogen atom from a single carbon atom of a parent aromatic ring system. For example, an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms. Exemplary aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), naphthalene, anthracene, biphenyl, and the like.
[0045] "Carbocyclyl" or "carbocycle" refers to a non-aromatic hydrocarbon ring composed of carbon atoms and hydrogen atoms, having three to twenty carbon atoms, in certain embodiments three to fifteen carbon atoms, in certain embodiments three to ten carbon atoms, three to eight carbon atoms, three to seven carbon atoms, or 3 to 6 carbon atoms, and which is saturated or partially unsaturated and is attached to the rest of the molecule by a single bond. Carbocycles include, for example, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, and cyclooctane.
[0046] "Cycloalkyl" refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. As used herein, a cycloalkyl group has 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl) or 3 to 6 ring carbon atoms (i.e., C 3-6 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems having one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems.
[0047] "Cyano" or "carbonitrile" refers to the group CN.
[0048] As used herein, "halo" or "halogen" refers to fluorine (-F), chlorine (-Cl), bromine (-Br), and iodine (-I).
[0049] "Haloalkyl" is an alkyl group as defined above in which one or more of the hydrogen atoms of the alkyl group is replaced by a halogen atom. The alkyl portion of the haloalkyl group may have from 1 to 20 carbon atoms (i.e., C1-C 20 haloalkyl), 1 to 12 carbon atoms (i.e., C1-C 12Examples of suitable haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3, fluorochloromethyl, difluorochloromethyl, 1,1,1-trifluoroethyl, and pentafluoroethyl.
[0050] "Heteroaryl" refers to an aromatic group, including groups having aromatic tautomers or resonance structures, monocyclic, polycyclic or polycondensed rings, having at least one heteroatom in the ring, i.e., one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein the nitrogen or sulfur may be oxidized. Thus, the term includes rings having one or more cyclic O, N, S, S(O), S(O)2 and N-oxide groups. The term includes rings having one or more cyclic C(O) groups. As used herein, heteroaryl includes 5 to 20 ring atoms (i.e., 5 to 20 membered heteroaryl), 5 to 12 ring atoms (i.e., 5 to 12 membered heteroaryl) or 5 to 10 ring atoms (i.e., 5 to 10 membered heteroaryl) and 1 to 5 heteroatoms independently selected from nitrogen, oxygen and sulfur, as well as oxidized forms of heteroatoms. Examples of heteroaryl groups include, but are not limited to, pyridin-2(1H)-one, pyridazin-3(2H)-one, pyrimidin-4(3H)-one, quinolin-2(1H)-one, pyrimidinyl, purinyl, pyridinyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass or overlap with aryl as defined above.
[0051] "Heterocycle" or "heterocyclic radical" refers to a saturated or unsaturated cyclic alkyl, wherein one or more ring heteroatoms are independently selected from nitrogen, oxygen and sulphur.Heterocyclic radical can be a single ring or multiple rings, wherein the multiple rings can be fused, bridged or spiral.As used herein, heterocyclic radical has 3 to 20 ring atoms (i.e., 3 to 20 yuan of heterocyclic radicals), 3 to 12 ring atoms (i.e., 3 to 12 yuan of heterocyclic radicals), 3 to 10 ring atoms (i.e., 3 to 10 yuan of heterocyclic radicals), 3 to 8 ring atoms (i.e., 3 to 8 yuan of heterocyclic radicals), 4 to 12 ring carbon atoms (i.e., 4 to 12 yuan of heterocyclic radicals), 4 to 8 ring atoms (i.e., 4 to 8 yuan of heterocyclic radicals) or 4 to 6 ring atoms (i.e., 4 to 6 yuan of heterocyclic radicals).The example of heterocyclic radical includes pyrrolidinyl, piperidyl, piperazinyl, oxetanyl, dioxolane, azetidinyl and morpholinyl.
[0052] The term "optionally substituted" with respect to a particular moiety of the compounds disclosed herein (eg, an optionally substituted aryl group) refers to the moiety wherein all substituents are hydrogen or wherein one or more hydrogens of the moiety may be replaced with the listed substituents.
[0053] "Oxo" refers to the group (=O) or (O).
[0054] Also provided are pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. "Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, formulations, dosage forms, and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.
[0055] The compounds described herein can be prepared and / or formulated as pharmaceutically acceptable salts, or as free bases where appropriate. Pharmaceutically acceptable salts are non-toxic salts of the free base form of the compound that have the desired pharmacological activity of the free base. These salts can be derived from inorganic acids, organic acids, or bases. For example, compounds containing basic nitrogen can be prepared as pharmaceutically acceptable salts by contacting the compound with an inorganic or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, hexanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyrates, succinates, octanedioates ... Pharmaceutically acceptable salts include benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, methylsulfonate, propylsulfonate, benzenesulfonate, xylenesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, and mandelate. A list of other suitable pharmaceutically acceptable salts can be found in "Remington: The Science and Practice of Pharmacy," 21st edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.
[0056] Examples of "pharmaceutically acceptable salts" of the compounds disclosed herein also include those derived from suitable bases such as alkali metals (eg, sodium, potassium), alkaline earth metals (eg, magnesium), ammonium, and NX4. + (wherein X is C1-C4 alkyl). Also included are base addition salts such as sodium or potassium salts.
[0057] Also provided are compounds as described herein or pharmaceutically acceptable salts, isomers or mixtures thereof, wherein 1 to n hydrogen atoms attached to a carbon atom may be substituted by deuterium atoms or D, where n is the number of hydrogen atoms in the molecule. As known in the art, a deuterium atom is a non-radioactive isotope of a hydrogen atom. Such compounds can increase resistance to metabolism and are therefore useful for increasing the half-life of a compound as described herein or a pharmaceutically acceptable salt, isomer or mixture thereof when administered to a mammal. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., Vol. 5, No. 12, pp. 524-527, 1984. Such compounds are synthesized by methods well known in the art, for example, by using a starting material in which one or more hydrogen atoms have been replaced by deuterium. The compounds disclosed herein may be deuterated at various positions, including but not limited to the following positions:
[0058]
[0059] Examples of isotopes that may be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. Use of positron-emitting isotopes such as 11 C. 18 F. 15 O and 13 Substitution of N can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of Formula I to Formula II can generally be prepared by conventional techniques known to those skilled in the art, or by methods analogous to those described in the Examples listed below, using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed.
[0060] The compounds of the embodiments disclosed herein or their pharmaceutically acceptable salts may include one or more asymmetric centers and therefore may produce enantiomers, diastereomers, and other stereoisomeric forms that can be defined as (R)- or (S)- or as (D)- or (L)- for amino acids based on absolute stereochemistry. The disclosure is intended to include all such possible isomers and their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)- or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for preparing / separating individual enantiomers include chiral synthesis from suitable optically pure precursors or using, for example, chiral high pressure liquid chromatography (HPLC) to resolve racemates (or racemates of salts or derivatives). When the compounds described herein contain olefinic double bonds or other geometric asymmetric centers, and unless otherwise indicated, it is intended that the compounds include E and Z geometric isomers. Likewise, it is also intended to include all tautomeric forms. Where a compound is represented in its chiral form, it is understood that the embodiment encompasses, but is not limited to, the specific diastereoisomer or enantiomerically enriched form. Where chirality is not specified but present, it is understood that the embodiment relates to the specific diastereoisomer or enantiomerically enriched form; or a racemic or non-racemic mixture of such a compound. As used herein, a "non-racemic mixture" is a mixture of stereoisomers that is not in a 1:1 ratio.
[0061] The term "prevention" means any treatment of any disease or condition that results in the non-development of clinical symptoms of the disease or condition. The term "prevention" also encompasses the administration of a compound or composition according to the embodiments disclosed herein after a subject has been exposed to a virus but before symptoms of the disease appear and / or before the virus is detected in the blood, to prevent the onset of disease symptoms and / or to prevent the virus from reaching detectable levels in the blood, as well as the administration of a compound or composition according to the embodiments disclosed herein to prevent the perinatal transmission of viral infection from mother to infant by administration to the mother before delivery and to the child within a few days of birth.
[0062] "Racemate" refers to a mixture of enantiomers. The mixture may contain equal or unequal amounts of each enantiomer.
[0063] One or more "stereoisomers" refer to compounds with different chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers. If a compound has one or more asymmetric centers or a double bond with asymmetrical substitution, the compound can exist in stereoisomeric forms and can therefore be prepared as a single stereoisomer or as a mixture. Unless otherwise indicated, this specification is intended to include single stereoisomers and mixtures. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see, for example, Chapter 4 of Advanced Organic Chemistry, 4th edition, J. March, John Wiley and Sons, New York, 1992).
[0064] "Subject" or "patient" refers to a human or a vertebrate, including dogs, cats, marmosets, marmosets, horses, cows, pigs, sheep, goats, elephants, giraffes, chickens, lions, monkeys, owls, rats, squirrels, lorises, and mice. "Packed pets" refers to a group of vertebrates that can fit into a pocket, for example, hamsters, chinchillas, ferrets, rats, guinea pigs, gerbils, rabbits, and sugar gliders.
[0065] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Dashes at the beginning or end of a chemical group are for convenience; a chemical group can be depicted without one or more dashes without losing its ordinary meaning. A wavy line drawn through the line in the structure indicates the point of attachment of the group. A dotted line represents an optional bond. Unless chemically or structurally required, the order in which the chemical groups are written or the points at which they are attached to the rest of the molecule do not indicate or imply directionality. For example, the group "-SO2CH2-" is equivalent to "-CH2SO2-", and the two can be attached in either direction. Similarly, an "arylalkyl" group can be attached to the rest of the molecule, for example, at the aryl or alkyl portion of the group. Prefixes such as "C u- C v ” or “(C u -C v )" means that the group following it has u to v carbon atoms. For example, "C 1-6 "C1-C6 alkyl" and "C1-C6 alkyl" both mean an alkyl group having 1 to 6 carbon atoms.
[0066] Unless otherwise indicated, the carbon atoms of the compounds of Formula I to Formula II are intended to have a valence of four. If, in some chemical structure representations, a carbon atom is not attached to a sufficient number of variables to produce a valence of four, the remaining carbon substituents required to provide the four valences are assumed to be hydrogen.
[0067] The term "treating" as used herein is intended to mean administering a compound or composition according to the embodiments disclosed herein to alleviate or eliminate symptoms of a viral infection and / or reduce viral load in a subject.
[0068] As used herein, the term "therapeutically effective amount" is the amount of a compound disclosed herein present in a formulation described herein that is required to provide the desired level of drug in the secretions and tissues of the airways and lungs, or alternatively, when such a formulation is administered by a selected route of administration, to produce the desired physiological response or desired biological effect in the bloodstream of the subject to be treated. The exact amount will depend on many factors, such as the specific compound disclosed herein, the specific activity of the formulation, the delivery device employed, the physical properties of the formulation and its intended use, as well as considerations of the subject such as the severity of the disease, the subject's cooperation, etc., and the exact amount can be readily determined by one skilled in the art based on the information provided herein. The term "therapeutically effective amount" or "effective amount" also refers to an amount that eliminates or reduces the viral load and / or viral reservoir of a subject.
[0069] As used herein, the term "adjacent carbons" refers to consecutive carbon atoms that are directly connected to each other. For example, in In , C1 and C2 are adjacent carbons, C2 and C3 are adjacent carbons, C3 and C4 are adjacent carbons, and C4 and C5 are adjacent carbons. Similarly, in , C1 and C2 are adjacent carbons, C2 and C3 are adjacent carbons, C3 and C4 are adjacent carbons, and C4 and C5 are adjacent carbons, C5 and C6 are adjacent carbons, and C6 and C1 are adjacent carbons.
[0070] As used herein, "solvate" refers to the result of the interaction of a solvent and a compound. Also provided are solvates of the salts of the compounds described herein. Also provided are hydrates of the compounds described herein.
[0071] As used herein, a "prodrug" is a derivative of a drug that is converted to the parent drug according to some chemical or enzymatic pathway when administered to the human body.
[0072] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and combinations thereof. The use of pharmaceutically acceptable carriers and pharmaceutically acceptable excipients for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, their use in therapeutic formulations is contemplated. Supplementary active ingredients may also be incorporated into the formulation. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not physiologically deleterious to the recipient thereof.
[0073] III. Compounds
[0074] Disclosed herein are, among other things, compounds of formula I:
[0075]
[0076] or a pharmaceutically acceptable salt thereof, wherein:
[0077] R 1 OH, OC(O)R 4 or OC(O)OR 4 ,and
[0078] R 2 OH, OC(O)R 5 or OC(O)OR 5 ;or
[0079] R 1 and R 2 Combined to form -OC(O)O- or -OCHR 6 O-, where
[0080] R 6 is H, C1-C6 alkyl, C1-C6 alkoxy or C6-C 10 aryl;
[0081] R 3 is H or C(O)OR 7 ,or
[0082] R 1 and R 3 together to form -OC(O)-;
[0083] R 4 、R 5 and R 7 Each is independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 carbocyclyl, C6-C 10 aryl, a 4- to 6-membered heterocyclyl containing 1, 2 or 3 O atoms, or a 5- to 6-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O and S;
[0084] where R 4 、R 5 and R 7 Each independently optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, -N3, -OR 8 、C1-C8 alkyl、-NR 9 R 10, C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl; and
[0085] Each R 8 are independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl;
[0086] Each R 9 are independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl;
[0087] Each R 10 are independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl;
[0088] and
[0089] The base is in
[0090] R 11 Is -OP(O)(OH)2 or -OC(O)R 12 Substituted C1-C6 alkyl;
[0091] R 12 is C1-C8 alkyl or C1-C8 alkoxy; and
[0092] R 13 Is -OP(O)(OH)2 or -OC(O)R 12 Substituted C1-C6 alkyl;
[0093] wherein the compound is not
[0094] In some embodiments, the compound of Formula I has Formula II:
[0095]
[0096]
[0097] R 1 Can be OH, OC(O)R 4 or OC(O)OR 4 In some embodiments, R 1 In some embodiments, R 1 It is OC(O)R 4 In some embodiments, R 1 It is OC(O)OR 4 .
[0098] R 2Can be OH, OC(O)R 5 or OC(O)OR 5 In some embodiments, R 2 In some embodiments, R 2 It is OC(O)R 5 In some embodiments, R 2 It is OC(O)OR 5 .
[0099] In some embodiments, R 1 is OH and R 2 In some embodiments, R 1 and R 2 together to form -OC(O)O-.
[0100] In some embodiments, R 1 and R 2 are combined to form -OCH2O-. In some embodiments, R 1 and R 2 Put together to form -OCHR 6 O-.
[0101] R 3 Can be H or C(O)OR 7 In some embodiments, R 3 is H. In some embodiments, R 3 It is C(O)OR 7 In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from
[0102] In some embodiments, R 3 Selected from In some embodiments, R 3 Selected from
[0103] In some embodiments, R 1 and R 3 together to form -OC(O)-.
[0104] R 4 It can be C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 carbocyclic, C6-C 10 aryl, 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms, or 5- to 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O and S; wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups may be optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, -N3, -OR 8 、C1-C8 alkyl、-NR 9 R 10 , C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl; and R 8 It can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; R 9 can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; and R 10 It can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.
[0105] In some embodiments, R 4It is C1-C6 (for example C1, C2, C3, C4, C5 or C6) alkyl.In some embodiments, C1-C6 alkyl is methyl, ethyl,-n-propyl, isopropyl,-n-butyl, isobutyl,-sec-butyl,-tert-butyl,-n-pentyl,-2-pentyl,-3-pentyl,-2-methyl-2-butyl,-3-methyl-2-butyl,-3-methyl-1-butyl,-2-methyl-1-butyl,-1-hexyl,-2-hexyl,-3-hexyl,-2-methyl-2-pentyl,-3-methyl-2-pentyl,-4-methyl-2-pentyl,-3-methyl-3-pentyl,-2-methyl-3-pentyl,-2,3-dimethyl-2-butyl or-3,3-dimethyl-2-butyl.In some embodiments, C1-C6 alkyl is C1-C3 alkyl. In some embodiments, C1-C6 alkyl is C2-C5 alkyl. In some embodiments, C1-C6 alkyl is C4-C6 alkyl. In some embodiments, C1-C6 alkyl is branched C1-C6 alkyl. In some embodiments, C1-C6 alkyl is unbranched C1-C6 alkyl. In some embodiments, C1-C6 alkyl is unsubstituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is substituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is branched unsubstituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is branched substituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is unbranched unsubstituted C1-C6 alkyl. In some embodiments, R 4 is a C3-C5 alkyl group. In some embodiments, R 4 It is tert-butyl or isobutyl.
[0106] In some embodiments, R 4 is a C2-C8 (e.g., C2, C3, C4, C5, C6, C7, or C8) alkenyl group. In some embodiments, the C2-C8 alkenyl group has at least one (e.g., at least 2, at least 3, at least 3, at least 4, or at least 5) double bond. In some embodiments, the C2-C8 alkenyl group is an unsubstituted C2-C8 alkenyl group. In some embodiments, the C2-C8 alkenyl group is a substituted C2-C8 alkenyl group. Examples of the C2-C8 alkenyl group include, but are not limited to, vinyl (vinyl / ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. In some embodiments, R 4 is an unsubstituted C2-C8 alkenyl.4 It is a substituted C2-C8 alkenyl group.
[0107] In some embodiments, R 4 It is a C2-C8 (e.g., C2, C3, C4, C5, C6, C7, or C8) alkynyl group. In some embodiments, the C2-C8 alkynyl group has at least one triple bond. In some embodiments, the C2-C8 alkynyl group has at least one triple bond and at least one double bond. Exemplary C2-C8 alkynyl groups include, but are not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-4-ynyl, and pent-1,4-diynyl. In some embodiments, the C2-C8 alkynyl group is an unsubstituted C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is a substituted C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is a branched C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is an unbranched C2-C8 alkynyl group.
[0108] In some embodiments, R 4 It is C3-C8 (for example C3, C4, C5, C6, C7 or C8) carbocyclyl. In some embodiments, C3-C8 carbocyclyl is saturated. In some embodiments, C3-C8 carbocyclyl is partially unsaturated. Exemplary C3-C8 carbocycles include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene and cyclooctane. In some embodiments, C3-C8 carbocyclyl is unsubstituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is substituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is unbranched C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is branched C3-C8 carbocyclyl.
[0109] In some embodiments, R 4 It is C6-C 10 In some embodiments, C6-C 10 Aryl is C6 aryl (e.g. phenyl) or C 10 Aryl (e.g., naphthyl). In some embodiments, C6-C 10 Aryl is an unsubstituted C6-C 10 In some embodiments, C6-C 10 Aryl is a substituted C6-C 10 In some embodiments, C6-C 10 Aryl is phenyl. In some embodiments, C6-C 10 Aryl is naphthyl.
[0110] In some embodiments, R4 is a 4- to 6-membered (e.g., 4, 5, 6)-membered heterocyclyl containing one, two, or three O's. In some embodiments, a 4- to 6-membered heterocyclyl is a 4-membered heterocyclyl containing one heteroatom selected from O's. In some embodiments, a 4- to 6-membered heterocyclyl is a 4-membered heterocyclyl containing two O's. In some embodiments, a 4- to 6-membered heterocyclyl is a 4-membered heterocyclyl containing three O's. In some embodiments, a 4- to 6-membered heterocyclyl is a 5-membered heterocyclyl containing one O's. In some embodiments, a 4- to 6-membered heterocyclyl is a 5-membered heterocyclyl containing two O's. In some embodiments, R 4 In some embodiments, the 4- to 6-membered heterocyclyl is a 6-membered heterocyclyl containing three O's. In some embodiments, the 4- to 6-membered heterocyclyl is a 6-membered heterocyclyl containing one m O's. In some embodiments, the 4- to 6-membered heterocyclyl is a 6-membered heterocyclyl containing two O's. In some embodiments, the 4- to 6-membered heterocyclyl is a 6-membered heterocyclyl containing three O's. In some embodiments, the 4- to 6-membered heterocyclyl is an unsubstituted 4- to 6-membered heterocyclyl. In some embodiments, the 4- to 6-membered heterocyclyl is a substituted 4- to 6-membered heterocyclyl.
[0111] In some embodiments, R 4 is a 5- to 6-membered heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing one heteroatom selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing two heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing three heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing one heteroatom selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing two heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing three heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a pyridyl group. In some embodiments, the 5- to 6-membered heteroaryl group is a pyrimidinyl group. In some embodiments, the 5- to 6-membered heteroaryl is an unsubstituted 5- to 6-membered heteroaryl. In some embodiments, the 5- to 6-membered heteroaryl is a substituted 5- to 6-membered heteroaryl.
[0112] In some embodiments, R 4 is unsubstituted. In some embodiments, R 4 In some embodiments, R 4 is substituted with two substituents. In some embodiments, R 4 In some embodiments, R 4 is substituted with one, two or three substituents, wherein at least one substituent is a halo group.4 is substituted with one, two or three substituents, at least one of which is oxo. 4 is substituted with one, two or three substituents, at least one of which is cyano. 4 is substituted with one, two or three substituents, wherein at least one substituent is N3. In some embodiments, R 4 Substituted with one, two or three substituents, at least one of which is OR 8 .
[0113] In some embodiments, R 4 Substituted with one, two or three substituents, at least one of which is C1-C8 (e.g., C1, C2, C3, C4, C5, C6, C7 or C8) alkyl. In some embodiments, C1-C8 alkyl is methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl or -3,3-dimethyl-2-butyl. In some embodiments, the C1-C8 alkyl group is a C1-C6 alkyl group. In some embodiments, the C1-C8 alkyl group is a C1-C3 alkyl group. In some embodiments, the C1-C8 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C8 alkyl group is a C4-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched unsubstituted C1-C8 alkyl group.
[0114] In some embodiments, R 4 Substituted with one, two or three substituents, at least one of which is NR 9 R 10 In some embodiments, R 4 Substituted with one, two or three substituents, at least one of which is NH2.
[0115] In some embodiments, R 4Substituted by one, two or three substituents, wherein at least one substituent is C3-C8 (e.g., C3, C4, C5, C6, C7 or C8) carbocyclyl. In some embodiments, C3-C8 carbocyclyl is saturated. In some embodiments, C3-C8 carbocyclyl is partially unsaturated. Exemplary C3-C8 carbocycles include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene and cyclooctane. In some embodiments, C3-C8 carbocyclyl is unsubstituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is substituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is unbranched C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is branched C3-C8 carbocyclyl.
[0116] In some embodiments, R 4 is substituted with one, two or three substituents, wherein at least one substituent is phenyl. 4 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 4 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents, wherein at least one substituent is a halo group (e.g., fluoro, chloro, iodo, bromo). In some embodiments, R 4 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents, wherein at least one substituent is cyano. In some embodiments, R 4 is substituted with at least one halo and at least one oxo. 4 is substituted with at least one halo and at least one cyano. 4 is substituted with at least one halo and at least one N3. 4 At least one halo group and at least one OR 8 In some embodiments, R 4 At least one halo group and at least one NR 9 R 10 In some embodiments, R 4 is substituted with at least one halo group and at least one C3-C8 carbocyclyl group. 4 is substituted with at least one halo group and at least one unsubstituted phenyl group. 4is substituted with at least one halo group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo groups, cyano groups and C1-C6 alkyl groups. 4 is substituted with at least one oxo and at least one cyano. 4 is substituted with at least one oxo and at least one N3. 4 by at least one oxo group and at least one OR 8 In some embodiments, R 4 is substituted with at least one oxo and at least one C1-C8 alkyl. 4 At least one oxo group and at least one NR 9 R 10 In some embodiments, R 4 is substituted with at least one oxo and at least one C3-C8 carbocyclyl. 4 is substituted with at least one oxo and at least one unsubstituted phenyl. 4 is substituted with at least one oxo group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 4 is substituted with at least one cyano group and at least one N3. In some embodiments, R 4 By at least one N3 and at least one OR 8 In some embodiments, R 4 is substituted with at least one cyano group and at least one C1-C8 alkyl group. 4 by at least one cyano group and at least one NR 9 R 10 In some embodiments, R 4 is substituted with at least one cyano group and at least one C3-C8 carbocyclyl group. 4 is substituted with at least one cyano group and at least one unsubstituted phenyl group. 4 is substituted with at least one cyano group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 4 By at least one N3 and at least one OR 8 In some embodiments, R 4 is substituted with at least one N3 and at least one C1-C8 alkyl. 4 By at least one N3 and at least one NR9 R 10 In some embodiments, R 4 is substituted with at least one N3 and at least one C3-C8 carbocyclyl. 4 is substituted with at least one N3 and at least one unsubstituted phenyl. 4 is substituted with at least one N3 and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 4 By at least one OR 8 and at least one C1-C8 alkyl group. 4 By at least one OR 8 and at least one NR 9 R 10 In some embodiments, R 4 By at least one OR 8 and at least one C3-C8 carbocyclyl. In some embodiments, R 4 By at least one OR 8 and at least one unsubstituted phenyl. In some embodiments, R 4 By at least one OR 8 and at least one phenyl group substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 4 At least one C1-C8 alkyl group and at least one NR 9 R 10 In some embodiments, R 4 is substituted with at least one C1-C8 alkyl group and at least one C3-C8 carbocyclyl group. 4 is substituted with at least one C1-C8 alkyl group and at least one unsubstituted phenyl group. 4 is substituted with at least one C1-C8 alkyl group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 4 is substituted with at least one C3-C8 carbocyclyl and at least one unsubstituted phenyl. 4 is substituted by at least one C3-C8 carbocyclyl and at least one phenyl group, wherein the at least one phenyl group is substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl.
[0117] R 5It can be C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 carbocyclic, C6-C 10 aryl, 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms, or 5- to 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O and S; wherein R 5 may be optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, -N3, -OR 8 、C1-C8 alkyl、-NR 9 R 10 , C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl; and R 8 It can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; R 9 can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; and R 10 It can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.
[0118] In some embodiments, R 5 It is C1-C6 (for example C1, C2, C3, C4, C5 or C6) alkyl.In some embodiments, C1-C6 alkyl is methyl, ethyl,-n-propyl, isopropyl,-n-butyl, isobutyl,-sec-butyl,-tert-butyl,-n-pentyl,-2-pentyl,-3-pentyl,-2-methyl-2-butyl,-3-methyl-2-butyl,-3-methyl-1-butyl,-2-methyl-1-butyl,-1-hexyl,-2-hexyl,-3-hexyl,-2-methyl-2-pentyl,-3-methyl-2-pentyl,-4-methyl-2-pentyl,-3-methyl-3-pentyl,-2-methyl-3-pentyl,-2,3-dimethyl-2-butyl or-3,3-dimethyl-2-butyl.In some embodiments, C1-C6 alkyl is C1-C3 alkyl. In some embodiments, the C1-C6 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C6 alkyl group is a C4-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unsubstituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched unsubstituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched unsubstituted C1-C6 alkyl group.
[0119] In some embodiments, R 5 is a C2-C8 (e.g., C2, C3, C4, C5, C6, C7, or C8) alkenyl group. In some embodiments, the C2-C8 alkenyl group has at least one (e.g., at least 2, at least 3, at least 3, at least 4, or at least 5) double bond. In some embodiments, the C2-C8 alkenyl group is an unsubstituted C2-C8 alkenyl group. In some embodiments, the C2-C8 alkenyl group is a substituted C2-C8 alkenyl group. Examples of the C2-C8 alkenyl group include, but are not limited to, vinyl (vinyl / ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. In some embodiments, R 5 is an unsubstituted C2-C8 alkenyl. 5 It is a substituted C2-C8 alkenyl group.
[0120] In some embodiments, R 5 It is a C2-C8 (e.g., C2, C3, C4, C5, C6, C7, or C8) alkynyl group. In some embodiments, the C2-C8 alkynyl group has at least one triple bond. In some embodiments, the C2-C8 alkynyl group has at least one triple bond and at least one double bond. Exemplary C2-C8 alkynyl groups include, but are not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-4-ynyl, and pent-1,4-diynyl. In some embodiments, the C2-C8 alkynyl group is an unsubstituted C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is a substituted C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is a branched C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is an unbranched C2-C8 alkynyl group.
[0121] In some embodiments, R 5It is C3-C8 (for example C3, C4, C5, C6, C7 or C8) carbocyclyl. In some embodiments, C3-C8 carbocyclyl is saturated. In some embodiments, C3-C8 carbocyclyl is partially unsaturated. Exemplary C3-C8 carbocycles include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene and cyclooctane. In some embodiments, C3-C8 carbocyclyl is unsubstituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is substituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is unbranched C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is branched C3-C8 carbocyclyl.
[0122] In some embodiments, R 5 It is C6-C 10 In some embodiments, C6-C 10 Aryl is C6 aryl (e.g. phenyl) or C 10 Aryl (e.g., naphthyl). In some embodiments, C6-C 10 Aryl is an unsubstituted C6-C 10 In some embodiments, C6-C 10 Aryl is a substituted C6-C 10 In some embodiments, C6-C 10 Aryl is phenyl. In some embodiments, C6-C 10 Aryl is naphthyl.
[0123] In some embodiments, R 5 is a 4- to 6-membered (e.g., 4, 5, or 6-membered) heterocyclyl group containing one, two, or three O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 4-membered heterocyclyl group containing one heteroatom selected from O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 4-membered heterocyclyl group containing two O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 4-membered heterocyclyl group containing three O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 5-membered heterocyclyl group containing one O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 5-membered heterocyclyl group containing two O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 5-membered heterocyclyl group containing three O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 6-membered heterocyclyl group containing one O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 6-membered heterocyclyl group containing two O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 6-membered heterocyclyl group containing three O atoms. In some embodiments, the 4- to 6-membered heterocyclyl is an unsubstituted 4- to 6-membered heterocyclyl. In some embodiments, the 4- to 6-membered heterocyclyl is a substituted 4- to 6-membered heterocyclyl.
[0124] In some embodiments, R 5 is a 5- to 6-membered heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing one heteroatom selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing two heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing three heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing one heteroatom selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing two heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing three heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a pyridyl group. In some embodiments, the 5- to 6-membered heteroaryl group is a pyrimidinyl group. In some embodiments, the 5- to 6-membered heteroaryl is an unsubstituted 5- to 6-membered heteroaryl. In some embodiments, the 5- to 6-membered heteroaryl is a substituted 5- to 6-membered heteroaryl.
[0125] In some embodiments, R 5 is unsubstituted. In some embodiments, R 5 In some embodiments, R 5 is substituted with two substituents. In some embodiments, R 5 In some embodiments, R 5 is substituted with one, two or three substituents, wherein at least one substituent is a halo group. 5 is substituted with one, two or three substituents, at least one of which is oxo. 5 is substituted with one, two or three substituents, at least one of which is cyano. 5 is substituted with one, two or three substituents, wherein at least one substituent is N3. In some embodiments, R 5 Substituted with one, two or three substituents, at least one of which is OR 8 .
[0126] In some embodiments, R 5Substituted with one, two or three substituents, at least one of which is C1-C8 (e.g., C1, C2, C3, C4, C5, C6, C7 or C8) alkyl. In some embodiments, C1-C8 alkyl is methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl or -3,3-dimethyl-2-butyl. In some embodiments, the C1-C8 alkyl group is a C1-C6 alkyl group. In some embodiments, the C1-C8 alkyl group is a C1-C3 alkyl group. In some embodiments, the C1-C8 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C8 alkyl group is a C4-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched unsubstituted C1-C8 alkyl group.
[0127] In some embodiments, R 5 Substituted with one, two or three substituents, at least one of which is NR 9 R 10 In some embodiments, R 5 Substituted with one, two or three substituents, at least one of which is NH2.
[0128] In some embodiments, R 5Substituted by one, two or three substituents, wherein at least one substituent is C3-C8 (e.g., C3, C4, C5, C6, C7 or C8) carbocyclyl. In some embodiments, C3-C8 carbocyclyl is saturated. In some embodiments, C3-C8 carbocyclyl is partially unsaturated. Exemplary C3-C8 carbocycles include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene and cyclooctane. In some embodiments, C3-C8 carbocyclyl is unsubstituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is substituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is unbranched C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is branched C3-C8 carbocyclyl.
[0129] In some embodiments, R 5 is substituted with one, two or three substituents, wherein at least one substituent is phenyl. 5 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 5 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents, wherein at least one substituent is a halo group (e.g., fluoro, chloro, iodo, bromo). In some embodiments, R 5 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents, wherein at least one substituent is cyano. In some embodiments, R 5 is substituted with at least one halo and at least one oxo. 5 is substituted with at least one halo and at least one cyano. 5 is substituted with at least one halo and at least one N3. 5 At least one halo group and at least one OR 8 In some embodiments, R 5 At least one halo group and at least one NR 9 R 10 In some embodiments, R 5 is substituted with at least one halo group and at least one C3-C8 carbocyclyl group. 5 is substituted with at least one halo group and at least one unsubstituted phenyl group. 5is substituted with at least one halo group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo groups, cyano groups and C1-C6 alkyl groups. 5 is substituted with at least one oxo and at least one cyano. 5 is substituted with at least one oxo and at least one N3. 5 by at least one oxo group and at least one OR 8 In some embodiments, R 5 is substituted with at least one oxo and at least one C1-C8 alkyl. 5 At least one oxo group and at least one NR 9 R 10 In some embodiments, R 5 is substituted with at least one oxo and at least one C3-C8 carbocyclyl. 5 is substituted with at least one oxo and at least one unsubstituted phenyl. 5 is substituted with at least one oxo group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 5 is substituted with at least one cyano group and at least one N3. In some embodiments, R 5 By at least one N3 and at least one OR 8 In some embodiments, R 5 is substituted with at least one cyano group and at least one C1-C8 alkyl group. 5 by at least one cyano group and at least one NR 9 R 10 In some embodiments, R 5 is substituted with at least one cyano group and at least one C3-C8 carbocyclyl group. 5 is substituted with at least one cyano group and at least one unsubstituted phenyl group. 5 is substituted with at least one cyano group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 5 By at least one N3 and at least one OR 8 In some embodiments, R 5 is substituted with at least one N3 and at least one C1-C8 alkyl. 5 By at least one N3 and at least one NR9 R 10 In some embodiments, R 5 is substituted with at least one N3 and at least one C3-C8 carbocyclyl. 5 is substituted with at least one N3 and at least one unsubstituted phenyl. 5 is substituted with at least one N3 and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 5 By at least one OR 8 and at least one C1-C8 alkyl group. 5 By at least one OR 8 and at least one NR 9 R 10 In some embodiments, R 5 By at least one OR 8 and at least one C3-C8 carbocyclyl. In some embodiments, R 5 By at least one OR 8 and at least one unsubstituted phenyl. In some embodiments, R 5 By at least one OR 8 and at least one phenyl group substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 5 At least one C1-C8 alkyl group and at least one NR 9 R 10 In some embodiments, R 5 is substituted with at least one C1-C8 alkyl group and at least one C3-C8 carbocyclyl group. 5 is substituted with at least one C1-C8 alkyl group and at least one unsubstituted phenyl group. 5 is substituted with at least one C1-C8 alkyl group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 5 is substituted with at least one C3-C8 carbocyclyl and at least one unsubstituted phenyl. 5 is substituted by at least one C3-C8 carbocyclyl and at least one phenyl group, wherein the at least one phenyl group is substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl.
[0130] R 6It can be C1-C6 alkyl, C1-C6 alkoxy or C6-C 10 In some embodiments, R 6 It is C1-C6 (for example C1, C2, C3, C4, C5 or C6) alkyl.In some embodiments, C1-C6 alkyl is methyl, ethyl,-n-propyl, isopropyl,-n-butyl, isobutyl,-sec-butyl,-tert-butyl,-n-pentyl,-2-pentyl,-3-pentyl,-2-methyl-2-butyl,-3-methyl-2-butyl,-3-methyl-1-butyl,-2-methyl-1-butyl,-1-hexyl,-2-hexyl,-3-hexyl,-2-methyl-2-pentyl,-3-methyl-2-pentyl,-4-methyl-2-pentyl,-3-methyl-3-pentyl,-2-methyl-3-pentyl,-2,3-dimethyl-2-butyl or-3,3-dimethyl-2-butyl.In some embodiments, C1-C6 alkyl is C1-C3 alkyl. In some embodiments, the C1-C6 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C6 alkyl group is a C4-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unsubstituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched unsubstituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched unsubstituted C1-C6 alkyl group.
[0131] In some embodiments, R 6 The alkyl group of the alkoxy group may have 1, 2, 3, 4, 5 or 6 carbon atoms (i.e., C1-C6 alkoxy) or 1, 2 or 3 carbon atoms (i.e., C1-C3 alkoxy). Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), isopropoxy (-O-CH(CH3)2), tert-butoxy (-OC(CH3)3 or -OtBu), and the like. Other examples of suitable alkoxy groups include, but are not limited to, sec-butoxy, tert-butoxy, pentyloxy, and hexyloxy.
[0132] In some embodiments, R 6 It is C6-C 10 Aryl (e.g., C6-C7 aryl, C6-C8 aryl, C6-C9 aryl, C7-C8 aryl, C7-C9 aryl, C7-C 10 Aryl, C8-C9 aryl, C8-C 10 Aryl or C9-C 10 In some embodiments, C6-C10 Aryl is C6 aryl (e.g. phenyl), C7 aryl, C8 aryl, C9 aryl or C 10 Aryl (e.g., naphthyl). In some embodiments, C6-C 10 Aryl is an unsubstituted C6-C 10 In some embodiments, C6-C 10 Aryl is phenyl. In some embodiments, C6-C 10 Aryl is naphthyl.
[0133] R 7 It can be C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 carbocyclic, C6-C 10 aryl, 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms, or 5- to 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O and S; wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups may be optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, -N3, -OR 8 、C1-C8 alkyl、-NR 9 R 10 , C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl; and R 8 It can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; R 9 can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; and R 10 It can be H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.
[0134] In some embodiments, R 7It is C1-C6 (for example C1, C2, C3, C4, C5 or C6) alkyl.In some embodiments, C1-C6 alkyl is methyl, ethyl,-n-propyl, isopropyl,-n-butyl, isobutyl,-sec-butyl,-tert-butyl,-n-pentyl,-2-pentyl,-3-pentyl,-2-methyl-2-butyl,-3-methyl-2-butyl,-3-methyl-1-butyl,-2-methyl-1-butyl,-1-hexyl,-2-hexyl,-3-hexyl,-2-methyl-2-pentyl,-3-methyl-2-pentyl,-4-methyl-2-pentyl,-3-methyl-3-pentyl,-2-methyl-3-pentyl,-2,3-dimethyl-2-butyl or-3,3-dimethyl-2-butyl.In some embodiments, C1-C6 alkyl is C1-C3 alkyl. In some embodiments, C1-C6 alkyl is C2-C5 alkyl. In some embodiments, C1-C6 alkyl is C4-C6 alkyl. In some embodiments, C1-C6 alkyl is branched C1-C6 alkyl. In some embodiments, C1-C6 alkyl is unbranched C1-C6 alkyl. In some embodiments, C1-C6 alkyl is unsubstituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is substituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is branched unsubstituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is branched substituted C1-C6 alkyl. In some embodiments, C1-C6 alkyl is unbranched unsubstituted C1-C6 alkyl. In some embodiments, R 7 is a C1-C6 alkyl group optionally substituted by one, two or three substituents independently selected from halo, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. In some embodiments, R 7 is optionally substituted by one, two or three independently selected from halo, OR 8 , C3-C8 carbocyclic group and phenyl substituted C1-C6 alkyl, wherein R 8 is C1-C6 alkyl. In some embodiments, R 7 is C1-C6 alkyl substituted with one, two or three F. In some embodiments, R 7 is a C1-C6 alkyl group substituted with a C3-C8 carbocyclyl group. 7 It is a C1-C6 alkyl group substituted by a phenyl group.
[0135] In some embodiments, R 7is a C2-C8 (e.g., C2, C3, C4, C5, C6, C7, or C8) alkenyl group. In some embodiments, the C2-C8 alkenyl group has at least one (e.g., at least 2, at least 3, at least 3, at least 4, or at least 5) double bond. In some embodiments, the C2-C8 alkenyl group is an unsubstituted C2-C8 alkenyl group. In some embodiments, the C2-C8 alkenyl group is a substituted C2-C8 alkenyl group. Examples of the C2-C8 alkenyl group include, but are not limited to, vinyl (vinyl / ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. In some embodiments, R 7 is an unsubstituted C2-C8 alkenyl. 7 It is a substituted C2-C8 alkenyl group.
[0136] In some embodiments, R 7 It is a C2-C8 (e.g., C2, C3, C4, C5, C6, C7, or C8) alkynyl group. In some embodiments, the C2-C8 alkynyl group has at least one triple bond. In some embodiments, the C2-C8 alkynyl group has at least one triple bond and at least one double bond. Exemplary C2-C8 alkynyl groups include, but are not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-4-ynyl, and pent-1,4-diynyl. In some embodiments, the C2-C8 alkynyl group is an unsubstituted C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is a substituted C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is a branched C2-C8 alkynyl group. In some embodiments, the C2-C8 alkynyl group is an unbranched C2-C8 alkynyl group.
[0137] In some embodiments, R 7Is C3-C8 (e.g., C3, C4, C5, C6, C7, or C8) carbocyclyl. In some embodiments, C3-C8 carbocyclyl is saturated. In some embodiments, C3-C8 carbocyclyl is partially unsaturated. Exemplary C3-C8 carbocycles include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene, and cyclooctane. In some embodiments, C3-C8 carbocyclyl is unsubstituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is substituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is unbranched C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is branched C3-C8 carbocyclyl. In some embodiments, R 7 is a C3-C8 carbocyclyl group optionally substituted by one, two or three substituents independently selected from halo and C1-C6 alkyl.
[0138] In some embodiments, R 7 It is C6-C 10 In some embodiments, C6-C 10 Aryl is C6 aryl (e.g. phenyl) or C 10 Aryl (e.g., naphthyl). In some embodiments, C6-C 10 Aryl is an unsubstituted C6-C 10 In some embodiments, C6-C 10 Aryl is a substituted C6-C 10 In some embodiments, C6-C 10 Aryl is phenyl. In some embodiments, C6-C 10 Aryl is naphthyl.
[0139] In some embodiments, R 7is a 4- to 6-membered (e.g., 4, 5, or 6-membered) heterocyclyl group containing one, two, or three O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 4-membered heterocyclyl group containing one O atom. In some embodiments, a 4- to 6-membered heterocyclyl group is a 4-membered heterocyclyl group containing two O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 4-membered heterocyclyl group containing three O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 5-membered heterocyclyl group containing one O atom. In some embodiments, a 4- to 6-membered heterocyclyl group is a 5-membered heterocyclyl group containing two O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 5-membered heterocyclyl group containing three O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 6-membered heterocyclyl group containing one heteroatom selected from O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 6-membered heterocyclyl group containing two O atoms. In some embodiments, a 4- to 6-membered heterocyclyl group is a 6-membered heterocyclyl group containing three O atoms. In some embodiments, the 4- to 6-membered heterocyclyl is an unsubstituted 4- to 6-membered heterocyclyl. In some embodiments, the 4- to 6-membered heterocyclyl is a substituted 4- to 6-membered heterocyclyl.
[0140] In some embodiments, R 7 is a 5- to 6-membered heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing one heteroatom selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing two heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 5-membered heteroaryl group containing three heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing one heteroatom selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing two heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a 6-membered heteroaryl group containing three heteroatoms selected from N, O, and S. In some embodiments, the 5- to 6-membered heteroaryl group is a pyridyl group. In some embodiments, the 5- to 6-membered heteroaryl group is a pyrimidinyl group. In some embodiments, the 5- to 6-membered heteroaryl is an unsubstituted 5- to 6-membered heteroaryl. In some embodiments, the 5- to 6-membered heteroaryl is a substituted 5- to 6-membered heteroaryl.
[0141] In some embodiments, R 7 is unsubstituted. In some embodiments, R 7 In some embodiments, R 7 is substituted with two substituents. In some embodiments, R 7 In some embodiments, R 7 is substituted with one, two or three substituents, wherein at least one substituent is a halo group. 7is substituted with one, two or three substituents, at least one of which is oxo. 7 is substituted with one, two or three substituents, at least one of which is cyano. 7 is substituted with one, two or three substituents, wherein at least one substituent is N3. In some embodiments, R 7 Substituted with one, two or three substituents, at least one of which is OR 8 .
[0142] In some embodiments, R 7 Substituted with one, two or three substituents, at least one of which is C1-C8 (e.g., C1, C2, C3, C4, C5, C6, C7 or C8) alkyl. In some embodiments, C1-C8 alkyl is methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl or -3,3-dimethyl-2-butyl. In some embodiments, the C1-C8 alkyl group is a C1-C6 alkyl group. In some embodiments, the C1-C8 alkyl group is a C1-C3 alkyl group. In some embodiments, the C1-C8 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C8 alkyl group is a C4-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched substituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched unsubstituted C1-C8 alkyl group.
[0143] In some embodiments, R 7 Substituted with one, two or three substituents, at least one of which is NR 9 R 10 In some embodiments, R 7 Substituted with one, two or three substituents, at least one of which is NH2.
[0144] In some embodiments, R 7Substituted by one, two or three substituents, wherein at least one substituent is C3-C8 (e.g., C3, C4, C5, C6, C7 or C8) carbocyclyl. In some embodiments, C3-C8 carbocyclyl is saturated. In some embodiments, C3-C8 carbocyclyl is partially unsaturated. Exemplary C3-C8 carbocycles include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, 1,3-cyclohexadiene, 1,4-cyclohexadiene, cycloheptane, cycloheptene and cyclooctane. In some embodiments, C3-C8 carbocyclyl is unsubstituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is substituted C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is unbranched C3-C8 carbocyclyl. In some embodiments, C3-C8 carbocyclyl is branched C3-C8 carbocyclyl.
[0145] In some embodiments, R 7 is substituted with one, two or three substituents, wherein at least one substituent is phenyl. 7 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 7 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents, wherein at least one substituent is a halo group (e.g., fluoro, chloro, iodo, bromo). In some embodiments, R 7 is substituted with one, two or three substituents, wherein at least one substituent is phenyl substituted with one, two or three substituents, wherein at least one substituent is cyano. In some embodiments, R 7 is substituted with at least one halo and at least one oxo. 7 is substituted with at least one halo and at least one cyano. 7 is substituted with at least one halo and at least one N3. 7 At least one halo group and at least one OR 8 In some embodiments, R 7 At least one halo group and at least one NR 9 R 10 In some embodiments, R 7 is substituted with at least one halo group and at least one C3-C8 carbocyclyl group. 7 is substituted with at least one halo group and at least one unsubstituted phenyl group. 7is substituted with at least one halo group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo groups, cyano groups and C1-C6 alkyl groups. 7 is substituted with at least one oxo and at least one cyano. 7 is substituted with at least one oxo and at least one N3. 7 by at least one oxo group and at least one OR 8 In some embodiments, R 7 is substituted with at least one oxo and at least one C1-C8 alkyl. 7 At least one oxo group and at least one NR 9 R 10 In some embodiments, R 7 is substituted with at least one oxo and at least one C3-C8 carbocyclyl. 7 is substituted with at least one oxo and at least one unsubstituted phenyl. 7 is substituted with at least one oxo group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 7 is substituted with at least one cyano group and at least one N3. In some embodiments, R 7 By at least one N3 and at least one OR 8 In some embodiments, R 7 is substituted with at least one cyano group and at least one C1-C8 alkyl group. 7 by at least one cyano group and at least one NR 9 R 10 In some embodiments, R 7 is substituted with at least one cyano group and at least one C3-C8 carbocyclyl group. 7 is substituted with at least one cyano group and at least one unsubstituted phenyl group. 7 is substituted with at least one cyano group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 7 By at least one N3 and at least one OR 8 In some embodiments, R 7 is substituted with at least one N3 and at least one C1-C8 alkyl. 7 By at least one N3 and at least one NR9 R 10 In some embodiments, R 7 is substituted with at least one N3 and at least one C3-C8 carbocyclyl. 7 is substituted with at least one N3 and at least one unsubstituted phenyl. 7 is substituted with at least one N3 and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 7 By at least one OR 8 and at least one C1-C8 alkyl group. 7 By at least one OR 8 and at least one NR 9 R 10 In some embodiments, R 7 By at least one OR 8 and at least one C3-C8 carbocyclyl. In some embodiments, R 7 By at least one OR 8 and at least one unsubstituted phenyl. In some embodiments, R 7 By at least one OR 8 and at least one phenyl group substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 7 At least one C1-C8 alkyl group and at least one NR 9 R 10 In some embodiments, R 7 is substituted with at least one C1-C8 alkyl group and at least one C3-C8 carbocyclyl group. 7 is substituted with at least one C1-C8 alkyl group and at least one unsubstituted phenyl group. 7 is substituted with at least one C1-C8 alkyl group and at least one phenyl group, wherein the at least one phenyl group is substituted with one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl. 7 is substituted with at least one C3-C8 carbocyclyl and at least one unsubstituted phenyl. 7 is substituted by at least one C3-C8 carbocyclyl and at least one phenyl group, wherein the at least one phenyl group is substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl.
[0146] Each R 8R may independently be H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl. 8 is H. In some embodiments, at least one R 8 R is C1-C6 (e.g., C1, C2, C3, C4, C5, or C6) alkyl, such as methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl, or -3,3-dimethyl-2-butyl. In some embodiments, at least one R 8 is a C1-C3 alkyl group. In some embodiments, at least one R 8 is a C2-C5 alkyl group. In some embodiments, at least one R 8 is a C4-C6 alkyl group. In some embodiments, at least one R 8 is a branched C1-C6 alkyl. 8 is an unbranched C1-C6 alkyl. In some embodiments, at least one R 8 is an unsubstituted C1-C6 alkyl. In some embodiments, at least one R 8 is a branched unsubstituted C1-C6 alkyl. In some embodiments, at least one R 8 It is an unbranched, unsubstituted C1-C6 alkyl group.
[0147] In some embodiments, at least one R 8It is a C1-C6 (eg, C1, C2, C3, C4, C5, or C6) haloalkyl group, wherein the C1-C6 alkyl group is substituted with at least one halo group (eg, fluorine, iodine, chlorine, or bromine). Exemplary C1-C6 haloalkyl groups include halomethyl, haloethyl, halo-n-propyl, haloisopropyl, halo-n-butyl, halo-isobutyl, halo-sec-butyl, halo-tert-butyl, halo-n-pentyl, halo-2-pentyl, halo-3-pentyl, halo-2-methyl-2-butyl, halo-3-methyl-2-butyl, halo-3-methyl-1-butyl, halo-2-methyl-1-butyl, halo-1-hexyl, halo-2-hexyl, halo-3-hexyl, halo-2-methyl-2-pentyl, halo-3-methyl-2-pentyl, halo-4-methyl-2-pentyl, halo-3-methyl-3-pentyl, halo-2-methyl-3-pentyl, halo-2,3-dimethyl-2-butyl, or halo-3,3-dimethyl-2-butyl. In some embodiments, C1-C6 haloalkyl contains at least one (e.g., one, two, three, four, or five) halo group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group. In some embodiments, C1-C6 haloalkyl contains at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one chlorine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group and at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one iodine group and at least one bromine group. Examples of suitable C1-C6 haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3, fluorochloromethyl, difluorochloromethyl, 1,1,1-trifluoroethyl, and pentafluoroethyl.
[0148] In some embodiments, at least one R 8 is C3-C6 (e.g., C3, C4, C5, or C6) cycloalkyl. 8 is C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl or C6 cycloalkyl. 10 The cycloalkyl group is saturated. In some embodiments, the C3-C6 cycloalkyl group is partially saturated. In some embodiments, the C3-C6 cycloalkyl group includes a partially unsaturated ring system containing at least (e.g., one, two) double bonds. In some embodiments, R 8is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0149] Each R 9 R may independently be H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl. 9 is H. In some embodiments, at least one R 9 R is C1-C6 (e.g., C1, C2, C3, C4, C5, or C6) alkyl, such as methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl, or -3,3-dimethyl-2-butyl. In some embodiments, at least one R 9 is a C1-C3 alkyl group. In some embodiments, at least one R 9 is a C2-C5 alkyl group. In some embodiments, at least one R 9 is a C4-C6 alkyl group. In some embodiments, at least one R 9 is a branched C1-C6 alkyl. 9 is an unbranched C1-C6 alkyl. In some embodiments, at least one R 9 is an unsubstituted C1-C6 alkyl. In some embodiments, at least one R 9 is a branched unsubstituted C1-C6 alkyl. In some embodiments, at least one R 9 It is an unbranched, unsubstituted C1-C6 alkyl group.
[0150] In some embodiments, at least one R 9It is a C1-C6 (eg, C1, C2, C3, C4, C5, or C6) haloalkyl group, wherein the C1-C6 alkyl group is substituted with at least one halo group (eg, fluorine, iodine, chlorine, or bromine). Exemplary C1-C6 haloalkyl groups include halomethyl, haloethyl, halo-n-propyl, haloisopropyl, halo-n-butyl, halo-isobutyl, halo-sec-butyl, halo-tert-butyl, halo-n-pentyl, halo-2-pentyl, halo-3-pentyl, halo-2-methyl-2-butyl, halo-3-methyl-2-butyl, halo-3-methyl-1-butyl, halo-2-methyl-1-butyl, halo-1-hexyl, halo-2-hexyl, halo-3-hexyl, halo-2-methyl-2-pentyl, halo-3-methyl-2-pentyl, halo-4-methyl-2-pentyl, halo-3-methyl-3-pentyl, halo-2-methyl-3-pentyl, halo-2,3-dimethyl-2-butyl, or halo-3,3-dimethyl-2-butyl. In some embodiments, C1-C6 haloalkyl contains at least one (e.g., one, two, three, four, or five) halo group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group. In some embodiments, C1-C6 haloalkyl contains at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one chlorine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group and at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one iodine group and at least one bromine group. Examples of suitable C1-C6 haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3, fluorochloromethyl, difluorochloromethyl, 1,1,1-trifluoroethyl, and pentafluoroethyl.
[0151] In some embodiments, at least one R 9 is C3-C6 (e.g., C3, C4, C5, or C6) cycloalkyl. 9 is C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl or C6 cycloalkyl. 10 The cycloalkyl group is saturated. In some embodiments, the C3-C6 cycloalkyl group is partially saturated. In some embodiments, the C3-C6 cycloalkyl group includes a partially unsaturated ring system containing at least (e.g., one, two) double bonds. In some embodiments, R 9is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0152] Each R 10 R may independently be H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl. 10 is H. In some embodiments, at least one R 10 R is C1-C6 (e.g., C1, C2, C3, C4, C5, or C6) alkyl, such as methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl, or -3,3-dimethyl-2-butyl. In some embodiments, at least one R 10 is a C1-C3 alkyl group. In some embodiments, at least one R 10 is a C2-C5 alkyl group. In some embodiments, at least one R 10 is a C4-C6 alkyl group. In some embodiments, at least one R 10 is a branched C1-C6 alkyl. 10 is an unbranched C1-C6 alkyl. In some embodiments, at least one R 10 is an unsubstituted C1-C6 alkyl. In some embodiments, at least one R 10 is a branched unsubstituted C1-C6 alkyl. In some embodiments, at least one R 10 It is an unbranched, unsubstituted C1-C6 alkyl group.
[0153] In some embodiments, at least one R 10It is a C1-C6 (eg, C1, C2, C3, C4, C5, or C6) haloalkyl group, wherein the C1-C6 alkyl group is substituted with at least one halo group (eg, fluorine, iodine, chlorine, or bromine). Exemplary C1-C6 haloalkyl groups include halomethyl, haloethyl, halo-n-propyl, haloisopropyl, halo-n-butyl, halo-isobutyl, halo-sec-butyl, halo-tert-butyl, halo-n-pentyl, halo-2-pentyl, halo-3-pentyl, halo-2-methyl-2-butyl, halo-3-methyl-2-butyl, halo-3-methyl-1-butyl, halo-2-methyl-1-butyl, halo-1-hexyl, halo-2-hexyl, halo-3-hexyl, halo-2-methyl-2-pentyl, halo-3-methyl-2-pentyl, halo-4-methyl-2-pentyl, halo-3-methyl-3-pentyl, halo-2-methyl-3-pentyl, halo-2,3-dimethyl-2-butyl, or halo-3,3-dimethyl-2-butyl. In some embodiments, C1-C6 haloalkyl contains at least one (e.g., one, two, three, four, or five) halo group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group. In some embodiments, C1-C6 haloalkyl contains at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one chlorine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group and at least one iodine group. In some embodiments, C1-C6 haloalkyl contains at least one fluorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one chlorine group and at least one bromine group. In some embodiments, C1-C6 haloalkyl contains at least one iodine group and at least one bromine group. Examples of suitable C1-C6 haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3, fluorochloromethyl, difluorochloromethyl, 1,1,1-trifluoroethyl, and pentafluoroethyl.
[0154] In some embodiments, at least one R 10 is C3-C6 (e.g., C3, C4, C5, or C6) cycloalkyl. 10 is C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl or C6 cycloalkyl. 10 The cycloalkyl group is saturated. In some embodiments, the C3-C6 cycloalkyl group is partially saturated. In some embodiments, the C3-C6 cycloalkyl group includes a partially unsaturated ring system containing at least (e.g., one, two) double bonds. In some embodiments, R 10is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0155] The base can be In some embodiments, the base is In some embodiments, the base is In some embodiments, the base is In some embodiments, the base is
[0156] R 11 Can be -OP(O)(OH)2 or -OC(O)R 12 Substituted C1-C6 (such as C1, C2, C3, C4, C5 or C6) alkyl.In some embodiments, C1-C6 alkyl is methyl, ethyl,-n-propyl, isopropyl,-n-butyl, isobutyl,-sec-butyl,-tert-butyl,-n-pentyl,-2-pentyl,-3-pentyl,-2-methyl-2-butyl,-3-methyl-2-butyl,-3-methyl-1-butyl,-2-methyl-1-butyl,-1-hexyl,-2-hexyl,-3-hexyl,-2-methyl-2-pentyl,-3-methyl-2-pentyl,-4-methyl-2-pentyl,-3-methyl-3-pentyl,-2-methyl-3-pentyl,-2,3-dimethyl-2-butyl or-3,3-dimethyl-2-butyl.In some embodiments, C1-C6 alkyl is C1-C3 alkyl. In some embodiments, the C1-C6 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C6 alkyl group is a C4-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is substituted by -OP(O)(OH)2. In some embodiments, the C1-C6 alkyl group is substituted by -OC(O)R 12 replace.
[0157] R 12 Can be C1-C8 alkyl or C1-C8 alkoxy. In some embodiments, R 12It is C1-C8 (for example, C1, C2, C3, C4, C5, C6, C7 or C8) alkyl. In some embodiments, C1-C8 alkyl is methyl, ethyl, -n-propyl, isopropyl, -n-butyl, isobutyl, -sec-butyl, -tert-butyl, -n-pentyl, -2-pentyl, -3-pentyl, -2-methyl-2-butyl, -3-methyl-2-butyl, -3-methyl-1-butyl, -2-methyl-1-butyl, -1-hexyl, -2-hexyl, -3-hexyl, -2-methyl-2-pentyl, -3-methyl-2-pentyl, -4-methyl-2-pentyl, -3-methyl-3-pentyl, -2-methyl-3-pentyl, -2,3-dimethyl-2-butyl or -3,3-dimethyl-2-butyl. In some embodiments, the C1-C8 alkyl group is a C1-C6 alkyl group. In some embodiments, the C1-C8 alkyl group is a C1-C3 alkyl group. In some embodiments, the C1-C8 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C8 alkyl group is a C4-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is a branched unsubstituted C1-C8 alkyl group. In some embodiments, the C1-C8 alkyl group is an unbranched unsubstituted C1-C8 alkyl group.
[0158] In some embodiments, R 12 The alkyl group of the alkoxy group may be C1-C8 (e.g., C1, C2, C3, C4, C5, C6, C7, or C8) alkoxy. The alkyl portion of the alkoxy group may have 1, 2, 3, 4, 5, or 6 carbon atoms (i.e., C1-C6 alkoxy) or 1, 2, or 3 carbon atoms (i.e., C1-C3 alkoxy). Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), isopropoxy (-O-CH(CH3)2), tert-butoxy (-OC(CH3)3 or -OtBu), and the like. Other examples of suitable alkoxy groups include, but are not limited to, sec-butoxy, tert-butoxy, pentyloxy, and hexyloxy.
[0159] R 13 Can be -OP(O)(OH)2 or -OC(O)R 12Substituted C1-C6 (such as C1, C2, C3, C4, C5 or C6) alkyl.In some embodiments, C1-C6 alkyl is methyl, ethyl,-n-propyl, isopropyl,-n-butyl, isobutyl,-sec-butyl,-tert-butyl,-n-pentyl,-2-pentyl,-3-pentyl,-2-methyl-2-butyl,-3-methyl-2-butyl,-3-methyl-1-butyl,-2-methyl-1-butyl,-1-hexyl,-2-hexyl,-3-hexyl,-2-methyl-2-pentyl,-3-methyl-2-pentyl,-4-methyl-2-pentyl,-3-methyl-3-pentyl,-2-methyl-3-pentyl,-2,3-dimethyl-2-butyl or-3,3-dimethyl-2-butyl.In some embodiments, C1-C6 alkyl is C1-C3 alkyl. In some embodiments, the C1-C6 alkyl group is a C2-C5 alkyl group. In some embodiments, the C1-C6 alkyl group is a C4-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is a branched substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is an unbranched substituted C1-C6 alkyl group. In some embodiments, the C1-C6 alkyl group is substituted by -OP(O)(OH)2. In some embodiments, the C1-C6 alkyl group is substituted by -OC(O)R 12 replace.
[0160] The compounds disclosed herein are not In some embodiments, when R 3 When it is H, the base is not In some embodiments, when R 3 When it is H, R 1 In some embodiments, when R 3 When it is H, R 2 In some embodiments, when R 3 When it is H, R 1 Not OH, R 2 is not OH, and the base is not
[0161] In some embodiments, R 1 is OH and R 2 In some embodiments, R 1 is OH and R 3 It is C(O)OR 7 , where R 7 is a C3-C8 carbocyclic ring (e.g., cyclopentyl). 1is OH and R 3 It is C(O)OR 7 , where R 7 is C1-C8 alkyl (e.g., methyl, propyl, butyl, pentyl). 1 is OH and R 3 It is C(O)OR 7 , where R 7 is a C3-C8 carbocycle (e.g., cyclopropyl) substituted with a C1-C8 alkyl (e.g., methyl). 1 is OH and R 3 It is C(O)OR 7 , where R 7 is a C1-C8 alkyl group (e.g., ethyl) substituted with a phenyl group. 1 is OH and R 3 It is C(O)OR 7 , where R 7 is a 4- to 6-membered (eg, 6-membered) heterocyclyl group containing 1, 2, or 3 (eg, one) O. In some embodiments, R 2 is OH and R 3 It is C(O)OR 7 , where R 7 is a C3-C8 carbocyclic ring (e.g., cyclopentyl). 2 is OH and R 3 It is C(O)OR 7 , where R 7 is C1-C8 alkyl (e.g., methyl, propyl, butyl, pentyl). 2 is OH and R 3 It is C(O)OR 7 , where R 7 is a C3-C8 carbocycle (e.g., cyclopropyl) substituted with a C1-C8 alkyl (e.g., methyl). 2 is OH and R 3 It is C(O)OR 7 , where R 7 is a C1-C8 alkyl group (e.g., ethyl) substituted with a phenyl group. 2 is OH and R 3 It is C(O)OR 7 , where R 7 is a 4- to 6-membered (eg 6-membered) heterocyclic group containing 1, 2 or 3 (eg one) O groups.
[0162] In some embodiments, R 1 It's OH, R 2 is OH, and R3 It is C(O)OR 7 , where R 7 is a C3-C8 carbocyclic ring (e.g., cyclopentyl). 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 is C1-C8 alkyl (e.g., methyl, propyl, butyl, pentyl). 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 is a C3-C8 carbocycle (e.g., cyclopropyl) substituted with a C1-C8 alkyl (e.g., methyl). 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 is a C1-C8 alkyl group (e.g., ethyl) substituted with a phenyl group. 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 is a 4- to 6-membered (eg, 6-membered) heterocyclyl group containing 1, 2, or 3 (eg, one) O. In some embodiments, R 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 is a C3-C5 alkyl group. In some embodiments, R 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 In some embodiments, R 1 It's OH, R 2 is OH, and R 3 It is C(O)OR 7 , where R 7 It is tert-butyl.
[0163] In some embodiments, R 1 and R 2 together to form -OC(O)O-, and R 3 It is C(O)OR 7 , where R7 is C1-C8 alkyl (e.g., butyl). 1 is OH and R 3 is H. In some embodiments, R 1 is OH and the base is In some embodiments, R 2 is OH and the base is In some embodiments, R 1 is OH and the base is In some embodiments, R 1 is OH, the base is And R 12 is C1-C8 alkyl (e.g., butyl). 1 is OH and the base is In some embodiments, R 2 is OH and the base is In some embodiments, R 2 is OH, the base is And R 12 is C1-C8 alkyl (e.g., butyl). 1 It's OH, R 2 is OH, and the base is In some embodiments, R 1 It's OH, R 2 is OH, and the base is And R 12 is C1-C8 alkyl (e.g., butyl). 1 It's OH, R 2 is OH, and the base is In some embodiments, R 3 is H and the base is In some embodiments, R 3 is H and the base is In some embodiments, R 3 It is C(O)OR 7 , R 7 is a C3-C8 carbocyclic group, and the base is In some embodiments, R 3 It is C(O)OR 7 , R 7 is a C3-C8 carbocyclic group substituted by a C1-C8 alkyl group, and the base is In some embodiments, R 3 It is C(O)OR 7 , R 7 is a C1-C8 alkyl, and the base is In some embodiments, R 3 It is C(O)OR 7 , R 7 is a C1-C8 alkyl group substituted with a phenyl group, and the base is In some embodiments, R 3 It is C(O)OR 7 , R 7 is a 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms, and the base is
[0164] It is known to those skilled in the art that the groups disclosed herein (e.g., R 1 ) can be combined with the remaining groups (e.g., R 2 、R 3 Any other embodiment of each of Formula (I) or (II) or any formula described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, is considered to be within the scope of the present disclosure.
[0165] In some embodiments, the compounds of Formula I and pharmaceutically acceptable salts thereof include the compounds in Table 1 and pharmaceutically acceptable salts thereof. In some embodiments, the compounds disclosed herein include the compounds in Table 1.
[0166] Table 1: Some compounds disclosed herein
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175] Also within the scope of this disclosure are the in vivo metabolic products of the compounds described herein. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compound, primarily due to enzymatic processes. Thus, novel and non-obvious compounds are produced by methods comprising contacting the compound with a mammal for a period of time sufficient to produce its metabolic products. Such products are typically identified by preparing a radiolabel (e.g., 14 C or 3 H) compound, a detectable dose (e.g., greater than about 0.5 mg / kg) of the radiolabeled compound is administered parenterally to an animal (such as a rat, mouse, guinea pig, monkey, or human), sufficient time is allowed for metabolism (usually about 30 seconds to 30 hours), and its conversion products are isolated from urine, blood, or other biological samples. These products are easily isolated because they are labeled (other products are isolated by using antibodies that can bind to epitopes that survive in the metabolites). The metabolite structure is determined in a conventional manner, for example, by MS or NMR analysis. Generally, the analysis of metabolites is performed in the same manner as conventional drug metabolism studies. The conversion products can be used for diagnostic determination of therapeutic doses of the compound, as long as they are not otherwise found in vivo, even if they do not have HSV antiviral activity themselves.
[0176] The formula and method for determining the stability of the compound in the alternative gastrointestinal secretion are known.Compound is defined herein as being stable in the gastrointestinal tract, wherein after incubation at 37 DEG C for 1 hour, less than about 50 mol % of the blocking group is deprotected in the alternative intestinal fluid or gastric fluid.Just because the compound is stable to the gastrointestinal tract does not mean that they can not be hydrolyzed in vivo.Prodrugs are generally stable in the digestive system, but can be in the digestive cavity, liver, lung or other metabolic organs or generally speaking in the cell substantially hydrolyzed to the parent drug.As used herein, prodrug is understood to be chemically designed to effectively release the compound of the parent drug after overcoming the oral delivery biological barrier (that is, compound 0 below).
[0177] IV. Pharmaceutical Compositions
[0178] Also disclosed herein are pharmaceutical compositions comprising a pharmaceutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I to Formula II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. Also provided herein is a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
[0179] The compounds disclosed herein can be formulated with conventional carriers and excipients. Tablets may contain, for example, excipients, glidants, fillers, binders, or combinations thereof. Aqueous formulations are prepared in a sterile form and, when intended to be delivered by parenteral administration, will generally be isotonic. Exemplary excipients include, but are not limited to, those described in "HANDBOOK OF PHARMACEUTICAL EXCIPIENTS" (1986). Excipients may include, for example, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextran, hydroxyalkyl cellulose, hydroxyalkyl methyl cellulose, stearic acid, and combinations thereof. In some embodiments, the formulation is alkaline. In some embodiments, the formulation is acidic. In some embodiments, the formulation has a neutral pH. In some embodiments, the pH of the formulation is between 2 and 11 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 4-11, 5-6, 5-7, 5-8, 5-9, 5-10, 5-11, 6-7, 6-8, 6-9, 6-10, 6-11, 7-8, 7-9, 7-10, 7-11, 8-9, 8-10, 8-11, 9-10, or 9-11).
[0180] In some embodiments, the compounds disclosed herein have pharmacokinetic properties (e.g., oral bioavailability) suitable for oral administration of the compound. Formulations suitable for oral administration can, for example, be provided in discrete units such as capsules, sachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient can also be administered, for example, as a pill, elixir, or paste.
[0181] Tablet can be prepared by optionally compressing or molding together with at least auxiliary component.Compressed tablet can be prepared by compressing the active component of free-flowing form (such as, for example powdered or granular) in a suitable machine, optionally mixed with binding agent, lubricant, inert diluent, preservative, surfactant, dispersant or their combination.Moulded tablet can be prepared by molding the mixture of the powdered active component moistened with inert liquid diluent in a suitable machine.Tablet can be optionally coated or scored, and optionally formulated to provide active component therefrom slowly or controlled release.
[0182] For infections of the eye or other external tissues (e.g., mouth and skin), the formulations can be applied as topical ointments or creams containing the active ingredients in amounts of, for example, 0.075 to 20% w / w (including active ingredients in a range between 0.1% and 20% in increments of 0.1% w / w, such as 0.6% w / w, 0.7% w / w, etc.), 0.2% to 15% w / w, or 0.5% to 10% w / w. When formulated as an ointment, in some embodiments the active ingredient can be used with a paraffin base or a water-miscible ointment base. Alternatively, the active ingredient can be formulated into a cream with an oil-in-water cream base.
[0183] In some embodiments, the aqueous phase of the cream base may comprise, for example, 30% to 90% (e.g., 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%) w / w of a polyol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol, and polyethylene glycol (including PEG 400), and mixtures thereof. In some embodiments, the cream base may comprise, for example, a compound that enhances the absorption or penetration of the active ingredient through the skin or other affected area. Examples of such skin penetration enhancers include, but are not limited to, dimethyl sulfoxide and related analogs. In some embodiments, the cream or emulsion does not include water.
[0184] The oil phase of the emulsion can be composed of known ingredients in a known manner. In some embodiments, the phase comprises only an emulsifier (also referred to as an emulsifier). In some embodiments, the phase comprises a mixture of at least one emulsifier with a fat, an oil, or a combination thereof. In some embodiments, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer. The emulsifier, with or without a stabilizer, can together constitute a so-called emulsifying wax, and the wax, together with the oil and fat, constitutes a so-called emulsifying ointment base that can form the oily dispersed phase of the cream formulation.
[0185] Emulsifiers and emulsion stabilizers suitable for the formulation may include but are not limited to 60. 80. 80, cetearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate and combinations thereof.
[0186] The appropriate oil or fat may be selected for the formulation based on achieving the desired cosmetic properties. In some embodiments, the cream may be a non-greasy, non-staining, and washable product with a suitable consistency to avoid leakage from tubes or other containers. In some embodiments, an ester may be included, for example, a linear or branched mono- or di-alkyl ester such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate, known as A mixture of branched chain esters of CAP or a combination thereof. In some embodiments, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils may be included.
[0187] In some embodiments, the compounds disclosed herein are administered alone. In some embodiments, the compounds disclosed herein are administered in pharmaceutical compositions. In some embodiments, such pharmaceutical compositions are for veterinary use. In some embodiments, such pharmaceutical compositions are for human use. In some embodiments, the pharmaceutical compositions disclosed herein include at least one additional therapeutic agent.
[0188] The pharmaceutical compositions disclosed herein may be in any form suitable for the intended method of administration. The pharmaceutical compositions disclosed herein may be in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical field. Exemplary techniques and formulations may be found, for example, in "Remington's Pharmaceutical Sciences" (Mack Publishing Co., Easton, PA). Such methods may include the step of associating the compounds disclosed herein with a carrier constituting at least an auxiliary component. Generally speaking, the formulation may be prepared by uniformly and closely associating the active ingredient with a liquid carrier or a finely dispersed solid carrier or both, and then, if desired, shaping the product.
[0189] For example, when used for oral administration, tablets, lozenges, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, solutions, syrups or elixirs can be prepared. Formulations intended for oral use can be prepared according to any method known in the art for making pharmaceutical compositions, and such formulations can contain at least agents, including sweeteners, flavorings, colorants and preservatives, to provide a palatable formulation. Tablets containing the active ingredient mixed with non-toxic pharmaceutically acceptable excipients suitable for making tablets are acceptable. These excipients can be, for example, inert diluents such as calcium carbonate or sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating agents and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. Tablets can be uncoated or can be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract, thereby providing a sustained effect over a longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
[0190] Formulations for oral use may also be provided as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0191] Aqueous suspensions can contain active substances mixed with excipients suitable for making aqueous suspensions. Such excipients can include, for example, suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum and gum arabic; and dispersants or wetting agents, such as naturally occurring phosphatides (e.g., lecithin), condensation products of alkylene oxides and fatty acids (e.g., polyoxyethylene stearate), condensation products of ethylene oxide and long-chain fatty alcohols (e.g., heptadecanol), condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol anhydrides (e.g., polyoxyethylene sorbitan monooleate). Aqueous suspensions can also contain, for example, at least preservatives (such as ethyl parahydroxybenzoate or n-propyl parahydroxybenzoate), one or more coloring agents, one or more flavoring agents, one or more sweeteners (such as sucrose or saccharin) or combinations thereof. Other non-limiting examples of suspending agents include cyclodextrins. In some embodiments, the suspending agent is sulfobutyl ether β-cyclodextrin (SEB-β-CD), e.g.
[0192] Oily suspensions can be prepared by suspending the active ingredient in a vegetable oil (e.g., peanut oil, olive oil, sesame oil, or coconut oil, or a combination thereof), a mineral oil (such as liquid paraffin), or a combination thereof. Oral suspensions can contain, for example, thickeners such as beeswax, hard paraffin, cetyl alcohol, or a combination thereof. In some embodiments, sweeteners (such as those described above) and / or flavorings are added to provide a palatable oral formulation. In some embodiments, the formulations disclosed herein are preserved by adding an antioxidant such as ascorbic acid.
[0193] Dispersible powders and granules suitable for preparing an aqueous suspension by adding water can provide the active ingredient in admixture with a dispersant or wetting agent, a suspending agent, a preservative, and combinations thereof. Suitable dispersants or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, such as sweeteners, flavorings, and coloring agents, may also be present.
[0194] Such pharmaceutical compositions can also be in the form of oil-in-water emulsions. The oil phase can be a vegetable oil (such as olive oil or peanut oil), a mineral oil (such as liquid paraffin), or a mixture thereof. Suitable emulsifiers include naturally occurring gums such as gum arabic and tragacanth; naturally occurring phospholipids such as soy lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. Emulsions may also contain sweeteners and flavorings. Syrups and elixirs may be formulated with sweeteners such as, for example, glycerol, sorbitol, or sucrose. Such preparations may also contain, for example, a demulcent, a preservative, a flavoring, a coloring agent, or a combination thereof.
[0195] Such pharmaceutical compositions can be in the form of sterile injectable or intravenous preparations, such as sterile injectable aqueous or oily suspensions. The suspension can be prepared according to known techniques using the suitable dispersants or wetting agents and suspending agents mentioned above. Sterile injectable or intravenous preparations can also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents (such as solutions in 1,3-butanediol), or prepared as lyophilized powders. Acceptable solvents and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils can be used as solvents or suspending media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can also be used to prepare injections. Acceptable solvents and solvents that can be used include, but are not limited to, water, Ringer's solution, isotonic sodium chloride solution, and hypertonic sodium chloride solution.
[0196] The amount of active ingredient that can be combined with carrier material to produce single dosage form will change according to the host being treated and specific mode of administration.For example, it is intended that the sustained-release preparation for oral administration to people can contain about 1mg to 2000mg of active material, and this active material is compounded with the carrier material of suitable and convenient amount, and this carrier material can change between 5% to 95% (weight: weight) of total preparation.For example, it is intended that the sustained-release preparation for oral administration to people can contain about 1mg to 1000mg of active material, and this active material is compounded with the carrier material of suitable and convenient amount, and this carrier material can change between 5% to 95% (weight: weight) of total preparation. Pharmaceutical composition can be prepared to provide the dosage that is easy to measure.For example, it is intended that every milliliter of solution of aqueous solution for intravenous infusion can contain 3 μ g to 500 μ g of active ingredient, so that suitable volume is infused at a rate of 30mL / hr.
[0197] Formulations suitable for topical administration to the eye also include eye drops in which the active ingredient is dissolved or suspended in a suitable carrier, particularly an aqueous solvent for the active ingredient. In some embodiments, the compounds disclosed herein are included in the pharmaceutical compositions disclosed herein at a concentration of 0.5% to 20% (e.g., 0.5% to 10%, 1.5% w / w).
[0198] Formulations suitable for topical administration in the mouth include lozenges which may contain the active ingredient (i.e., a compound disclosed herein and / or an additional therapeutic agent) in a flavored basis, usually sucrose and acacia or tragacanth; lozenges containing an inert active ingredient such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
[0199] Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
[0200] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
[0201] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes to render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
[0202] The preparation can be present in unit dose or multidose containers, such as sealed ampoules and vials, and can be stored under freeze-dried (lyophilized) conditions, requiring only the addition of a sterile liquid carrier, such as water for injection, immediately before use. Extemporaneous injections and suspensions are prepared from sterile powders, granules, and tablets of the aforementioned types. Preferred unit dose formulations are preparations containing a daily dose or unit daily subdose of the active ingredient as described above, or an appropriate portion thereof.
[0203] It should be understood that in addition to the ingredients particularly mentioned above the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
[0204] Also provided are veterinary formulations comprising a compound disclosed herein and a veterinary carrier therefor.
[0205] Veterinary carriers are materials useful for administering the formulation and can be solid, liquid, or gaseous materials that are otherwise inert or acceptable in the veterinary art and compatible with the active ingredient. These veterinary formulations can be administered orally, parenterally, or by any other desired route.
[0206] The compounds herein are useful in providing controlled-release pharmaceutical compositions ("controlled-release formulations") containing one or more of these compounds as active ingredients, wherein the release of the active ingredient can be controlled and regulated to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of a given active ingredient.
[0207] The effective dose of the active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is used prophylactically (lower dose) or for combating active viral infection, the method of delivery, and the pharmaceutical composition, and will be determined by a clinician using conventional dose escalation studies. In some embodiments, the effective dose is 0.0001 mg / kg body weight to 100 mg / kg body weight per day; for example, 10 mg / kg body weight to 30 mg / kg body weight per day; 15 mg / kg body weight to 25 mg / kg body weight per day; 10 mg / kg body weight to 15 mg / kg body weight per day; or 20 mg / kg body weight to 30 mg / kg body weight per day. For example, a candidate daily dose range for an adult weighing approximately 70 kg can be 1 mg to 2000 mg (e.g., 5 mg to 500 mg, 500 mg to 1000 mg, 1000 mg to 1500 mg, 1500 mg to 2000 mg), and can be in the form of a single dose or multiple doses. For example, a candidate daily dosage for an adult human weighing approximately 70 kg may range from 1 mg to 1000 mg (eg, 5 mg to 500 mg), and may be in the form of a single dose or multiple doses.
[0208] V. Kit
[0209] Also provided herein are kits comprising the compounds disclosed herein or pharmaceutically acceptable salts thereof. In some embodiments, the kits described herein may include labels and / or instructions for using the compounds to treat a disease or condition in a subject (e.g., a human) in need thereof. In some embodiments, the disease or condition is a viral infection.
[0210] In some embodiments, the kit may further comprise one or more additional therapeutic agents and / or instructions for using the additional therapeutic agents in combination with the compounds disclosed herein to treat a disease or condition in a subject (e.g., a human) in need thereof.
[0211] In some embodiments, the kits provided herein contain individual dosage units of a compound as described herein, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate, or solvate thereof. Examples of individual dosage units may include pills, tablets, capsules, prefilled syringes or syringes, IV bags, inhalers, nebulizers, and the like, each of which includes a therapeutically effective amount of the compound in question, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate, or solvate thereof. In some embodiments, the kit may contain a single dosage unit, and in other embodiments, there may be a plurality of dosage units, such as the number of dosage units required for a given regimen or cycle.
[0212] Also provided are articles of manufacture comprising: a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof; and a container. In some embodiments, the container of the article of manufacture is a vial, a jar, an ampoule, a prefilled syringe, a blister pack, a can, a tin, a bottle, a box, an intravenous bag, an inhaler, or a nebulizer.
[0213] VI. Application
[0214] One or more compounds of the present invention are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, inhalation, pulmonary, topical (including buccal and sublingual), vaginal, and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural). In some embodiments, the compounds disclosed herein are administered by inhalation or intravenously. It should be understood that the route may vary depending on, for example, the condition of the recipient.
[0215] In the method for treating viral infection of the present invention, the compound of the present invention can be applied to a subject who can be exposed to the virus or has already suffered from a viral infection at any time. In some embodiments, the compound of the present invention can be applied to a subject who is in contact with a subject suffering from a viral infection or is at risk of contacting a person suffering from a viral infection, such as a healthcare provider. In some embodiments, the application of the compound of the present invention can be applied to a subject who is positive for a viral infection test but has not yet shown symptoms of a viral infection. In the method for treating viral infection of the present invention, the compound of the present invention can be applied to a person who may be exposed to the virus or has already suffered from a viral infection at any time. In some embodiments, the compound of the present invention can be applied to a person who is in contact with a person suffering from a viral infection or is at risk of contacting a person suffering from a viral infection, such as a healthcare provider. In some embodiments, the application of the compound of the present invention can be applied to a person who is positive for a viral infection test but has not yet shown symptoms of a viral infection. In some embodiments, the compound of the present invention can be applied to a person at the beginning of the symptoms of a viral infection.
[0216] In some embodiments, the methods disclosed herein comprise event-driven administration of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a subject.
[0217] As used herein, the term "event-driven" or "event-driven administration" refers to administration of a compound of Formula I to Formula II, or a pharmaceutically acceptable salt thereof, (1) prior to (e.g., 2 hours, 1 day, 2 days, 5 days, or 7 days or more prior to) an event that will expose a subject to a virus (or will otherwise increase the risk of a subject acquiring a viral infection); and / or (2) during an event (or more than one recurring event) that will expose a subject to a virus (or will otherwise increase the risk of a subject acquiring a viral infection); and / or (3) after (or after the final event in a series of recurring events) an event that will expose a subject to a virus (or will otherwise increase the risk of a subject acquiring a viral infection). In some embodiments, event-driven administration is performed before the subject is exposed to the virus. In some embodiments, event-driven administration is performed after the subject is exposed to the virus. In some embodiments, event-driven administration is performed before and after the subject is exposed to the virus.
[0218] In certain embodiments, the methods disclosed herein involve administration before and / or after an event that will expose a subject to a virus or will otherwise increase the risk of a subject acquiring a viral infection, for example, as pre-exposure prophylaxis (PrEP) and / or as post-exposure prophylaxis (PEP). In some embodiments, the methods disclosed herein include pre-exposure prophylaxis (PrEP). In some embodiments, the methods disclosed herein include post-exposure prophylaxis (PEP).
[0219] In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is administered to a subject prior to exposure to a virus.
[0220] In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered before and after exposure of a subject to a virus.
[0221] In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, is administered after the subject has been exposed to the virus.
[0222] An example of an event-driven dosing regimen includes administering a compound disclosed herein, or a pharmaceutically acceptable salt thereof, within 24 to 2 hours prior to the virus, followed by administration of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, every 24 hours during the exposure period, followed by further administration of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, after the last exposure, and a final administration of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, 24 hours later.
[0223] Another example of an event-driven dosing regimen includes administering a compound of any one of Formula I to Formula II, or a pharmaceutically acceptable salt thereof, within 24 hours prior to viral exposure, followed by daily administration during exposure, and then a final administration (which may be in increasing doses, such as double doses) approximately 24 hours after the last exposure.
[0224] The effective dose of the active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is used prophylactically or to combat active viral infection, the method of delivery, and the pharmaceutical composition, and will be determined by the clinician using conventional dose escalation studies. It can be expected to be 0.0001 mg / kg to 100 mg / kg body weight per day (e.g., 0.01 mg / kg to 10 mg / kg body weight per day); from 0.01 mg / kg to 5 mg / kg body weight per day; from 0.05 mg / kg to 0.5 mg / kg body weight per day). In some embodiments, the daily candidate dose for an adult weighing approximately 70 kg is 1 mg to 4000 mg (e.g., 5 mg to 500 mg, 500 mg to 1000 mg, 1000 mg to 1500 mg, 1500 mg to 2000 mg, 2000 mg to 3000 mg, 3000 mg to 4000 mg), and can be in the form of a single dose or multiple doses (e.g., 2 doses per day, 3 doses per day). For example, a candidate daily dosage for an adult human weighing approximately 70 kg may range from 1 mg to 1000 mg (eg, 5 mg to 500 mg), and may be in the form of a single dose or multiple doses.
[0225] Any suitable time period for administering the disclosed compounds is contemplated. For example, administration can last from 1 day to 100 days, including 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90 days. Administration can also last from 1 week to 15 weeks, including 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks. Longer administration times are also contemplated.
[0226] In some embodiments, the compounds disclosed herein are administered once daily. In some embodiments, the compounds disclosed herein are administered twice daily. In some embodiments, the compounds disclosed herein are administered once every other day. In some embodiments, the compounds disclosed herein are administered once weekly. In some embodiments, the compounds disclosed herein are administered twice weekly.
[0227] In some embodiments, one or more compounds disclosed herein are administered once daily. A once daily dose may be administered as needed, for example, for up to 5 days, up to 7 days, up to 10 days, up to 15 days, up to 20 days, up to 25 days, up to one month, or longer. In some embodiments, a once daily dose is administered for up to 20 days, up to 15 days, up to 14 days, up to 13 days, up to 12 days, up to 10 days, up to 8 days, up to 6 days, up to 4 days, up to 3 days, up to 2 days, or 1 day.
[0228] In some embodiments, one or more compounds disclosed herein are administered once a day for 6 to 12 days, for example, for 8 to 10 days. In some embodiments, the one or more compounds are administered once a day for 9 days. In some embodiments, the one or more compounds are administered once a day for 10 days. In some embodiments, 50-150 mg of one or more compounds disclosed herein are administered once daily for 5-12 days, for example, for 5, 6, 7, 8, 9, 10, 11, or 12 days. In some embodiments, 100 mg of one or more compounds disclosed herein are administered once a day for 5-12 days, for example, for 5, 6, 7, 8, 9, 10, 11, or 12 days. In some embodiments, 500-2000 mg (e.g., 500-1000 mg, 1000-1500 mg) of one or more compounds disclosed herein is administered once daily for 5-12 days, e.g., for 5, 6, 7, 8, 9, 10, 11, or 12 days.
[0229] In some embodiments, one or more compounds disclosed herein are administered twice daily. Twice daily doses may be administered as needed, for example, for up to 5 days, up to 7 days, up to 10 days, up to 15 days, up to 20 days, up to 25 days, up to one month, or longer. In some embodiments, twice daily doses are administered for up to 20 days, up to 15 days, up to 14 days, up to 13 days, up to 12 days, up to 10 days, up to 8 days, up to 6 days, up to 4 days, up to 3 days, up to 2 days, or 1 day.
[0230] In some embodiments, one or more compounds disclosed herein are administered twice a day for about 6 to 12 days, for example, for about 8 to 10 days. In some embodiments, the one or more compounds are administered twice a day for 9 days. In some embodiments, the one or more compounds are administered twice a day for 10 days. In some embodiments, 1 mg-2000 mg of one or more compounds disclosed herein are administered twice a day for 5 to 12 days, for example, for 5, 6, 7, 8, 9, 10, 11 or 12 days. In some embodiments, 500 mg-2000 mg (e.g., 500 mg-1000 mg, 1000 mg-1500 mg, 1500 mg-2000 mg) of one or more compounds disclosed herein are administered twice a day for 5 to 12 days, for example, for 5, 6, 7, 8, 9, 10, 11 or 12 days.
[0231] VII. Instructions for use
[0232] The present disclosure also provides methods of treating or preventing a viral infection in a subject (eg, a human) in need thereof, comprising administering to the subject a compound described herein.
[0233] In some embodiments, the present disclosure provides methods of treating a viral infection in a subject (eg, a human) in need thereof, comprising administering to the subject in need thereof a compound described herein.
[0234] In some embodiments, the present disclosure provides methods of treating or preventing a viral infection in a subject (e.g., a human) in need thereof, comprising administering to the subject a compound disclosed herein and at least one additional active therapeutic or prophylactic agent.
[0235] In some embodiments, the present disclosure provides methods of treating a viral infection in a subject (eg, a human) in need thereof, comprising administering to the subject a compound disclosed herein and at least one additional active therapeutic agent.
[0236] In some embodiments, the present disclosure provides methods of inhibiting viral polymerase in a cell, comprising contacting a cell infected with a virus with a compound disclosed herein, thereby inhibiting the viral polymerase.
[0237] In some embodiments, the present disclosure provides methods of inhibiting viral polymerase in a cell, comprising contacting a cell infected with a virus with a compound disclosed herein and at least one additional active therapeutic agent, thereby inhibiting the viral polymerase.
[0238] Also provided herein are uses of the compounds disclosed herein for treating or preventing a viral infection in a subject in need thereof. For example, provided herein are uses of the compounds disclosed herein for treating a viral infection in a subject in need thereof.
[0239] A. Paramyxoviridae
[0240] In some embodiments, the viral infection is a Paramyxoviridae virus infection. Therefore, in some embodiments, the present disclosure provides a method for treating a Paramyxoviridae infection in a subject (e.g., a human) in need thereof, the method comprising administering a compound disclosed herein to the subject. In some embodiments, the Paramyxoviridae virus includes a BSL4 pathogen. Paramyxoviridae viruses include, but are not limited to, Nipah virus, Hendra virus, measles, mumps, and parainfluenza virus.
[0241] In some embodiments, the present disclosure provides a method for preparing a medicament for treating a Paramyxoviridae virus infection in a subject (e.g., a human) in need thereof, characterized by using a compound of the present disclosure or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides the use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a Paramyxoviridae virus infection in a subject (e.g., a human).
[0242] In some embodiments, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating a Paramyxoviridae infection in a subject (eg, a human) in need thereof.
[0243] B. Pneumoviridae
[0244] In some embodiments, the viral infection is a Pneumoviridae virus infection. In some embodiments, the present disclosure provides a method for treating a Pneumoviridae virus infection in a subject (e.g., a person) in need thereof, the method comprising administering a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof to the person. Pneumoviridae viruses include but are not limited to respiratory syncytial virus (RSV) and human metapneumovirus. In some embodiments, the Pneumoviridae virus infection is a respiratory syncytial virus (RSV) infection. In some embodiments, the Pneumoviridae virus infection is a human metapneumovirus infection.
[0245] In some embodiments, the present disclosure provides a method for preparing a drug for treating a Pneumoviridae virus infection in a subject (e.g., a human) in need thereof, characterized in that a compound of the present disclosure or a pharmaceutically acceptable salt thereof is used. In some embodiments, the present disclosure provides the use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for preparing a drug for treating a Pneumoviridae virus infection in a subject (e.g., a human). In some embodiments, the Pneumoviridae virus infection is a respiratory syncytial virus infection. In some embodiments, the Pneumoviridae virus infection is a human metapneumovirus infection.
[0246] In some embodiments, the present disclosure provides a method for preparing a medicament for treating a Pneumoviridae virus infection in a person in need thereof, characterized in that a compound of the present disclosure or a pharmaceutically acceptable salt thereof is used. In some embodiments, the present disclosure provides the use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a Pneumoviridae virus infection in a person. In some embodiments, the Pneumoviridae virus infection is a respiratory syncytial virus infection. In some embodiments, the Pneumoviridae virus infection is a human metapneumovirus infection.
[0247] In some embodiments, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Pneumoviridae virus infection in a human in need thereof. In some embodiments, the Pneumoviridae virus infection is a respiratory syncytial virus (RSV) infection. In some embodiments, the Pneumoviridae virus infection is a human metapneumovirus infection.
[0248] In certain embodiments, the present disclosure provides a method for treating RSV infection, the method comprising administering a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof to a subject (e.g., a person) infected with respiratory syncytial virus. In some embodiments, the person suffers from chronic respiratory syncytial virus infection. In some embodiments, the person is acutely infected with RSV.
[0249] In certain embodiments, a method of inhibiting RSV replication is provided, comprising administering to a subject (eg, a human) a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
[0250] In certain embodiments, the present disclosure provides a method for reducing viral load associated with RSV infection, wherein the method comprises administering a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, to a subject (e.g., a human) infected with RSV, wherein the therapeutically effective amount is sufficient to reduce the RSV viral load in the subject.
[0251] As described more fully herein, the compounds of the present disclosure can be administered to a subject (e.g., a human) infected with RSV together with one or more additional therapeutic agents. The additional therapeutic agent can be administered to an infected subject (e.g., a human) simultaneously with the compounds of the present disclosure or before or after the compounds of the present disclosure.
[0252] In certain embodiments, there is provided a compound of the present disclosure for treating or preventing RSV infection, or a pharmaceutically acceptable salt thereof. In certain embodiments, there is provided a compound of the present disclosure (e.g., a compound of Formula I to Formula II) or a pharmaceutically acceptable salt thereof for the manufacture of a medicine for treating or preventing RSV infection.
[0253] In some embodiments, methods of inhibiting RSV replication are provided, wherein the methods comprise administering a compound disclosed herein to a subject (eg, a human) in need thereof, wherein the administration is by inhalation.
[0254] In some embodiments, the present disclosure provides methods for reducing viral load associated with RSV infection, wherein the method comprises administering a compound disclosed herein to a human infected with RSV.
[0255] C. Picornaviridae
[0256] In some embodiments, viral infection is a picornaviridae virus infection. In some embodiments, the present disclosure provides a method for treating a picornaviridae virus infection in a person in need thereof, the method comprising administering a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof to a subject (e.g., a person). Picornaviridae viruses are enteroviruses that cause heterogeneous infections including herpangina, aseptic meningitis, common cold-like syndrome (human rhinovirus infection), non-paralytic poliomyelitis-like syndrome, epidemic chest myalgia (acute, fever, infectious diseases that typically occur in epidemics), hand, foot and mouth syndrome, pediatric and adult pancreatitis and severe myocarditis. In some embodiments, picornaviridae virus infection is a human rhinovirus infection. In some embodiments, picornaviridae virus infection is an enterovirus infection. In some embodiments, the Picornaviridae virus infection is selected from the group consisting of: Coxsackie A virus infection, Coxsackie A virus infection, Enterovirus D68 infection, Enterovirus B69 infection, Enterovirus D70 infection, Enterovirus A71 infection, and Poliovirus infection. In some embodiments, the Picornaviridae virus is Foot-and-Mouth Disease Virus (FMDV).
[0257] In some embodiments, the present disclosure provides a method for preparing a medicament for treating a Picornaviridae virus infection in a subject (e.g., a human) in need thereof, characterized in that a compound of the present disclosure or a pharmaceutically acceptable salt thereof is used. In some embodiments, the present disclosure provides the use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a Picornaviridae virus infection in a subject (e.g., a human). In some embodiments, the Picornaviridae virus infection is a human rhinovirus infection.
[0258] In some embodiments, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Picornaviridae viral infection in a subject (e.g., a human) in need thereof. In some embodiments, the Picornaviridae viral infection is a human rhinovirus infection.
[0259] D. Flaviviridae
[0260] In some embodiments, the viral infection is a Flaviviridae virus infection. In some embodiments, the present disclosure provides a method for treating a Flaviviridae virus infection in a subject (e.g., a human) in need thereof, the method comprising administering to the subject (e.g., a human) a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof. Representative Flaviviridae viruses include, but are not limited to, dengue fever, yellow fever, West Nile, Zika, Japanese encephalitis virus, tick-borne encephalitis virus (TBEV), and hepatitis C virus (HCV). In some embodiments, the Flaviviridae virus infection is a dengue virus infection. In some embodiments, the Flaviviridae virus infection is a yellow fever virus infection. In some embodiments, the Flaviviridae virus infection is a West Nile virus infection. In some embodiments, the Flaviviridae virus infection is a Zika virus infection. In some embodiments, the Flaviviridae virus infection is a Japanese encephalitis virus infection. In some embodiments, the Flaviviridae virus infection is a tick-borne encephalitis virus (TBEV) infection. In some embodiments, the Flaviviridae virus infection is a hepatitis C virus infection. In some embodiments, the Flaviviridae virus infection is bovine viral diarrhea virus (BVDV). In some embodiments, the Flaviviridae viral infection is swine fever virus (SFV).
[0261] In some embodiments, the present disclosure provides a method for preparing a medicament for treating a Flaviviridae virus infection in a subject (e.g., a human) in need thereof, characterized in that a compound of the present disclosure or a pharmaceutically acceptable salt thereof is used. In some embodiments, the present disclosure provides the use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a Flaviviridae virus infection in a subject (e.g., a human). In some embodiments, the Flaviviridae virus infection is a dengue virus infection. In some embodiments, the Flaviviridae virus infection is a yellow fever virus infection. In some embodiments, the Flaviviridae virus infection is a West Nile virus infection. In some embodiments, the Flaviviridae virus infection is a Zika virus infection. In some embodiments, the Flaviviridae virus infection is a hepatitis C virus infection.
[0262] In some embodiments, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Flaviviridae infection in a human in need thereof. In some embodiments, the Flaviviridae infection is a dengue virus infection. In some embodiments, the Flaviviridae infection is a yellow fever virus infection. In some embodiments, the Flaviviridae infection is a West Nile virus infection. In some embodiments, the Flaviviridae infection is a Zika virus infection. In some embodiments, the Flaviviridae infection is a hepatitis C virus infection.
[0263] E. Filoviridae
[0264] In some embodiments, viral infection is Filoviridae virus infection. In some embodiments, the present disclosure provides a method for treating a Filoviridae virus infection in a subject (e.g., a person) in need thereof, the method comprising administering a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof to the subject (e.g., a person). Representative Filoviridae viruses include but are not limited to Ebola virus (variants Zaire, Bundibugio, Sudan, Tai Forest, or Reston) and Marburg virus. In some embodiments, Filoviridae virus infection is Ebola virus infection. In some embodiments, Filoviridae virus infection is Marburg virus infection.
[0265] In some embodiments, the present disclosure provides a method for preparing a medicament for treating a Filoviridae viral infection in a human in need thereof, characterized by using a compound of the present disclosure or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides the use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a Filoviridae viral infection in a human. In some embodiments, the Filoviridae viral infection is an Ebola virus infection.
[0266] In some embodiments, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Filoviridae virus infection in a subject (e.g., a human) in need thereof. In some embodiments, the Filoviridae virus infection is an Ebola virus infection. In some embodiments, the Filoviridae virus infection is a Marburg virus infection.
[0267] VIII. Combination Therapy
[0268] Compounds as described herein can also be used in combination with one or more additional therapeutic agents or preventive agents. Therefore, there is also provided herein a method for treating a viral infection in a subject in need, wherein these methods include administering a compound disclosed herein and one or more additional therapeutic agents or preventive agents of a therapeutically effective amount to the subject. In some embodiments, these methods include administering a compound disclosed herein and one or more additional therapeutic agents of a therapeutically effective amount to the subject. In some embodiments, compounds disclosed herein are combined with at least one other active therapeutic agent, wherein the combination is used to treat a viral infection in a subject in need. In some embodiments, the combination can be used to treat a variety of independent viral infections (e.g., RSV and HIV) in a subject. In some embodiments, compounds disclosed herein are combined with at least one other active therapeutic agent to cover a wider spectrum of respiratory viruses in a treatment without the need for diagnosis.
[0269] In some embodiments, the combination can be used to treat the same virus (e.g., RSV) in a subject. Active therapeutic agents include, but are not limited to, approved drugs, therapeutic agents currently in clinical trials, therapeutic agents that have shown efficacy in animal models, therapeutic agents that have shown efficacy in in vitro assays, or any of the above.
[0270] In some embodiments, the additional therapeutic agent is an antiviral agent. Any suitable antiviral agent can be used in the methods described herein. In some embodiments, the antiviral agent is selected from the group consisting of: 5-substituted 2'-deoxyuridine analogs, nucleoside analogs, pyrophosphate analogs, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, entry inhibitors, acyclic guanosine analogs, acyclic nucleoside phosphonate analogs, HCVNS5A / NS5B inhibitors, influenza virus inhibitors, interferons, immunostimulants, oligonucleotides, antimitotic inhibitors, and combinations thereof.
[0271] In some embodiments, the additional therapeutic agent is a 5-substituted 2'-deoxyuridine analog. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of ioduridine, trifluridine, brivudine [BVDU], and combinations thereof.
[0272] In some embodiments, the additional therapeutic agent is a nucleoside analog. For example, in some embodiments, the additional therapeutic agent is selected from: vidarabine, entecavir (ETV), telmivudine, lamivudine, adefovir dipivoxil, tenofovir disoproxil fumarate (TDF), and combinations thereof. In some embodiments, the additional therapeutic agent is favipiravir, ribavirin, galidesivir, β-D-N4-hydroxycytidine, or combinations thereof.
[0273] In some embodiments, the additional therapeutic agent is a pyrophosphate analog. For example, in some embodiments, the additional therapeutic agent is foscarnet or phosphonoacetic acid. In some embodiments, the additional therapeutic agent is foscarnet.
[0274] In some embodiments, the additional therapeutic agent is a nucleoside reverse transcriptase inhibitor. In some embodiments, the antiviral agent is zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, and combinations thereof.
[0275] In some embodiments, the additional therapeutic agent is a non-nucleoside reverse transcriptase inhibitor.In some embodiments, the antiviral agent is selected from the group consisting of nevirapine, delavirdine, efavirenz, etravirine, rilpivirine, and combinations thereof.
[0276] In some embodiments, the additional therapeutic agent is a protease inhibitor. In some embodiments, the protease inhibitor is an HIV protease inhibitor. For example, in some embodiments, the antiviral agent is selected from the group consisting of: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, darunavir, tipranavir, cobicistat, and combinations thereof. In some embodiments, the antiviral agent is selected from the group consisting of: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, darunavir, tipranavir, and combinations thereof. In some embodiments, the protease inhibitor is an HCV NS3 / 4A protease inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of: voxiprevir, anaprevir, boceprevir, paritaprevir, simeprevir, telaprevir, vanirepvir, grazoprevir, ribavirin, danoprevir, fadaprevir, vedoprevir, sovalprevir, deprevir, nalaprevir, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of: voxiprevir, anaprevir, boceprevir, paritaprevir, simeprevir, telaprevir, vanirepvir, grazoprevir, and combinations thereof.
[0277] In some embodiments, the additional therapeutic agent is an integrase inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of raltegravir, dolutegravir, elvitegravir, abacavir, lamivudine, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of bictegravir, raltegravir, dolutegravir, cabotegravir, elvitegravir, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of bictegravir, dolutegravir, and cabotegravir, and combinations thereof. In some embodiments, the additional therapeutic agent is bictegravir.
[0278] In some embodiments, the additional therapeutic agent is an entry inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of docosanol, enfuvirtide, maraviroc, ibalizumab, fotexavir, leronlimab, ibalizumab, fotexavir, leronlimab, palivizumab, intravenous respiratory syncytial virus immune globulin [RSV-IGIV], varicella zoster immune globulin [VariZIG], varicella zoster immune globulin [VZIG]), and combinations thereof.
[0279] In some embodiments, the additional therapeutic agent is an acyclovir analog. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of acyclovir, ganciclovir, valacyclovir (also known as valacyclovir), valganciclovir, penciclovir, famciclovir, and combinations thereof.
[0280] In some embodiments, the additional therapeutic agent is an acyclic nucleoside phosphonate analog. For example, in some embodiments, the additional therapeutic agent is selected from: cidofovir, adefovir, adefovir dipivoxil, tenofovir, TDF, emtricitabine, efavirenz, rilpivirine, elvitegravir and combinations thereof. In some embodiments, the additional therapeutic agent is selected from: cidofovir, adefovir, adefovir dipivoxil, tenofovir, TDF and combinations thereof. In some embodiments, the additional therapeutic agent is selected from: cidofovir, adefovir, adefovir dipivoxil, tenofovir, TDF and combinations thereof.
[0281] In some embodiments, the additional therapeutic agent is an HCV NS5A / NS5B inhibitor. In some embodiments, the additional therapeutic agent is an NS3 / 4A protease inhibitor. In some embodiments, the additional therapeutic agent is an NS5A protease inhibitor. In some embodiments, the additional therapeutic agent is a nucleoside / nucleotide NS5B polymerase inhibitor. In some embodiments, the additional therapeutic agent is a non-nucleoside NS5B polymerase inhibitor. In some embodiments, the additional therapeutic agent is selected from the group consisting of: daclatasvir, ledipasvir, velpatasvir, ombitasvir, elbasvir, sofosbuvir, dasabuvir, ribavirin, anaprevir, simeprevir, paritaprevir, ritonavir, elbasvir, gezoprevir, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of: daclatasvir, ledipasvir, velpatasvir, ombitasvir, elbasvir, sofosbuvir, dasabuvir, and combinations thereof.
[0282] In some embodiments, the additional therapeutic agent is an influenza virus inhibitor. In some embodiments, the additional therapeutic agent is a matrix 2 inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from: amantadine, rimantadine, and combinations thereof. In some embodiments, the additional therapeutic agent is a neuraminidase inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from: zanamivir, oseltamivir, peramivir, laninamivir octanoate, and combinations thereof. In some embodiments, the additional therapeutic agent is a polymerase inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from: ribavirin, favipiravir, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from: amantadine, rimantadine, arbidol (uminovir), baloxavir mapositate, oseltamivir, peramivir, ingavirine, laninamivir octanoate, zanamivir, favipiravir, ribavirin, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of amantadine, rimantadine, zanamivir, oseltamivir, peramivir, laninamivir octanoate, ribavirin, favipiravir, and combinations thereof.
[0283] In some embodiments, the additional therapeutic agent is interferon. In some embodiments, the additional therapeutic agent is selected from the group consisting of interferon alfacon 1, interferon alpha 1b, interferon alpha 2a, interferon alpha 2b, pegylated interferon alfacon 1, pegylated interferon alpha 1b, pegylated interferon alpha 2a (PegIFN alpha-2a), and PegIFN alpha-2b. In some embodiments, the additional therapeutic agent is selected from the group consisting of interferon alfacon 1, interferon alpha 1b, interferon alpha 2a, interferon alpha 2b, pegylated interferon alpha 2a (PegIFN alpha-2a), and PegIFN alpha-2b. In some embodiments, the additional therapeutic agent is selected from the group consisting of interferon alfacon 1, pegylated interferon alpha 2a (PegIFN alpha-2a), PegIFN alpha-2b, and ribavirin. In some embodiments, the additional therapeutic agent is pegylated interferon alpha-2a, pegylated interferon alpha-2b, or a combination thereof.
[0284] In some embodiments, the additional therapeutic agent is an immunostimulant. In some embodiments, the additional therapeutic agent is an oligonucleotide. In some embodiments, the additional therapeutic agent is an anti-mitotic inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of fomivirsen, podafilox, imiquimod, phenytoin, and combinations thereof.
[0285] In some embodiments, the additional therapeutic agent is selected from the group consisting of: besifovir, nitazoxanide, REGN2222, doravirine, sofosbuvir, velpatasvir, daclatasvir, anaprevir, becabuvir, FV100, and letermovir, and combinations thereof.
[0286] In some embodiments, the additional therapeutic agent is an agent used to treat RSV. For example, in some embodiments, the antiviral agent is ribavirin, ALS-8112, or prutegravir. For example, in some embodiments, the antiviral agent is ALS-8112 or prutegravir.
[0287] In some embodiments, the additional therapeutic agent is an agent used to treat picornaviruses. In some embodiments, the additional therapeutic agent is selected from hydantoins, guanidine hydrochloride, L-buthionine sulfoximine, Py-11, and combinations thereof. In some embodiments, the additional therapeutic agent is a picornavirus polymerase inhibitor. In some embodiments, the additional therapeutic agent is lupinquvir.
[0288] In some embodiments, the additional therapeutic agent is an agent used to treat malaria. In some embodiments, the additional therapeutic agent is chloroquine.
[0289] In some embodiments, the additional therapeutic agent is selected from the group consisting of hydroxychloroquine, chloroquine, artemether, lumefantrine, atovaquone, proguanil, tafenoquine, pyronaridine, artesunate, dihydroartemisinin, piperaquine, artesunate, amodiaquine, pyronaridine, artesunate, halofantrine, quinine sulfate, mefloquine, solithromycin, pyrimethamine, MMV-390048, ferrocenechloroquine, artemisinin mesylate, ganaplacide, DSM-265, sipagamine, artemisininone, and combinations thereof.
[0290] In some embodiments, the additional therapeutic agent is an agent used to treat coronavirus. In some embodiments, the additional therapeutic agent is an agent used to treat COVID-19 (coronavirus disease 2019, the disease caused by the virus designated SARS-CoV-2). In some embodiments, the additional therapeutic agent is selected from the group consisting of IFX-1, FM-201, CYNK-001, DPP4-Fc, ranpirnase, nafamostat, LB-2, AM-1, antiviral porins, remdesivir, VV116, GS-441524, GS-5245, and combinations thereof.
[0291] In some embodiments, the additional therapeutic agent is an agent used to treat Ebola virus. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of: ribavirin, palivizumab, motavizumab, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, amiodarone, dronedarone, verapamil, Ebola convalescent plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), favipiravir (also known as T-705 or
[00145] In some embodiments, the additional therapeutic agent is ZMapp, mAb114, REGEN-EB3, or a combination thereof.
[0292] In some embodiments, the additional therapeutic agent is a medicament for treating HCV. In some embodiments, the additional therapeutic agent is an HCV polymerase inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of: sofosbuvir, GS-6620, PSI-938, ribavirin, tegobuvir, radalbuvir, MK-0608, and combinations thereof. In some embodiments, the additional therapeutic agent is an HCV protease inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from: such as GS-9256, vedoprevir, voxiprevir, and combinations thereof.
[0293] In some embodiments, the additional therapeutic agent is an NS5A inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of ledipasvir, velpatasvir, and combinations thereof.
[0294] In some embodiments, the additional therapeutic agent is an anti-HBV agent. For example, in some embodiments, the additional therapeutic agent is tenofovir disoproxil fumarate and emtricitabine or a combination thereof. Examples of additional anti-HBV agents include, but are not limited to, α-hydroxytropolone, amides, antroquinol, β-hydroxycytidine, ARB-199, CCC-0975, ccc-R08, efcitabine, ezetimibe, cyclosporine A, gentioside (gentiopicroside), HH-003, hepalatide, JNJ-56136379, nitazoxanide, birenapam, NJK14047, NOV-205 (molixan, BAM-205), oligonucleotides, mivotifen, feron, GST-HG-131, levamisole, Ka Shu Ning, alloferon, WS-007, Y-101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3, BP-Inter-014, caryophyllin, HepB-nRNA, cTP-5(rTP-5), HSK-II-2, HEISCO-106-1, HEISCO-106, Hepbarna, IBPB-006IA, Hepuyinfen, DasKloster 0014--01, ISA-204, Jiangantai (Ganxikang), MIV-210, OB-AI-004, PF-06, picroside, DasKloster-0039, hepulantai, IMB-2613, TCM-800B, reduced glutathione, RO-6864018, RG-7834, QL-007, sofosbuvir, ledipasvir, UB-551 and ZH-2N, as well as US20150210682 (Roche), US2016 / 0122344 (Roche), WO2015173164, WO201602 In some embodiments, the additional therapeutic agent is a HBV polymerase inhibitor. Examples of HBV DNA polymerase inhibitors include, but are not limited to, adefovir. Emtricitabine Tenofovir disoproxil fumarate Tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir octadecyloxyethyl ester, CMX-157, tenofovir exalidex, besifovir, entecavir Entecavir maleate, telbivudine Feloxivir, pradefovir, clavudine, ribavirin, lamivudine Phosphorus azide, famciclovir, fusolin, metavavir, SNC-019754, FMCA, AGX-1009, AR-II-04-26, HIP-1302, tenofovir disoproxil aspartate, tenofovir disoproxil orotate, and HS- 10234. In some embodiments, the additional therapeutic agent is an HBV capsid inhibitor.
[0295] In some embodiments, the additional therapeutic agent is an agent used to treat HIV. In some embodiments, the additional therapeutic agent is selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, entry inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, acyclic nucleoside phosphonate analogs, and combinations thereof.
[0296] In some embodiments, the additional therapeutic agent is selected from the group consisting of: HIV protease inhibitors, HIV non-nucleoside or non-nucleotide reverse transcriptase inhibitors, HIV nucleoside or nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, immunomodulators, immunotherapeutics, antibody-drug conjugates, gene modifiers, gene editing agents (such as CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs) and cell therapies (such as chimeric antigen receptor T cells, CAR-T and engineered T cell receptors, TCR-T, autologous T cell therapy).
[0297] In some embodiments, the additional therapeutic agent is selected from the group consisting of: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversal agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies and bispecific antibodies and "antibody-like" therapeutic proteins, and combinations thereof.
[0298] In some embodiments, the additional therapeutic agent is an HIV combination drug. Examples of HIV combination drugs include, but are not limited to (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); (bicagvir, emtricitabine, and tenofovir alafenamide); ( rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); (tenofovir alafenamide and emtricitabine); (tenofovir alafenamide, emtricitabine, and rilpivirine); (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); (darunavir, tenofovir alafenamide hemifumarate, emtricitabine, and cobicistat); SYMFI TM (efavirenz, lamivudine, and tenofovir disoproxil fumarate); CIMDU TM (lamivudine and tenofovir disoproxil fumarate); tenofovir and lamivudine; tenofovir alafenamide and emtricitabine; tenofovir alafenamide hemifumarate and emtricitabine; tenofovir alafenamide hemifumarate, emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate, emtricitabine, cobicistat, and elvitegravir; (zidovudine and lamivudine; AZT+3TC); ( Abacavir sulfate and lamivudine; ABC+3TC); ( lopinavir and ritonavir); (dolutegravir, abacavir, and lamivudine); (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); atazanavir and cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate and ritonavir; darunavir and cobicistat; dolutegravir and rilpivirine; dolutegravir and rilpivirine hydrochloride; dolutegravir, abacavir sulfate, and lamivudine; lamivudine, nevirapine, and zidovudine; raltegravir and lamivudine; doravirine, lamivudine, and tenofovir disoproxil fumarate; doravirine, lamivudine, and tenofovir disoproxil fumarate; dapivirine + levonorgestrel, dolutegravir + lamivudine , dolutegravir + emtricitabine + tenofovir alafenamide, efavirenz + emtricitabine + tenofovir disoproxil fumarate, lamivudine + abacavir + zidovudine, lamivudine + abacavir, lamivudine + tenofovir disoproxil fumarate, lamivudine + zidovudine + nevirapine, lopinavir + ritonavir, lopinavir + ritonavir + abacavir + lamivudine, lopinavir + ritonavir + zidovudine + lamivudine, tenofovir + lamivudine and tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir, ritonavir, zidovudine and lamivudine.
[0299] In some embodiments, the additional therapeutic agent is an HIV capsid inhibitor (eg, lenacapvir).
[0300] In some embodiments, the additional therapeutic agent is an HIV protease inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, darunavir, tipranavir, cobicistat, ASC-09, AEBL-2, MK-8718, GS-9500, GS-1156, and combinations thereof. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, darunavir, tipranavir, cobicistat. In some embodiments, the additional therapeutic agent is selected from the group consisting of amprenavir, atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, TMC-310911, and combinations thereof.
[0301] In some embodiments, the additional therapeutic agent is an HIV integrase inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of: raltegravir, elvitegravir, dolutegravir, abacavir, lamivudine, bicagevir, and combinations thereof. In some embodiments, the additional therapeutic agent is bicagevir. In some embodiments, the additional therapeutic agent is selected from the group consisting of: bicagevir, elvitegravir, curcumin, a derivative of curcumin, chicoric acid, a derivative of chicoric acid, 3,5-dicaffeoylquinic acid, a derivative of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, a derivative of aurintricarboxylic acid, caffeic acid phenethyl ester, a derivative of caffeic acid phenethyl ester, a tyrosine kinase inhibitor, a derivative of a tyrosine kinase inhibitor, quercetin, a derivative of quercetin, raltegravir, dolutegravir, JTK-351, bicagevir, AVX-15567, BMS- 986197, cabotegravir (long-acting injection), diketoquinoline-4-1 derivatives, integrase-LEDGF inhibitors, ledgins, M-522, M-532, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, distilbenes disulfonic acid, T-169, VM-3500, cabotegravir, and combinations thereof.
[0302] In some embodiments, the additional therapeutic agent is an HIV entry inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from: enfuvirtide, maraviroc, and combinations thereof. Additional examples of HIV entry inhibitors include, but are not limited to, cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 ligation inhibitors, DS-003 (BMS-599793), gp120 inhibitors, and CXCR4 inhibitors. Examples of CCR5 inhibitors include apraviroc, vicoviroc, maraviroc, cenicriviroc, leronlimab (PRO-140), adatasvir (RAP-101), nifeviroc (TD-0232), anti-GP120 / CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, and vMIP (Haimipu). Examples of CXCR4 inhibitors include plerixafor, ALT-1188, N15 peptide, and vMIP (Haimipu).
[0303] In some embodiments, the additional therapeutic agent is an HIV nucleoside reverse transcriptase inhibitor. In some embodiments, the additional therapeutic agent is an HIV non-nucleoside reverse transcriptase inhibitor. In some embodiments, the additional therapeutic agent is an acyclic nucleoside phosphonate analog. In some embodiments, the additional therapeutic agent is an HIV capsid inhibitor.
[0304] In some embodiments, the additional therapeutic agent is an HIV nucleoside or nucleotide reverse transcriptase inhibitor. For example, the additional therapeutic agent is selected from the group consisting of: adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, and VIDEX (didanosine, ddl), abacavir, abacavir sulfate, alovudine, aritibine, sinavudine, didanosine, efavirenz, festinavir, fosalvudine tidoxil, CMX-157, dapivirine, doravirine, etravirine, OCR-5753, tenofovir disoproxil orotate, fosalvudine tidoxil, islatravir, lamivudine, phosphazid, stavudine, zalcitabine, zidovudine, rovafovir-etafoetida (GS-9131), GS-9148, MK-8504, MK-8591, MK-858, VM-2500, KP-1461, and combinations thereof.
[0305] In some embodiments, the additional therapeutic agent is an HIV non-nucleoside or non-nucleotide reverse transcriptase inhibitor. For example, the additional agent is selected from the group consisting of dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, MK-8583, nevirapine, rilpivirine, TMC-278LA, ACC-007, AIC-292, KM-023, PC-1005, efavirenz rilp (VM-1500), and combinations thereof.
[0306] In some embodiments, the additional therapeutic agent is selected from (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); ( rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); (tenofovir alafenamide and emtricitabine); (tenofovir alafenamide, emtricitabine, and rilpivirine); (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); adefovir; adefovir disoproxil; cobicistat; emtricitabine; tenofovir; tenofovir disoproxil fumarate; tenofovir alafenamide; tenofovir hemifumarate; (dolutegravir, abacavir, and lamivudine); dolutegravir, abacavir sulfate, and lamivudine; raltegravir; raltegravir and lamivudine; maraviroc; enfuvirtide; ( lopinavir and ritonavir); (zidovudine and lamivudine; AZT+3TC); ( Abacavir sulfate and lamivudine; ABC+3TC); (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride; atazanavir sulfate and cobicistat; atazanavir and cobicistat; darunavir and cobicistat; atazanavir; atazanavir sulfate; dolutegravir; elvitegravir; ritonavir; atazanavir sulfate and ritonavir; darunavir; lamivudine; platinum; fosamprenavir; fosamprenavir calcium and efavirenz; etravirine; nelfinavir; nelfinavir mesylate; interferon; didanosine; Stavudine; indinavir; indinavir sulfate; tenofovir and lamivudine; zidovudine; nevirapine; saquinavir; saquinavir mesylate; aldesleukin; zalcitabine; tipranavir; amprenavir; delavirdine; delavirdine mesylate; Radha-108 (receptor alcohol); lamivudine and tenofovir disoproxil fumarate; efavirenz, lamivudine, and tenofovir disoproxil fumarate; phosphinothricin; lamivudine, nevirapine, and zidovudine; abacavir; and abacavir sulfate.
[0307] In some embodiments, the additional therapeutic agent is selected from the group consisting of: colistin, valrubicin, icatibant, bepotastine, epirubicin, epoprosetnol, vapreotide, aprepitant, caspofungin, perphenazine, atazanavir, efavirenz, ritonavir, acyclovir, ganciclovir, penciclovir, prulifloxacin, bicarbavirin, nelfinavir, tegobuvi, nelfinavir, praziquantel, pitavastatin, perampanel, eszopiclone, and zopiclone.
[0308] In some embodiments, the additional therapeutic agent is an inhibitor of Bruton's tyrosine kinase (BTK, AGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLA; NCBI Gene ID: 695). For example, in some embodiments, the additional therapeutic agent is selected from: (S)-6-amino-9-(1-(but-2-ynyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one, acalabrutinib (ACP-196), BGB-3111, CB988, HM71224, ibrutinib (Imbruvica), M-2951 (evobrutinib), M7583, tirabrutinib (ONO-4059), PRN-1008, sepretinib (CC-292), TAK-020, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS-12, TAS-5315, AZD6738, acalabrutinib, danvastatin, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of tilarutib, ibrutinib, acalabrutinib, and combinations thereof. In some embodiments, the additional therapeutic agent is selected from the group consisting of tilarutib, ibrutinib, and combinations thereof. In some embodiments, the additional therapeutic agent is the tyrosine kinase inhibitor A9 (A9).
[0309] In some embodiments, the additional therapeutic agent is a KRAS inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of AMG-510, COTI-219, MRTX-1257, ARS-3248, ARS-853, WDB-178, BI-3406, BI-1701963, ARS-1620 (G12C), SML-8-73-1 (G12C), compound 3144 (G12D), Kobe0065 / 2602 (Ras GTP), room temperature 11, MRTX-849 (G12C) and KRAS (G12D) selective inhibitory peptides, including KRpep-2, KRpep-2d, and combinations thereof.
[0310] In some embodiments, the additional therapeutic agent is a proteasome inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of ixazomib, carfilzomib, marizomib, bortezomib, and combinations thereof. In some embodiments, the additional therapeutic agent is carfilzomib.
[0311] In some embodiments, the additional therapeutic agent is a vaccine. For example, in some embodiments, the additional therapeutic agent is a DNA vaccine, an RNA vaccine, a live attenuated vaccine, a therapeutic vaccine, a prophylactic vaccine, a protein-based vaccine, or a combination thereof. In some embodiments, the additional therapeutic agent is mRNA-1273. In some embodiments, the additional therapeutic agent is INO-4800 or INO-4700. In some embodiments, the additional therapeutic agent is the live attenuated RSV vaccine MEDI-559, the anti-RSV human monoclonal antibody REGN2222, palivizumab, respiratory syncytial virus immune globulin, intravenous respiratory syncytial virus immune globulin [RSV-IGIV], and combinations thereof. In some embodiments, the additional therapeutic agent is an HBV vaccine, such as pediarix, engerix-B, and recombivax HB. In some embodiments, the additional therapeutic agent is a VZV vaccine, such as zostavax and varivax. In some embodiments, the additional therapeutic agent is an HPV vaccine, such as cervarix, gardasil9, and gardasil. In some embodiments, the additional therapeutic agent is an influenza virus vaccine. For example, (i) influenza A monovalent vaccine (e.g., influenza A [H5N1] virus monovalent vaccine and influenza A [H1N1] 2009 virus monovalent vaccine), (ii) influenza A and B trivalent vaccine (e.g., Afluria, Agriflu, Fluad, Fluarix, Flublok, Flucelvax, FluLaval, Fluvirin, and Fluzone), and (iii) influenza A and B quadrivalent vaccine (FluMist, Fluarix, Fluzone, and FluLaval). In some embodiments, the additional therapeutic agent is a human adenovirus vaccine (e.g., adenovirus type 4 and type 7 vaccine, live, oral). In some embodiments, the additional therapeutic agent is a rotavirus vaccine (e.g., Rotarix for rotavirus serotypes G1, G3, G4, or G9 and RotaTeq for rotavirus serotypes G1, G2, G3, or G4). In some embodiments, the additional therapeutic agent is a hepatitis A virus vaccine (e.g., Havrix and Vaqta). In some embodiments, the additional therapeutic agent is a polio virus vaccine (e.g., Kinrix, Quadracel, and Ipol). In some embodiments, the additional therapeutic agent is a yellow fever virus vaccine (e.g., YF-Vax). In some embodiments, the additional therapeutic agent is a Japanese encephalitis virus vaccine (e.g., Ixiaro and JE-Vax). In some embodiments, the additional therapeutic agent is a measles vaccine (e.g., MMR II and ProQuad). In some embodiments, the additional therapeutic agent is a mumps vaccine (e.g., MMR II and ProQuad).In some embodiments, the additional therapeutic agent is a rubella vaccine (e.g., MMR II and ProQuad). In some embodiments, the additional therapeutic agent is a varicella vaccine (e.g., ProQuad). In some embodiments, the additional therapeutic agent is a rabies vaccine (e.g., Imovax and RabAvert). In some embodiments, the additional therapeutic agent is a smallpox virus (variola) vaccine (ACAM2000). In some embodiments, the additional therapeutic agent is a hepatitis E virus (HEV) vaccine (e.g., HEV239). In some embodiments, the additional therapeutic agent is a SARS-COV-2 vaccine.
[0312] In some embodiments, the additional therapeutic agent is an antibody, such as a monoclonal antibody. For example, the additional therapeutic agent is selected from the group consisting of anti-SARS-CoV-2 antibodies: Regeneron antibodies, Wuxi antibodies, Vir Biotechnology antibodies, antibodies targeting the SARS-CoV-2 spike protein, antibodies that can neutralize SARS-CoV-2 (SARS-CoV-2 neutralizing antibodies), and combinations thereof. In some embodiments, the additional therapeutic agent is the anti-SARS CoV antibody CR-3022. In some embodiments, the additional therapeutic agent is an aPD-1 antibody.
[0313] In some embodiments, the additional therapeutic agent is an injection of a protein derived from a recombinant cytokine gene.
[0314] In some embodiments, the additional therapeutic agent is a polymerase inhibitor. In some embodiments, the additional therapeutic agent is a DNA polymerase inhibitor. For example, in some embodiments, the additional therapeutic agent is cidofovir. In some embodiments, the additional therapeutic agent is an RNA polymerase inhibitor. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of ribavirin, favipiravir, lamivudine, pimovir, and combinations thereof.
[0315] In some embodiments, the additional therapeutic agent is selected from the group consisting of lopinavir, ritonavir, interferon alpha-2b, ritonavir, arbidol, hydroxychloroquine, darunavir and cobicistat, arbidol hydrochloride, oseltamivir, litonavir, emtricitabine, tenofovir alafenamide fumarate, baloxavir mapositol, ruxolitinib, and combinations thereof.
[0316] In some embodiments, the additional therapeutic agent is selected from the group consisting of: 6'-fluorinated montraneline analogs, acyclovir fleximer analogs, disulfiram, thiopurine analogs, ASC09F, GC376, GC813, phenylisoserine derivatives, neuraminidase inhibitor analogs, pyrithione derivatives, bananin and 5-hydroxychromone derivatives, SSYA10-001, griffithsin, HR2P-M1, HR2P-M2, P21S10, dihydrotanshinone E-64-C and E-64-D, OC43-HR2P, ME RS-5HB, 229E-HR1P, 229E-HR2P, resveratrol, 1-thiophene-4-azaspiro[4.5]decan-3-one derivatives, gemcitabine hydrochloride, loperamide, recombinant interferon, cyclosporine A, alisporivir, imatinib mesylate, dasatinib, selumetinib, trametinib, rapamycin, saracatinib, chlorpromazine, triflupromazine, fluphenazine, thiethylperazine, promethazine, cyclophilin inhibitors, K11777, camostat, k22, teicoplanin derivatives, benzoheterocyclic amine derivative N30, mycophenolic acid, silvestrol, and combinations thereof.
[0317] In some embodiments, the additional therapeutic agent is an antibody. In some embodiments, the additional therapeutic agent is an antibody that binds to a coronavirus, such as an antibody that binds to SARS or MERS. In some embodiments, the additional therapeutic agent is an antibody that binds to the SARS-CoV-2 virus.
[0318] The formulations of the present disclosure are also used in combination with other active ingredients. For the treatment of SARS-COV-2 viral infection, in some embodiments, other active therapeutic agents have the activity of anti-coronavirus infection, such as the activity of anti-SARS-COV-2 viral infection. The compounds and formulations of the present disclosure are also intended to be used for general care provided to subjects with SARS-COV-2 viral infection, including parenteral fluids (including glucose saline and Ringer's lactate) and nutrients, antibiotics (including metronidazole and cephalosporin antibiotics, such as ceftriaxone and cefuroxime) and / or antifungal prophylaxis, fever and pain medications, antiemetics (such as metoclopramide) and / or antidiarrheals, vitamin and mineral supplements (including vitamin K and zinc sulfate), anti-inflammatory agents (such as ibuprofen or steroids), corticosteroids (such as methylprednisolone), immunomodulatory drugs (such as dry The invention also includes but is not limited to interferon, other small molecules or biological antiviral agents targeting SARS-COV-2 (such as, but not limited to, lopinavir / ritonavir, EIDD-1931, favipiravir, ribavirin, neutralizing antibodies, etc.), vaccines, pain medications, and medications for other common diseases in the subject population, such as antimalarials (including artemether and artesunate-lumefantrine combination therapy), typhoid medications (including quinolone antibiotics such as ciprofloxacin, macrolide antibiotics such as azithromycin, cephalosporin antibiotics such as ceftriaxone or aminopenicillins such as ampicillin), or shigellosis medications. In some embodiments, the additional therapeutic agent is dihydroartemisinin / piperaquine.
[0319] In some embodiments, the additional therapeutic agent is an immunomodulator. Examples of immune-based therapies include toll-like receptor modulators, such as tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12, and tlr13; programmed cell death protein 1 (PD-1) modulators; programmed death ligand 1 (PD-L1) modulators; IL-15 modulators; DermaVir; interleukin-7; plaquenil (hydroxychloroquine); prilocaine (aldesleukin, IL-2); interferon alpha; interferon alpha-2b; interferon alpha-n3; pegylated interferon alpha; interferon gamma; hydroxyurea; mycophenolate mofetil (MPA) and its ester derivatives In some embodiments, the additional therapeutic agent is fingolimod, leflunomide, or a combination thereof. In some embodiments, the additional therapeutic agent is thalidomide.
[0320] In some embodiments, the additional therapeutic agent is an IL-6 inhibitor, such as tocilizumab, salirumab, or a combination thereof.
[0321] In some embodiments, the additional therapeutic agent is an anti-TNF inhibitor. For example, the additional therapeutic agent is adalimumab, etanercept, golimumab, infliximab, or a combination thereof.
[0322] In some embodiments, the additional therapeutic agent is a JAK inhibitor, for example, the additional therapeutic agent is baricitinib, filgotinib, baricitinib, or a combination thereof.
[0323] In some embodiments, the additional therapeutic agent is an inflammation suppressant, such as pirfenidone.
[0324] In some embodiments, the additional therapeutic agent is an antibiotic for secondary bacterial pneumonia. For example, the additional therapeutic agent is a macrolide antibiotic (e.g., azithromycin, clarithromycin, and mycoplasma pneumoniae), a fluoroquinolone (e.g., ciprofloxacin and levofloxacin), a tetracycline (e.g., doxycycline and tetracycline), or a combination thereof.
[0325] In some embodiments, the compounds disclosed herein are used in combination with standard of care for pneumonia (see, e.g., Pediatric Community Pneumonia Guidelines, CID 2011:53 (October 1)). Treatment of pneumonia generally involves curing the infection and preventing complications. The specific treatment will depend on several factors, including the type and severity of pneumonia, the age and overall health of the subject. Options include: (i) antibiotics, (ii) cough medicine, and (iii) fever reducers / analgesics (e.g., aspirin, ibuprofen (Advil, Motrin IB, etc.) and acetaminophen (Tylenol, etc.)). In some embodiments, the additional therapeutic agent is a bromhexine cough suppressant.
[0326] In some embodiments, the compounds disclosed herein are used in combination with immunoglobulin from a recovered COVID-19 subject. In some embodiments, the compounds disclosed herein are used in combination with plasma transfusion. In some embodiments, the compounds disclosed herein are used in combination with stem cells.
[0327] In some embodiments, the additional therapeutic agent is a TLR agonist. Examples of TLR agonists include, but are not limited to, visammod (GS-9620), GS-986, IR-103, lefimod, tilsotolimod, rintatlimod, DSP-0509, AL-034, G-100, cobitolimod, AST-008, motolimod, GSK-1795091, GSK-2245035, VTX-1463, GS-9688, LHC-165, BDB-001, RG-7854, telratolimod, RO-7020531.
[0328] In some embodiments, the additional therapeutic agent is selected from the group consisting of bortezomib, flurazepam, ponatinib, sorafenib, paramethasone, clocortolone, flucloxacillin, sertindole, clevidipine, atorvastatin, cinoxazepam, clofazimine, fosaprepitant, and combinations thereof.
[0329] In some embodiments, the additional therapeutic agent is carlimycin, suramin, triazolin, dipyridamole, bevacizumab, mepozumab, GD31 (Rhizobium), an NLRP inflammasome inhibitor, or α-ketoamine. In some embodiments, the additional therapeutic agent is recombinant human angiotensin-converting enzyme 2 (rhACE2). In some embodiments, the additional therapeutic agent is viral macrophage inflammatory protein (vMIP).
[0330] In some embodiments, the additional therapeutic agent is an antiviral porin therapeutic agent. For example, the additional therapeutic agent is BIT-314 or BIT-225. In some embodiments, the additional therapeutic agent is a coronavirus E protein inhibitor. For example, the additional therapeutic agent is BIT-009. Additional examples of additional therapeutic agents include those described in WO-2004112687, WO-2006135978, WO-2018145148, and WO-2009018609.
[0331] Any compound of the present disclosure can also be combined with one or more additional active therapeutic agents in a single dosage form for simultaneous or sequential administration to a subject. Combination therapy can be administered as a simultaneous or sequential regimen. When administered sequentially, the combination can be administered in two or more administrations.
[0332] Co-administration of a compound of the present disclosure with one or more other active therapeutic agents generally refers to administering the compound of the present disclosure and the one or more other active therapeutic agents simultaneously or sequentially such that therapeutically effective amounts of both the compound of the present disclosure and the one or more other active therapeutic agents are present in the subject.
[0333] Co-administration includes administering a unit dose of a compound of the present disclosure before or after administering a unit dose of one or more other active therapeutic agents, for example, administering a compound of the present disclosure within seconds, minutes, or hours of administering one or more other active therapeutic agents. For example, a unit dose of a compound of the present disclosure may be administered first, followed by administering a unit dose of one or more other active therapeutic agents within seconds or minutes. Alternatively, a unit dose of one or more other therapeutic agents may be administered first, followed by administering a unit dose of a compound of the present disclosure within seconds or minutes. In some cases, it may be necessary to first administer a unit dose of a compound of the present disclosure, followed by administering a unit dose of one or more other active therapeutic agents after a few hours (e.g., 1 to 12 hours). In other cases, it may be necessary to first administer a unit dose of one or more other active therapeutic agents, followed by administering a unit dose of a compound of the present disclosure after a few hours (e.g., 1 to 12 hours).
[0334] Combination therapy can provide "synergy" and "synergy," that is, the effect achieved when the active ingredients are used together is greater than the sum of the effects produced by the compounds when used alone. A synergistic effect can be obtained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combination formulation; (2) delivered alternately or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect can be obtained when the compounds are administered or delivered sequentially, for example, in separate tablets, pills, or capsules or by different injections in separate syringes. Generally, during alternation therapy, an effective dose of each active ingredient is administered sequentially (i.e., continuously), whereas in combination therapy, effective doses of two or more active ingredients are administered together. A synergistic antiviral effect means that the antiviral effect is greater than the predicted purely additive effect of the individual compounds in the combination.
[0335] A. Combination Therapies for the Treatment of Pneumoviridae
[0336] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any active therapeutic agent discussed in Section VIII herein and / or with other active therapeutic agents for treating Pneumoviridae virus infections specifically discussed in Section VIII.A herein. In some embodiments, the other active therapeutic agent has activity against Pneumoviridae virus infections, particularly respiratory syncytial virus infections and / or metapneumovirus infections. As described more fully herein, the compounds of the present disclosure can be administered to subjects (e.g., humans) infected with RSV together with one or more additional therapeutic agents. In addition, in some embodiments, when used to treat or prevent RSV, the compounds of the present disclosure can be administered together with one or more (e.g., one, two, three, four or more) additional therapeutic agents selected from RSV combination drugs, RSV vaccines, RSV RNA polymerase inhibitors, immunomodulators toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, respiratory syncytial surface antigen inhibitors, cytotoxic T lymphocyte-associated protein 4 (ipi4) inhibitors, cyclophilin inhibitors, RSV viral entry inhibitors, antisense oligonucleotides targeting viral mRNA, short interfering RNA (siRNA) and ddRNAi endonuclease modulators, ribonucleotide reductase inhibitors, farnesoid X receptor agonists, RSV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nuclear protein modulators, retinoic acid-inducible gene 1 stimulators, NOD2 stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors, indoleamine-2,3-dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha-1, Bruton's tyrosine kinase (BTK) inhibitors, KDM inhibitors, RSV replication inhibitors, arginase inhibitors and other RSV drugs.
[0337] Non-limiting examples of these other active therapeutic agents that are active against RSV include active monoclonal antibodies and nanobody therapeutics, active agents against RSV infection, respiratory syncytial virus protein F inhibitors, viral replication inhibitors, RNA polymerase inhibitors, siRNA-based therapies, and combinations thereof. Non-limiting examples of active monoclonal antibodies and nanobody therapeutics include palivizumab, RSV-IGIV MEDI-557 (motavizumab), MEDI8897 (nirsevimab), MK-1654, ALX-0171, A-60444 (also known as RSV604), anti-RSV G protein antibodies, and mixtures thereof. Other non-limiting examples of other active therapeutic agents that are active against respiratory syncytial virus infection include respiratory syncytial virus protein F inhibitors such as MDT-637, BMS-433771, AK-0529, RV-521 (sisunatovir), JNJ-53718678 (rilematovir), BTA-585, and pusatovir; RNA polymerase inhibitors such as ribavirin, A-60444 (also known as RSV604), JNJ-64417184, ALS-8112 (JNJ-64041575; lumicitabine), and ALS-8112 (the parent of lumicitabine); viral replication inhibitors such as EDP-938 and nitazoxanide; siRNA-based therapies such as ALN-RSV01; and combinations thereof.
[0338] In some embodiments, the other active therapeutic agent may be a vaccine for the treatment or prevention of RSV, including but not limited to MVA-BN RSV, RSV-F, MEDI-8897, JNJ-64400141, DPX-RSV, SynGEM, GSK-3389245A, GSK-300389-1A, RSV-MEDI deltaM2-2 vaccine, VRC-RSVRGP084-00VP, Ad35-RSV-FA2, Ad26-RSV-FA2, and RSV fusion glycoprotein subunit vaccine.
[0339] Non-limiting examples of other active therapeutic agents active against metapneumovirus infection include sialidase modulators, such as DAS-181; RNA polymerase inhibitors, such as ALS-8112; and antibodies for treating metapneumovirus infection, such as EV-046113.
[0340] In some embodiments, the other active therapeutic agent may be a vaccine for treating or preventing metapneumovirus infection, including but not limited to mRNA-1653 and rHMPV-Pa vaccines.
[0341] B. Combination Therapies for the Treatment of Picornaviridae
[0342] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any active therapeutic agent discussed in Section VIII herein and / or with other active therapeutic agents for treating Picornaviridae viral infections specifically discussed in Section VIII.B herein. In some embodiments, the other active therapeutic agent is active against Picornaviridae viral infections, particularly enterovirus infections. Non-limiting examples of these other active therapeutic agents are capsid binding inhibitors such as pleconaril, BTA-798 (vapendavir), and other compounds disclosed by Wu et al. (US 7,078,403) and Watson (US 7,166,604); fusion sialidase proteins such as DAS-181; capsid protein VP1 inhibitors such as VVX-003 and AZN-001; viral protease inhibitors such as CW-33; phosphatidylinositol 4-kinase beta inhibitors such as GSK-480 and GSK-533; anti-EV71 antibodies.
[0343] In some embodiments, the other active therapeutic agent may be a vaccine for treating or preventing Picornaviridae viral infection, including but not limited to EV71 vaccine, TAK-021, and EV-D68 adenovirus vector-based vaccines.
[0344] C. Combination Therapies for the Treatment of Respiratory Viral Infections
[0345] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any of the active therapeutic agents discussed in Section VIII herein and / or other active therapeutic agents specifically discussed in Section VIII.C herein. Many infections caused by Pneumoviridae and Picornaviridae viruses are respiratory infections. Therefore, additional active therapeutic agents for treating respiratory symptoms and sequelae of infection can be used in combination with the compounds provided herein. The additional therapeutic agents can be administered orally or by direct inhalation. For example, other additional therapeutic agents used in combination with the compounds provided herein for treating viral respiratory infections include, but are not limited to, bronchodilators and corticosteroids.
[0346] Glucocorticoids
[0347] Glucocorticoids (Carryer, Journal of Allergy, 21, 282-287, 1950), first introduced as asthma therapy in 1950, remain the most effective and persistent therapy for this disease, but their mechanism of action is not yet fully understood (Morris, J. Allergy Clin. Immunol., 75 (1 Pt) 1-13, 1985). Unfortunately, oral glucocorticoid therapy is associated with serious adverse side effects, such as truncal obesity, hypertension, glaucoma, glucose intolerance, accelerated cataract formation, bone mineral loss and psychological effects, all of which limit its use as a long-term therapeutic agent (Goodman and Gilman, 10th edition, 2001). A solution to systemic side effects is to deliver steroid drugs directly to the site of inflammation. Inhaled corticosteroids (ICS) have been developed to alleviate the serious side effects of oral steroids. Non-limiting examples of corticosteroids that can be used in combination with the compounds provided herein are dexamethasone, dexamethasone sodium phosphate, fluorometholone, fluorometholone acetate, loteprednol, loteprednol etabonate, hydrocortisone, prednisolone, fludrocortisone, triamcinolone, triamcinolone acetonide, betamethasone, beclomethasone dipropionate, methylprednisolone, fluocinolone acetonide, fluocinolone acetonide, flunisolide, fluocortidine-21-butyrate, flumethasone, flumethasone pivalate, budesonide, halobetasol propionate, mometasone furoate, fluticasone, AZD-7594, ciclesonide; or pharmaceutically acceptable salts thereof.
[0348] anti-inflammatory agents
[0349] Other anti-inflammatory agents that work by anti-inflammatory cascade mechanism also can be used as additional therapeutic agent and compound combination provided herein for the treatment of viral respiratory tract infection.Application " anti-inflammatory signal transduction regulator " (being referred to as AISM in this text), such as phosphodiesterase inhibitor (for example, PDE-4, PDE-5 or PDE-7 specific), transcription factor inhibitor (for example, NFκB is blocked by IKK inhibition) or kinase inhibitor (for example, blocking P38 MAP, JNK, PI3K, EGFR or Syk) is a kind of logical method of cutting off inflammation, because these small molecules target the common intracellular pathway of limited number-as those signal transduction pathways of the key point of anti-inflammatory treatment intervention (referring to PJBarnes, 2006 review). These non-limiting additional therapeutic agents include: 5-(2,4-difluoro-phenoxy)-1-isobutyl-1H-indazole-6-carboxylic acid (2-dimethylamino-ethyl)-amide (P38 Map kinase inhibitor ARRY-797); 3-cyclopropylmethoxy-N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-benzamide (PDE-4 inhibitor roflumilast); 4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenyl]-1H-indazole-6-carboxylic acid (2-dimethylamino-ethyl)-amide (P38 Map kinase inhibitor ARRY-797); 3-cyclopropylmethoxy-N-(3,5-dichloro-pyridin-4-yl)-4-difluoromethoxy-benzamide (PDE-4 inhibitor roflumilast); [1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxo-acetamide (PDE-4 inhibitor AWD 12-281); 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide (PDE-4 inhibitor Schmidt, 1997); [1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl)-2-oxo-acetamide (PDE-4 inhibitor AWD 12-281); [1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl)-2-oxo-acet ... AWD 12-281); [1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl)-2-oxo-acetamide (PDE-4 inhibitor AWD 12-281); [1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl)-2-oxo-acetamide (PDE-4 inhibitor A 351591); 4-[5-(4-fluorophenyl)-2-(4-methanesulfinyl-phenyl)-1H-imidazol-4-yl]-pyridine (P38 inhibitor SB-203850); 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-but-3-yn-1-ol (P38 inhibitor RWJ-67657); 4-cyano-4-(3-cyclopentyloxy-4-methoxy-phenyl)-cyclohexanecarboxylic acid 2 -diethylamino-ethyl ester (2-diethyl-ethyl ester prodrug of cilomilast, a PDE-4 inhibitor); (3-chloro-4-fluorophenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (gefitinib, an EGFR inhibitor); and 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (imatinib, an EGFR inhibitor).
[0350] β2-adrenergic receptor agonist bronchodilator
[0351] Combinations comprising an inhaled β2-adrenergic receptor agonist bronchodilator such as formoterol, albuterol, or salmeterol and a compound provided herein are also suitable, but non-limiting, combinations useful for treating respiratory viral infections.
[0352] The combination of an inhaled β2-adrenergic agonist bronchodilator such as formoterol or salmeterol with ICS can be used to treat bronchoconstriction and inflammation (respectively and Combinations comprising these ICS and β2-adrenergic receptor agonist combinations and the compounds provided herein are also suitable, but non-limiting, combinations useful for treating respiratory viral infections.
[0353] Other examples of beta2 adrenergic receptor agonists include, but are not limited to, bedoradrine, vilanterol, indacaterol, olodaterol, tulobuterol, formoterol, abitrol, albuterol, arformoterol, levalbuterol, fenoterol, and TD-5471.
[0354] Anticholinergics
[0355] Anticholinergic agents have potential use for the treatment or prevention of pulmonary bronchoconstriction and thus may be used as additional therapeutic agents in combination with the compounds provided herein for the treatment of viral respiratory infections.These anticholinergics include, but are not limited to, antagonists of muscarinic receptors (particularly the M3 subtype), which have demonstrated therapeutic efficacy in humans for controlling cholinergic tone in COPD (Witek, 1999); 1-{4-hydroxy-1-[3,3,3-tris-(4-fluorophenyl)-propionyl]-pyrrolidine-2-carbonyl}-pyrrolidine-2-carboxylic acid (1-methyl-piperidin-4-ylmethyl)-amide; 3-[3-(2-diethylamino-acetoxy)-2-phenyl-propionyloxy]-8-isopropyl-8-methyl-8-azonia-bicyclo[3.2.1]octane (ipratropium-N,N-diethylglycinate); 1-cyclohexyl-3,4-dihydro-1H-isoquinolin-2-carboxylate; 1-Aza-bicyclo[2.2.2]oct-3-yl ester of 2-hydroxymethyl-4-methanesulfinyl-2-phenyl-butyric acid (Revatropate); 2-{1-[2-(2,3-dihydro-benzofuran-5-yl)-ethyl]-pyrrolidin-3-yl}-2,2-diphenyl-acetamide (Darifenacin); 4-Azacycloheptan-1-yl-2,2-diphenyl-butyramide (Buzepide); 7-[3-(2-diethylamino-acetoxy)-2-phenyl-propionyloxy]-9-ethyl-9-methyl-3-oxa-9-azonia-tricyclo[3.3.1.02,4]nonane (Oxytropine-N ,N-diethylglycinate); 7-[2-(2-diethylamino-acetoxy)-2,2-di-thiophen-2-yl-acetoxy]-9,9-dimethyl-3-oxa-9-azonia-tricyclo[3.3.1.02,4]nonane (tiotropium-N,N-diethylglycinate); dimethylamino-acetic acid 2-(3-diisopropylamino-1-phenyl-propyl)-4-methyl-phenyl ester (tolterodine-N,N-dimethylglycinate); 3-[4,4-bis-(4-fluorophenyl)-2-oxo-imidazolidin-1-yl]-1-methyl-1-(2-oxo-2-pyridin-2-yl-ethyl)-pyrrolidinium; 1-[1-(3-fluorobenzyl)-piperidin-4-yl]- 4,4-Bis-(4-fluorophenyl)-imidazolidin-2-one; 1-cyclooctyl-3-(3-methoxy-1-aza-bicyclo[2.2.2]octan-3-yl)-1-phenyl-prop-2-yn-1-ol; 3-[2-(2-diethylamino-acetoxy)-2,2-dithiophen-2-yl-acetoxy]-1-(3-phenoxy-propyl)-1-azonia-bicyclo[2.2.2]octane (aclidinium bromide-N,N-diethylglycinate); or (2-diethylamino-acetoxy)-dithiophen-2-yl-acetic acid 1-methyl-1-(2-phenoxy-ethyl)-piperidin-4-yl ester; revenacin, glycopyrrolate, umeclidinium, tiotropium, aclidinium, and bencyclidine.
[0356] mucolytics
[0357] The compounds provided herein can also be combined with mucolytics to treat symptoms of infection and respiratory tract infection. A non-limiting example of a mucolytic is ambroxol. Similarly, the compounds can be combined with expectorants to treat symptoms of infection and respiratory tract infection. A non-limiting example of an expectorant is guaifenesin.
[0358] Nebulized hypertonic saline is used to improve immediate and long-term clearance of the small airways in subjects with lung disease (Kuzik, J. Pediatrics 2007, 266). Therefore, the compounds provided herein can also be combined with nebulized hypertonic saline, particularly when viral infection is complicated by bronchiolitis. The combination of the compounds provided herein with hypertonic saline can also include any of the additional agents discussed above. In some embodiments, 3% hypertonic saline is used.
[0359] D. Combination Therapies for the Treatment of COPD
[0360] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any active therapeutic agent discussed in Section VIII herein and / or with other active therapeutic agents for treating respiratory exacerbations of COPD specifically discussed in Section VIII.D herein. In some embodiments, the other active therapeutic agents include other active agents for treating COPD. Non-limiting examples of these other active therapeutic agents include anti-IL5 antibodies, such as benralizumab, mepolizumab; dipeptidyl peptidase I (DPP1) inhibitors, such as AZD-7986 (INS-1007); DNA gyrase inhibitors / topoisomerase IV inhibitors, such as ciprofloxacin hydrochloride; MDR-related protein 4 / phosphodiesterase (PDE) 3 and 4 inhibitors, such as RPL-554; CFTR stimulants, such as ivacaftor, QBW-251; MMP-9 / MMP-12 inhibitors, such as RBx-10017609; adenosine A1 receptor antagonists, such as PBF-680; GATA 3 transcription factor inhibitors, such as SB-010; muscarinic receptor modulators / nicotinic acetylcholine receptor agonists, such as ASM-024; MARCKS protein inhibitors, such as BIO-11006; kit tyrosine kinase / PDGF inhibitors, such as masitinib; phosphodiesterase (PDE) 4 inhibitors, such as roflumilast and CHF-6001; phosphoinositide-3 kinase delta inhibitors, such as nemiralisib; 5-lipoxygenase inhibitors, such as TA-270; muscarinic receptor antagonists / β2 adrenergic receptor agonists, such as betafenadol succinate, AZD-887, and ipratropium bromide; TRN-157; elastase inhibitors, such as erdosteine; metalloproteinase-12 inhibitors, such as FP-025; Interleukin-18 ligand inhibitors, such as tadekinig α; skeletal muscle troponin activators, such as CK-2127107; p38 MAP kinase inhibitors, such as acumapimod; IL-17 receptor modulators, such as CNTO-6785; CXCR2 chemokine antagonists, such as danirixin; leukocyte elastase inhibitors, such as POL-6014; epoxide hydrolase inhibitors, such as GSK-2256294; HNE inhibitors, such as CHF-6333; VIP agonists, such as atidipidil; phosphoinositide-3 kinase δ / γ inhibitors, such as RV-1729; complement C3 inhibitors, such as APL-1; and G-protein coupled receptor-44 antagonists, such as AM-211.
[0361] Other non-limiting examples of active therapeutic agents also include, but are not limited to, budesonide, adipocell, nitric oxide, PUR-1800, YLP-001, LT-4001, azithromycin, gamunex, QBKPN, sodium pyruvate, MUL-1867, mannitol, MV-130, MEDI-3506, BI-443651, VR-096, OPK-0018, TEV-48107, doxofylline, TEV-46017, OligoG-COPD-5 / 20, ZP-051 and lysine acetylsalicylate.
[0362] In some embodiments, the other active therapeutic agent may be a vaccine with anti-COPD activity, including but not limited to MV-130 and GSK-2838497A.
[0363] E. Combination Therapies for the Treatment of Flaviviridae Virus Infections
[0364] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any of the active therapeutic agents discussed herein in Section VIII and / or with other active therapeutic agents specifically discussed herein in Section VIII.E for the treatment of Flaviviridae infections. In some embodiments, the other active therapeutic agent is active against Flaviviridae infections.
[0365] For the treatment of Flaviviridae infections, non-limiting examples of other active therapeutic agents are host cell factor modulators such as GBV-006; fenretinide ABX-220, BRM-211; alpha-glucosidase 1 inhibitors such as celgosivir; platelet-activating factor receptor (PAFR) antagonists such as modipaban; cadherin-5 / factor Ia modulators such as FX-06; NS4B inhibitors such as JNJ-8359; viral RNA splicing modulators such as ABX-202; NS5 polymerase inhibitors; NS3 protease inhibitors; and TLR modulators.
[0366] In some embodiments, the other active therapeutic agent may be a vaccine for the treatment or prevention of dengue fever, including but not limited to TETRAVAX-DV, DPIV-001, TAK-003, live attenuated dengue vaccine, quadrivalent dengue vaccine, quadrivalent DNA vaccine, rDEN2delta30-7169, and DENV-1PIV.
[0367] F. Combination Therapies for the Treatment of Filoviridae Infections
[0368] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any active therapeutic agent discussed in Section VIII herein and / or with other active therapeutic agents for treating Filoviridae infections specifically discussed in Section VIII.F herein. In some embodiments, the other active therapeutic agents are active against Filoviridae infections (e.g., Marburg virus, Ebola virus, Sudan virus, and Kuwa virus infections). Non-limiting examples of these other active therapeutic agents include: MR186-YTE, Remdesivir, Ribavirin, Palivizumab, Movizumab, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, amiodarone, dronedarone, verapamil, Ebola convalescent plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), TKM-Ebola, T-705 monophosphate, T-705 diphosphate, T-705 triphosphate, FGI-106 (1-N,7-N-bis[3-(dimethylamino)-3-nitropropene]pyrimidine-7-yl)pyrimidine-3,4-diol) )propyl]-3,9-dimethylquinolino[8,7-h]quinolone-1,7-diamine), rNAPc2, OS-2966, brincidofovir, remdesivir; RNA polymerase inhibitors such as galidesivir, favipiravir (also known as T-705 or Avigan), JK-05; host cell factor modulators such as GMV-006; cadherin-5 / factor Ia modulators such as FX-06; and antibodies for the treatment of Ebola such as INMAZEB (atevirumab, matevirumab, and osevirumab), ZMapp, and mAb114 (EBANGA).
[0369] Other non-limiting active therapeutic agents with anti-Ebola activity include, but are not limited to, alpha-glucosidase 1 inhibitors, cathepsin B inhibitors, CD29 antagonists, dendritic ICAM-3-grabbing non-integrin 1 inhibitors, estrogen receptor antagonists, factor VII antagonists, HLA class II antigen modulators, host cell factor modulators, interferon alpha ligands, neutral alpha-glucosidase AB inhibitors, Niemann-Pick C1 protein inhibitors, nucleoprotein inhibitors, polymerase cofactor VP35 inhibitors, serine protease inhibitors, tissue factor inhibitors, TLR-3 agonists, viral envelope glycoprotein inhibitors, and Ebola virus entry inhibitors (NPC1 inhibitors).
[0370] In some embodiments, the other active therapeutic agent may be a vaccine for the treatment or prevention of Ebola, including but not limited to VRC-EBOADC076-00-VP, adenovirus-based Ebola vaccine, rVSV-EBOV, rVSVN4CT1-EBOVGP, MVA-BN Filo+Ad26-ZEBOV regimen, INO-4212, VRC-EBODNA023-00-VP, VRC-EBOADC069-00-VP, GamEvac-combi vaccine, SRC VB vector, HPIV3 / EboGP vaccine, MVA-EBOZ, Ebola recombinant glycoprotein vaccine, Vaxart adenovirus vector 5-based Ebola vaccine, FiloVax vaccine, GOVX-E301, and GOVX-E302.
[0371] Compound provided herein can also be used in combination with phosphoramidate morpholino oligomers (PMOs), which are synthetic antisense oligonucleotide analogs designed to interfere with translation process by forming base pair duplexes with specific RNA sequences. The example of PMO includes but is not limited to AVI-7287, AVI-7288, AVI-7537, AVI-7539, AVI-6002 and AVI-6003.
[0372] The compounds provided herein are also intended for use with general care provided to subjects with Filoviridae infections, including parenteral fluids (including dextrose saline and Ringer's lactate) and nutrients, antibiotics (including metronidazole and cephalosporin antibiotics such as ceftriaxone and cefuroxime) and / or antifungal prophylaxis, fever and pain medications, antiemetics (such as metoclopramide) and / or antidiarrheal medications, vitamin and mineral supplements (including vitamin K and zinc sulfate), anti-inflammatory agents (such as ibuprofen), pain medications, and medications for other common diseases in the subject population, such as antimalarials (including artemether and artesunate-lumefantrine combination therapy), typhoid vaccines (including quinolone antibiotics such as ciprofloxacin, macrolide antibiotics such as azithromycin, cephalosporin antibiotics such as ceftriaxone, or aminopenicillins such as ampicillin) or shigellosis vaccines.
[0373] G. Combination Therapies for the Treatment of Influenza
[0374] The compounds disclosed herein and their pharmaceutically acceptable salts can be used in combination with any active therapeutic agent discussed in Section VIII herein and / or with other active therapeutic agents for treating influenza virus infection specifically discussed in Section VIII.G herein. In some embodiments, the compounds provided herein are also used in combination with other active therapeutic agents for treating influenza virus infection. The compounds and compositions provided herein are also used in combination with other active therapeutic agents. In some embodiments, the compounds provided herein can also be combined with influenza treatment. In some embodiments, when treating influenza virus, the compounds provided herein are used together with influenza treatment. In some embodiments, the compounds provided herein are used together with influenza treatment to treat a wider spectrum of respiratory viruses, such as those disclosed herein. In some embodiments, influenza treatment is a neuraminidase (NA) inhibitor. In some embodiments, influenza treatment is an M2 inhibitor. Examples of influenza treatments include, but are not limited to, AB-5080, ALS-1, amantadine, , AV-001, AV-5124, AVM-0703, Mabaloxavir CB-012, CC-42344, CD-388, CT-P27, Codivir, DAS-181, DNK-651, ENOB-FL-01, ENOB-FL-11, favipiravir, GP-584, GP-681, H-015, HC-imAb, HEC-116094HCl·3H2O, HNC-042, histamine glutarimide, IFV-PA, ingavirine, INI-2004, INNA-051, KYAH01-2019-121, laninamivir, monoprevir, niclosamide, nitazoxanide, norketotifen, NX-2016, oseltamivir phosphate Peramivir REVTx-99, rimantadine, S-416, SAB-176, STP-702, T-705IV, TG-1000, TJ-27, TSR-066, 7HP-349, VIR-2482, VIS-410, VIS-FLX, XC-221, zanamivir Zanamivir-dinitrophenyl conjugate, ZSP-1273, and ZX-7101A.
[0375] IX. Compound Preparation
[0376] In some embodiments, the present disclosure provides methods and intermediates that can be used to prepare the compounds disclosed herein or pharmaceutically acceptable salts thereof.
[0377] Compounds as disclosed herein can be purified by any method known in the art, including chromatographic methods, including but not limited to high performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including but not limited to normal phase and reverse phase and ionic resins. In some embodiments, the disclosed compounds are purified by silica gel and / or alumina chromatography.
[0378] During any of the methods for preparing the compounds provided herein, it may be necessary and / or desirable to protect sensitive or reactive groups on any molecule of interest. This can be accomplished by conventional protecting groups as described in standard texts such as TW Greene and PGM Wuts, "Protective Groups in Organic Synthesis," 4th edition, Wiley, New York 2006. The protecting groups can be removed at a convenient subsequent stage using methods known in the art.
[0379] The exemplary chemical entities that can be used for the method for embodiment will now be described by reference to the general preparation of this paper and the illustrative synthesis scheme of the specific example below. It will be appreciated by the skilled person that in order to obtain the various compounds herein, the starting material can be appropriately selected so that the final desired substituent is carried to produce the desired product by the reaction scheme that is carried out or not protected as the case may be. Alternatively, it may be necessary or desirable to replace the final desired substituent with a suitable group that can carry out the reaction scheme and optionally replace with the desired substituent. In addition, it will be appreciated by those skilled in the art that the conversion shown in the following scheme can be performed in any order compatible with the functionality of the specific side group.
[0380] The methods of the present disclosure generally provide a specific enantiomer or diastereomer as the desired product, although the stereochemistry of the enantiomer or diastereomer may not be determined in all cases. When the stereochemistry of a specific stereocenter in an enantiomer or diastereomer is not determined, the compound is drawn without showing any stereochemistry at that specific stereocenter, even though the compound may be substantially enantiomerically or diastereomerically pure.
[0381] Representative syntheses of compounds of the present disclosure are described in the following schemes and in the specific examples that follow.
[0382] Solution 1
[0383]
[0384] Scheme 1 shows the general synthesis of compounds to react intermediate I-2 with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR7 ) to give intermediate S1b. Thereafter, the acetonide is cleaved under acidic conditions (such as HCl) to give the final compound of type S1c.
[0385] Option 2
[0386]
[0387] Scheme 2 shows the general synthesis of the compounds, starting with the reaction of intermediate I-2 with 1,1-dimethoxy-N,N-dimethylmethanamine to give amidine-protected base S2a. S2a is reacted with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR under basic conditions (e.g., pyridine) to give a base containing a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR 7 ) to afford intermediate S2c. Cleavage of the acetonide and amidine protecting groups under acidic conditions (eg, HCl) affords final compounds of type S2d.
[0388] Option 3
[0389]
[0390] Scheme 3 shows the general synthesis of compounds, starting with the reaction of intermediate I-2 with carbonyldiimidazole (CDI) to give intermediate S3a. Coupling of S3a with alcohol S3b under basic conditions (e.g., DBU) gives intermediate S3c. Cleavage of the acetonide group under acidic conditions (e.g., HCl) gives final compounds of type S3d.
[0391] Option 4
[0392]
[0393] Scheme 4 shows the general synthesis of compounds starting with the reaction of compound 0 with anhydride S4a under basic conditions (eg DBU) to give final compounds of type S4b.
[0394] Option 5
[0395]
[0396] Scheme 5 shows the general synthesis of compounds, starting with the reaction of compound 0 with 1,1-dimethoxy-N,N-dimethylmethanamine to give the amidine-protected base S5a. The 5′-alcohol is protected with a silyl protecting group reagent (e.g., TBSCl) in the presence of a base (e.g., imidazole) to give the intermediate S5b. S5b is reacted with a leaving group (e.g., LG═Cl or anhydride -OC(═O)OR under basic conditions (e.g., pyridine) to give the intermediate S5b. 4) to give intermediates S5d and S5e. The silyl and amidine protecting groups are cleaved under acidic conditions (e.g., HCl) to give final compounds of type S5f and type S5g. Alternatively, intermediates S5d and S5e can be reacted under basic conditions (e.g., pyridine) with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR 5 ) to afford intermediates S5i and S5j. Cleavage of the silyl and amidine protecting groups under acidic conditions (eg, HCl) affords final compounds of type S5k and type S5l.
[0397] Option 6
[0398]
[0399] Scheme 6 shows the general synthesis of compounds, starting with the reaction of compound 0 with 1,1-dimethoxy-N,N-dimethylmethanamine to give the amidine-protected base S6a. The 5′-alcohol is protected with a silyl protecting group reagent (e.g., TBSCl) in the presence of a base (e.g., imidazole) to give the intermediate S6b. S6b is reacted with a leaving group (e.g., LG═Cl or anhydride -OC(═O)OR under basic conditions (e.g., pyridine) to give the intermediate S6b. 5 ) to give intermediates S6d and S6e. The silyl and amidine protecting groups are cleaved under acidic conditions (e.g., HCl) to give final compounds of type S6f and type S6g. Alternatively, intermediates S6d and S6e can be reacted with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR under basic conditions (e.g., pyridine) 4 ) to afford intermediates S6i and S6j. Cleavage of the silyl and amidine protecting groups under acidic conditions (eg, HCl) affords final compounds of type S6k and type S6l.
[0400] Option 7
[0401]
[0402] Scheme 7 shows the general synthesis of compounds to react intermediate I-2 with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR 7 ) to give intermediate S7b. Under basic conditions (such as DMAP), S7b is reacted with a leaving group (such as LG=Cl or anhydride -OC(=O)OR 12) to afford intermediate S7d. Cleavage of the silyl and amidine protecting groups under acidic conditions (eg, HCl) affords final compounds of type S7e.
[0403] Option 8
[0404]
[0405] Scheme 8 shows the general synthesis of compounds starting with the reaction of S1c with S8a in the presence of an iodide (e.g., KI) to give compounds of type S8b. Alternatively, S1c and S8c can be coupled in the presence of an iodide (e.g., KI) followed by cleavage of the benzyl group under hydrogenation conditions (e.g., H2, Pd / C) to give compounds of type S8d.
[0406] Option 9
[0407]
[0408] Scheme 9 shows the general synthesis of compounds, starting with the reaction of S1c with CDI to give compounds of type S9a.
[0409] Plan 10
[0410]
[0411] Scheme 10 shows the general synthesis of compounds, starting with the reaction of compound 0 with CDI to give compounds of type S10a and type S10b.
[0412] Plan 11
[0413]
[0414] Scheme 11 shows the general synthesis of compounds starting with the reaction of S1c with orthoformate S11a under acidic conditions (eg p-toluenesulfonic acid) to give compounds of type S11b.
[0415] Plan 12
[0416]
[0417] Scheme 12 shows the general synthesis of compounds starting with the reaction of compound 0 with orthoformate S12a under acidic conditions (eg p-toluenesulfonic acid) to give compounds of type S12b.
[0418] Plan 13
[0419]
[0420] Scheme 13 shows the general synthesis of compounds to react S5k with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR 7 ) is reacted with S13a to give a compound of type S13b.
[0421] Plan 14
[0422]
[0423] Scheme 14 shows the general synthesis of compounds to react S1c with a leaving group (e.g., LG=Cl or anhydride -OC(=O)OR b ) is reacted with S14a to give a compound of type S14b.
[0424] Plan 15
[0425]
[0426] Scheme 15 shows the general synthesis of compounds to react S1c with a leaving group (e.g., LG=Cl or anhydride -OC(=O)R) under basic conditions (e.g., DMAP) b ) is reacted with S15a to give a compound of type S15b.
[0427] Plan 16
[0428]
[0429] Scheme 16 shows the general synthesis of compounds to react intermediate I-1 with a leaving group (e.g., LG=Cl or anhydride -OC(=O)R under basic conditions (e.g., DMAP) b ) to give intermediate S15b. Removal of the silyl protecting group with a fluoride (such as TBAF) and cleavage of the acetonide under acidic conditions (such as HCl) affords compounds of type S16c.
[0430] Example
[0431] A. Abbreviation
[0432] Certain abbreviations and acronyms are used to describe the experimental details. Although most of these abbreviations and acronyms will be understood by those skilled in the art, Table 2 contains a list of many of these abbreviations and acronyms.
[0433] Table 2. List of abbreviations and acronyms
[0434]
[0435]
[0436] B.Intermediates
[0437] Intermediate I-1: (3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4- (((tert-Butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxetine Pentene-4-carbonitrile
[0438]
[0439] Intermediate I-1 was prepared according to WO2015 / 069939. For example, pages 127-138 of WO2015 / 069939 provide a method for preparing this compound (identified as compound 14k in WO2015 / 069939).
[0440] Intermediate I-2: (3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4- (Hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile
[0441]
[0442] Intermediate I-1 (18.87 mmol) is dissolved in THF (100 mL). TBAF 1.0 M (28.31 mmol) in THF is added once at ambient temperature. Stir for 10 min at ambient temperature. The reaction is determined to be complete by LCMS. The reaction mixture is quenched with water and organic matter is removed under reduced pressure. The crude product is distributed between EtOAc and water. The layers are separated and the aqueous phase is washed with EtOAc. The organic matter is combined and dried over sodium sulfate. The solid is filtered off and the solvent is removed under reduced pressure. The crude product is purified by silica gel chromatography (120 g chromatographic column, 0% to 10% CH 3 OH in CH 2 Cl 2) to obtain intermediate I-2. LC / MS: t R = 0.76 min, MS m / z = 332.14 [M+1]; LC system: Thermo Accela 1250 UHPLC. MS system: Thermo LCQ Fleet. Column: Kinetex 2.6μXB-C18100A, 50 × 3.00 mm. Solvent: Acetonitrile containing 0.1% formic acid, water containing 0.1% formic acid. Gradient: 2% to 100% ACN from 0 min to 2.4 min, 100% ACN from 2.4 min to 2.80 min, 100% to 2% ACN from 2.8 min to 2.85 min, 2% ACN from 2.85 min to 3.0 min, at a rate of 1.8 mL / min. 1H NMR (400MHz, DMSO-d6) δ7.87-7.80(m,3H),6.85(d,J=4.5Hz,1H),6.82(d,J=4.5Hz,1H),5.74(t,J=5.8Hz,1H),5.52(d, J=4.2Hz,1H),5.24(dd,J=6.8,4.2Hz,1H),4.92(d,J=6.8Hz,1H),3.65(dd,J=6.1,1.7Hz,2H),1.61(s,3H),1.33(s,3H).
[0443] Intermediate I-3: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyl ester
[0444]
[0445] To a solution of intermediate I-2 (3.0 mmol) and DMAP (0.76 mmol) in THF (10.0 mL) was added triethylamine (1.0 mL, 7.2 mmol). The solution was cooled in an ice bath, followed by addition of isobutyl chloroformate (0.47 mL, 3.6 mmol). The reaction mixture was stirred in an ice bath for 3 hours while reaching room temperature. The reactant was quenched with water (100 mL) and extracted with EtOAc (3 × 50 mL). The organic fractions were combined, washed with 1:1 brine: water, dried over Na2SO4, and concentrated in vacuo, then purified by silica gel chromatography (0%-10% EtOAc in hexane) to give intermediate I-3.
[0446] 1 H NMR (400MHz, DMSO-d6) δ7.94–7.74(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.7Hz,1H),5.10(d, J=6.6Hz,1H),4.51(d,J=11.5Hz,1H),4.40(d,J=11.5Hz,1H),3.92–3.87( m,2H),1.95–1.84(m,1H),1.64(s,3H),1.35(s,3H),0.87(d,J=6.7Hz,6H). MS m / z[M+1]=432.1.
[0447] Intermediate I-4: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl neopentyl ester
[0448]
[0449] To the solution of intermediate I-2 (0.45mmol) and DMAP (0.48mmol) in ACN (5.0mL) cooled in an ice bath, neopentyl chloroformate (68 μ L, 0.45mmol) is added. The solution is stirred in an ice bath for 3 hours, while gradually reaching room temperature. Reactant is processed with MeOH (0.5mL) and stirred at room temperature for 2 hours, then concentrated in vacuo. Crude residue is dissolved in EtOAc and filtered. The filtrate is concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexane) to obtain intermediate I-4.
[0450] 1 H NMR (400MHz, DMSO-d6) δ7.91–7.75(m,3H),6.87(d,J=4.6Hz,1H),6.83(d,J=4.4Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.6Hz ,1H),5.10(d,J=6.6Hz,1H),4.53(d,J=11.6Hz,1H),4.41(d,J=11.8Hz,1H),3.86–3.78(m,2H),1.64(s,3H),1.35(s,3H),0.89(s,9H). MS m / z[M+1]=446.1.
[0451] Intermediate I-5: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- methyl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0452]
[0453] Methyl chloroformate (51 μ L, 0.66 mmol) is added to the solution of intermediate I-2 (0.45 mmol) and DMAP (0.77 mmol) in ACN (5.0 mL) cooled in an ice bath. Reactant mixture is stirred in an ice bath, and room temperature is reached simultaneously for 2 hours 20 minutes, then processed and concentrated in vacuo with MeOH (0.5 mL). Crude material is dissolved in EtOAc and filtered. Filtrate is concentrated in vacuo, and thick residue is subjected to silica gel chromatography (0%-100% EtOAc / hexane), to obtain intermediate I-5.
[0454] 1H NMR (400MHz, DMSO-d6) δ7.99–7.67(m,3H),6.89–6.81(m,2H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.7,3.6Hz,1H ), 5.10 (d, J = 6.6Hz, 1H), 4.50 (d, J = 11.5Hz, 1H), 4.41 (d, J = 11.5Hz, 1H), 3.72 (s, 3H), 1.64 (s, 3H), 1.35 (s, 3H). MS m / z[M+1]=390.1.
[0455] Intermediate I-6: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylpropyl ester
[0456]
[0457] To the solution of intermediate I-2 (0.45mmol) and DMAP (0.77mmol) in ACN (5.0mL), propyl chloroformate (51 μL, 0.45mmol) is added. The reaction mixture is stirred at room temperature for 1 hour, then treated with MeOH (0.5mL) and concentrated in vacuo. The crude material is dissolved in EtOAc and filtered. After concentration, the residue is diluted with EtOAc (30mL) and water (30mL). Each layer is separated, and the aqueous layer is extracted again with EtOAc (30mL). The organic fractions are merged, washed with 1:1 water: brine (30mL), dried over Na2SO4, filtered, concentrated in vacuo, and silica gel chromatography (0%-100% EtOAc / hexane) is carried out to obtain intermediate I-6.
[0458] 1 H NMR (400MHz, DMSO-d6) δ7.94–7.75(m,3H),6.89–6.80(m,2H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.7,3.7Hz,1H),5.10(d,J=6.6Hz ,1H),4.50(d,J=11.6Hz,1H),4.40(d,J=11.5Hz,1H),4.05(t,J=6.6Hz,2H),1.67–1.55(m,5H),1.35(s,3H),0.87(t,J=7.4Hz,3H). MS m / z[M+1]=418.1.
[0459] Intermediate I-7: 1H-imidazole-1-carboxylic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2, 4-[(4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0460]
[0461] To a solution of intermediate I-2 (1.8 mmol) in ACN (20.0 mL) was added CDI (2.6 mmol). The solution was stirred at room temperature for 2.5 hours. The reactant was quenched with water (100 mL) and extracted with EtOAc (2 × 100 mL). The organic fractions were combined, washed with 1: 1 water: brine (80 mL), dried over MgSO, filtered and concentrated in vacuo to give intermediate I-7, which was used without further purification.
[0462] 1 H NMR (400MHz, DMSO-d6) δ8.28–8.26(m,1H),7.91–7.74(m,3H),7.60–7.57(m,1H),7.13–7.11(m,1H),6.84(d,J=4.4Hz,1H),6.80(d ,J=4.5Hz,1H),5.63(d,J=3.5Hz,1H),5.37–5.28(m,2H),4.86(d,J=11.6Hz,1H),4.73(d,J=11.6Hz,1H),1.66(s,3H),1.37(s,3H). MS m / z[M+1]=426.1.
[0463] Intermediate I-8: ((R)-sec-butyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1, 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0464]
[0465] To a solution of intermediate I-7 (0.47 mmol) in THF (5.0 mL) was added (R)-butan-2-ol (0.17 mL, 1.9 mmol) followed by a catalytic amount of DBU (one drop). The solution was stirred at room temperature for 1 hour before adding 2 more drops of DBU. Additional (R)-butan-2-ol (0.34 mL, 3.7 mmol, 7.9 equiv) was added and the solution was stirred for 20 minutes. The reaction mixture was concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexanes) to afford intermediate I-8.
[0466] 1H NMR (400MHz, DMSO-d6) δ7.92–7.75(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4. 5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.7,3.6Hz,1H),5.09(d,J=6.6Hz, 1H),4.65–4.55(m,1H),4.49(d,J=11.5Hz,1H),4.38(d,J=11.5Hz,1H),1.64(s ,3H),1.60–1.49(m,2H),1.35(s,3H),1.20(d,J=6.1Hz,3H),0.86–0.80(m,3H). MS m / z[M+1]=432.1.
[0467] Intermediate I-9: ((S)-sec-butyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1, 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0468]
[0469] To a solution of intermediate I-7 (0.34 mmol) in THF (5.0 mL) was added (S)-butan-2-ol (0.16 mL, 1.7 mmol) followed by DBU (0.02 mL, 0.14 mmol). The solution was stirred at room temperature for 3.5 hours. The reaction mixture was concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexane) to afford intermediate I-9.
[0470] 1 H NMR (400MHz, DMSO-d6) δ7.93–7.75(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4. 5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.6Hz,1H),5.09(d,J=6.6Hz, 1H),4.66–4.56(m,1H),4.50(d,J=11.5Hz,1H),4.38(d,J=11.5Hz,1H),1.64(s ,3H),1.61–1.50(m,2H),1.35(s,3H),1.18(d,J=6.3Hz,3H),0.88–0.82(m,3H). MS m / z[M+1]=432.1.
[0471] Intermediate I-10: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylpentan-3-yl ester
[0472]
[0473] To a solution of intermediate I-7 (0.35 mmol) in THF (5.0 mL) was added pentan-3-ol (0.15 mL, 1.4 mmol) followed by DBU (0.08 mL, 0.53 mmol). The solution was stirred at room temperature for 40 minutes before being concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexanes) to afford intermediate I-10.
[0474] 1 H NMR (400MHz, DMSO-d6) δ7.94–7.74(m,3H),6.86(d,J=4.4Hz,1H),6.83(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.31(dd,J=6.6, 3.6Hz,1H),5.09(d,J=6.7Hz,1H),4.56–4.46(m,2H),4.39(d,J=11.6Hz,1H),1.65–1.44(m,7H),1.35(s,3H),0.86–0.77(m,6H). MS m / z[M+1]=446.1.
[0475] Intermediate I-11: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isopropyl ester
[0476]
[0477] To a solution of intermediate I-7 (0.47 mmol) in THF (5.0 mL) was added isopropyl alcohol (0.14 mL, 1.9 mmol) followed by DBU (0.11 mL, 0.71 mmol). The solution was stirred at room temperature for 2 hours and 10 minutes. The reaction mixture was concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexane, then 0%-15% MeOH / EtOAc) to give intermediate I-11.
[0478] 1 H NMR (400MHz, DMSO-d6) δ7.93–7.76(m,3H),6.87(d,J=4.6Hz,1H),6.83(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.7Hz,1H ),5.09(d,J=6.6Hz,1H),4.82–4.71(m,1H),4.47(d,J=11.5Hz,1H),4.38(d,J=11.4Hz,1H),1.64(s,3H),1.35(s,3H),1.24–1.20(m,6H). MS m / z[M+1]=418.1.
[0479] Intermediate I-12: (7-((3aS,4S,6R,6aS)-6-cyano-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuran Isobutyl [3,4-d][1,3]dioxol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)carbamate
[0480]
[0481] To a solution of intermediate I-2 (0.45 mmol) and DMAP (0.26 mmol) in THF (5.0 mL) is added isobutyl chloroformate (0.06 mL, 0.45 mmol). The reaction mixture is stirred at room temperature for 5 hours and 30 minutes, then quenched with water and saturated NaHCO 1: 1 solution (20 mL) and extracted with EtOAc (2 × 20 mL). The organic fractions are combined, washed with brine (20 mL), dried over MgSO , filtered, concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexane) to give intermediate I-12.
[0482] 1 H NMR (400MHz, DMSO-d6) δ10.84(s,1H),8.29(s,1H),7.29–7.20(m,1H),7.10–7.02(m,1H),5.82–5.75(m,1H),5.62(d,J=3.9Hz,1H),5.29(dd,J=6 .7,4.0Hz,1H),4.96(d,J=6.7Hz,1H),3.99–3.93(m,2H),3.73–3.63(m, 2H), 2.05–1.90 (m, 1H), 1.64 (s, 3H), 1.35 (s, 3H), 0.96 (d, J = 6.7Hz, 6H). MS m / z[M+1]=432.1.
[0483] Intermediate I-13: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isopentyl ester
[0484]
[0485] To a mixture of intermediate I-2 (0.302 mmol) and isoamyl chloroformate (0.362 mmol) in ACN (2 mL) was added DMAP (0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-13.
[0486] 1H NMR (400 MHz, acetonitrile-d3) δ7.91 (s, 1H), 6.80 (d, J = 4.5 Hz, 1H), 6.77 (d, J = 4.5 Hz, 1H), 6.36 (s, 2H), 5.67 (d, J = 3.3 Hz, 1H), 5.32 (dd, J = 6.6, 3.4 Hz, 1H), 5.10 (d, J = 6.6 Hz, 1H ),4.50(d,J=11.3Hz,1H),4.43(d,J=11.3Hz,1H),4.18(m,2H),1.76–1.63(m,4H), 1.55(q,J=6.82Hz,2H), 1.39(s,3H), 0.94(d,J=1.3Hz,3H), 0.92(d,J=1.3Hz,3H). MS m / z[M+1]=446.0.
[0487] Intermediate I-14: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylcyclopentyl ester
[0488]
[0489] To a mixture of intermediate I-2 (0.302 mmol) and cyclopentyl chloroformate (0.045 mL, 0.362 mmol) in ACN (2 mL) was added DMAP (0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-14.
[0490] 1 H NMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.5Hz,1H),6.34(s,2H),5.67(d,J=3.3Hz,1H),5.32(dd,J=6.6,3.3H z,1H),5.14–5.00(m,2H),4.48(d,J=11.4Hz,1H),4.41(d,J=11.3Hz,1H),1.88(m,2H),1.81–1.67(m,7H),1.67–1.53(m,2H),1.39(s,3H). MS m / z[M+1]=443.9.
[0491] Intermediate I-15: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylphenethyl ester
[0492]
[0493] To a mixture of intermediate I-2 (0.341 mmol) and 2-phenylethyl chloroformate (0.409 mmol) in ACN (2 mL) was added DMAP (0.682 mmol). The resulting mixture was stirred at room temperature for 1 hour, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-15.
[0494] 1 H NMR (400MHz, acetonitrile-d3) δ7.91 (s, 1H), 7.37–7.22 (m, 5H), 6.79 (d, J = 4.5Hz, 1H), 6.77(d,J=4.5Hz,1H),6.30(s,2H),5.67(d,J=3.3Hz,1H),5.31(dd,J=6.7,3. 4Hz,1H),5.08(d,J=6.6Hz,1H),4.48(d,J=11.32Hz,1H),4.42(d,J=11.38Hz ,1H),4.37(t,J=6.8Hz,2H),2.98(t,J=6.8Hz,2H),1.72(s,3H),1.39(s,3H). MS m / z[M+1]=479.9.
[0495] Intermediate I-16: (1-methylcyclopropyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl) Methyl ester
[0496]
[0497] DBU (0.11mL, 0.71mmol) is added once in the solution of 1-methylcyclopropane-1-ol (0.17mL, 1.9mmol) in THF (5mL), and stirred at room temperature for 10 minutes.Intermediate I-7 (0.47mmol) is added once in the mixture stirred for a further 2 hours. The reaction mixture is concentrated in vacuo, the crude product is dissolved in DCM, loaded on 40g gold posts, eluted with hexane for 3 minutes, eluted with DCM for 1 minute, and eluted with 0%-100% EtOAc / DCM, to obtain intermediate I-16.
[0498] 1H NMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.5Hz,1H),6.28(s,2H),5.67(d,J=3.2Hz,1H),5.32(dd,J=6.6,3.4Hz,1H),5 .09(d,J=6.5Hz,1H),4.48(d,J=11.3Hz,1H),4.39(d,J=11.3Hz,1H),1.7 2(s,3H),1.53(s,3H),1.39(s,3H),0.95-0.92(m,2H),0.72–0.63(m,2H). MS m / z[M+1]=429.9.
[0499] Intermediate I-17: (tetrahydro-2H-pyran-4-yl)carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2, 1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole- 4-aminobenzoic acid methyl ester
[0500]
[0501] To a mixture of intermediate I-2 (0.302 mmol) and tetrahydropyran-4-yl chloroformate (0.362 mmol) in ACN (2 mL) was added DMAP (0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-17.
[0502] 1H NMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.5Hz ,1H),6.34(s,2H),5.68(d,J=3.3Hz,1H),5.33(dd,J=6.6,3.4Hz,1H),5.10 (d,J=6.6Hz,1H),4.79(m,1H),4.50(d,J=11.3Hz,1H),4.44(d,J=11.4Hz,1 H),3.85(m,2H),3.48(m,2H),1.95(m,2H),1.74–1.61(m,5H),1.39(s,3H). MS m / z[M+1]=459.9.
[0503] Intermediate I-18: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl cyclobutane
[0504]
[0505] To a solution of intermediate I-2 (0.2g, 0.604mmol) in ACN (3.0mL) is added DMAP (147mg, 1.21mmol) and cooled to 0°C. To the well-stirred mixture is added cyclobutyl chloroformate (99mg, 0.73mmol). The solution is warmed to room temperature and stirred for 30 minutes. The reactant is treated with MeOH (0.1mL) and stirred at room temperature for 10 minutes, then concentrated in vacuo. The crude residue is dissolved in EtOAc and filtered. The filtrate is concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / DCM) to obtain intermediate I-18. 1 H NMR (400MHz, DMSO-d6) δ7.90(s,1H),7.86(s,2H),6.88(d,J=4.5Hz,1H),6.84(d,J=4 .5Hz,1H),5.62(d,J=3.6Hz,1H),5.31(dd,J=6.6,3.6Hz,1H),5.10(d,J=6.7Hz,1H), 4.88-4.81(m,1H),4.48(d,J=11.5Hz,1H),4.39(d,J=11.5Hz,1H),2.31-2.23(m,2H) ,2.09–2.00(m,2H),1.82–1.67(m,1H),1.65(s,3H),1.61–1.51(m,1H),1.36(s,3H). MS m / z[M+1]=429.96.
[0506] Intermediate I-19A: (Z)-N'-(7-((3aS,4S,6R,6aS)-6-cyano-6-(hydroxymethyl)-2,2-dimethyltetrakis N,N-dihydrofuro[3,4-d][1,3]dioxol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)- Methylformamidine
[0507]
[0508] To a suspension of intermediate I-2 (3000 mg, 9.1 mmol) in toluene (20 mL) was added N,N-dimethylformamide dimethyl acetal (2.4 mL, 18 mmol) and heated at 50°C for 1 hour, during which time the reaction mixture became clear. LC-MS showed complete conversion to product. Toluene was distilled off; the residue was dissolved in 10 mL of methanol, 100 mL of water was added, and the mixture was stirred overnight. The precipitate was filtered and air-dried to give intermediate I-19A. MS m / z[M+1] = 387.1.
[0509] Intermediate I-19: ((3aS,4R,6S,6aS)-4-cyano-6-(4-(((Z)-(dimethylamino)methylene)amino)carbonic acid 1-f][1,2,4]triazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxadiene 4-pentenyl)methyl cyclooctyl ester
[0510]
[0511] To a solution of intermediate I-19A (500 mg, 1.3 mmol) in acetonitrile (5 mL) was added bis(2,5-dioxopyrrolidin-1-yl) carbonate (663 mg, 2.6 mmol), followed by triethylamine (0.72 mL, 5.2 mmol) and stirred at room temperature for 90 minutes. LC-MS showed the formation of intermediate (2,5-dioxopyrrolidin-1-yl)carbonate [(3aS,4R,6S,6aS)-4-cyano-6-[4-[(Z)-dimethylaminomethyleneamino]pyrrolo[2,1-f][1,2,4]triazin-7-yl]-2,2-dimethyl-6,6a-dihydro-3aH-furo[3,4-d][1,3]dioxol-4-yl]methyl ester (MS m / z[M+1]=528.1). To the reaction mixture was added cyclooctanol (1 mL, 7.8 mL), followed by dimethylaminopyridine (158 mg, 1.3 mmol) and stirring continued for 3 hours. After completion of the reaction, the reaction mixture was diluted with ethyl acetate (50 mL), washed with water and brine, dried, concentrated, and used in the next step. LC-MS (MS m / z [M+1] = 541.2).
[0512] Intermediate I-20: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylhexyl ester
[0513]
[0514] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 1H-imidazole-1-carboxylate (157 mg, 0.37 mmol, 1.0 equiv) in THF (5.0 mL) was added hexan-1-ol (0.23 mL, 1.8 mmol, 5.0 equiv) followed by DBU (0.08 mL, 0.55 mmol, 1.5 equiv). The solution was stirred at room temperature for 2 h before being concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexanes) to afford the title compound, Intermediate I-20. 1H NMR (400MHz, DMSO-d6) δ7.93–7.74(m,3H),6.87(d,J=4.5Hz,1H),6.82(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.7Hz,1H),5.0 9(d,J=6.6Hz,1H),4.50(d,J=11.5Hz,1H),4.40(d,J=11.5Hz,1H),4.12 –4.06(m,2H),1.67–1.52(m,5H),1.38–1.20(m,9H),0.88–0.81(m,3H). MS m / z[M+1]=460.1.
[0515] Intermediate I-21: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylpentyl ester
[0516]
[0517] To a solution of (3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile (150 mg, 0.45 mmol, 1.0 equiv) and DMAP (75 mg, 0.61 mmol, 1.4 equiv) in ACN (5.0 mL) was added amyl chloroformate (0.07 mL, 0.50 mmol, 1.1 equiv). The solution was stirred at room temperature for 1 hour and 40 minutes. The reaction was treated with MeOH (0.5 mL) and concentrated in vacuo. The crude residue was dissolved in EtOAc and filtered. The filtrate was concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexanes) to give the title compound, Intermediate I-21. 1 H NMR (400MHz, DMSO-d6) δ7.94–7.75(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.7,3.7Hz,1H),5.09(d,J =6.6Hz,1H),4.50(d,J=11.5Hz,1H),4.40(d,J=11.5Hz,1H),4.11–4.06(m, 2H),1.66–1.53(m,5H),1.35(s,3H),1.32–1.23(m,4H),0.89–0.81(m,3H). MS m / z[M+1]=446.1.
[0518] Intermediate I-22: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl cyclohexyl ester
[0519]
[0520] A round-bottom flask was charged with ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 1H-imidazole-1-carboxylate (173 mg, 0.41 mmol, 1.0 equiv). Cyclohexanol (253 mg, 2.5 mmol, 6.2 equiv) dissolved in THF (5.0 mL) was transferred to the flask followed by DBU (0.09 mL, 0.61 mmol, 1.5 equiv). The solution was stirred at room temperature for 2 h 30 min before being concentrated in vacuo and subjected to silica gel chromatography (0% to 100% EtOAc / hexanes) to provide the title compound, Intermediate I-22. 1 H NMR (400MHz, DMSO-d6) δ7.96–7.72(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.7 Hz,1H),5.09(d,J=6.6Hz,1H),4.57–4.44(m,2H),4.38(d,J=11.5Hz,1H),1.88–1.76(m,2H),1.70–1.59(m,5H),1.52–1.20(m,9H). MS m / z[M+1]=458.1.
[0521] Intermediate 23: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ethyl ester
[0522]
[0523] To a solution of (3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile (203 mg, 0.61 mmol, 1.0 equiv) and DMAP (95 mg, 0.78 mmol, 1.3 equiv) in ACN (5.0 mL) was added ethyl chloroformate (0.06 mL, 0.67 mmol, 1.1 equiv). The solution was stirred at room temperature for 1 hour. The reaction was treated with MeOH (0.5 mL) and concentrated in vacuo. The crude residue was dissolved in EtOAc and filtered. The filtrate was concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexanes) to give the title compound, Intermediate I-23. 1 H NMR (400MHz, DMSO-d6) δ7.97–7.73(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4.5Hz,1H),5.62(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.7Hz,1H),5 .10(d,J=6.6Hz,1H),4.49(d,J=11.5Hz,1H),4.40(d,J=11.4Hz,1H),4.14(q,J=7.1Hz,2H),1.64(s,3H),1.35(s,3H),1.21(t,J=7.1Hz,3H). MS m / z[M+1]=404.1.
[0524] Intermediate 24: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylcyclopropyl ester
[0525]
[0526] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 1H-imidazole-1-carboxylate (150 mg, 0.35 mmol, 1.0 equiv) in THF (5.0 mL) was added cyclopropanol (0.05 mL, 0.78 mmol, 2.2 equiv) followed by DBU (0.08 mL, 0.53 mmol, 1.5 equiv). The solution was stirred at room temperature for 45 minutes before being concentrated in vacuo and subjected to silica gel chromatography (0%-100% EtOAc / hexanes) to afford Intermediate I-24. 1H NMR (400MHz, DMSO-d6) δ7.94–7.74(m,3H),6.87(d,J=4.5Hz,1H),6.82(d,J=4.5Hz,1H),5.61(d,J=3.6Hz,1H),5.30(dd,J=6.6,3.7Hz,1H ),5.09(d,J=6.6Hz,1H),4.51(d,J=11.5Hz,1H),4.41(d,J=11.5Hz,1H),4.14–4.07(m,1H),1.64(s,3H),1.35(s,3H),0.73–0.66(m,4H). MS m / z[M+1]=416.1.
[0527] Intermediate I-25: ((R)-tetrahydrofuran-3-yl)carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2, 1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole- 4-aminobenzoic acid methyl ester
[0528]
[0529] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 1H-imidazole-1-carboxylate (109 mg, 0.26 mmol, 1.0 equiv) in THF (5.0 mL) was added (R)-tetrahydrofuran-3-ol (94 mg, 1.1 mmol, 4.2 equiv) followed by DBU (0.06 mL, 0.38 mmol, 1.5 equiv). The solution was stirred at room temperature for 15 minutes before being concentrated in vacuo and chromatographed twice on silica gel (0% to 100% EtOAc / hexanes) to provide intermediate I-25. 1 H NMR (400MHz, DMSO-d6) δ7.98–7.69(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4 .5Hz,1H),5.62(d,J=3.6Hz,1H),5.31(dd,J=6.6,3.6Hz,1H),5.19–5.14(m,1H ),5.10(d,J=6.6Hz,1H),4.50(d,J=11.5Hz,1H),4.40(d,J=11.5Hz,1H),3.83 –3.61(m,4H),2.21–2.09(m,1H),2.02–1.85(m,1H),1.63(s,3H),1.35(s,3H). MS m / z[M+1]=446.1.
[0530] Intermediate I-26: 1H-imidazole-1-carboxylic acid 1,1-difluoro-2-methylprop-2-yl ester
[0531]
[0532] To a solution of CDI (1.18 g, 7.28 mmol, 1.27 equiv) in DCM (15.0 mL) cooled in an ice bath was added 1,1-difluoro-2-methylpropan-2-ol (632 mg, 5.74 mmol, 1.0 equiv) dissolved in DCM (3.0 mL). The reaction mixture was stirred at room temperature for 2 days before being diluted with DCM (75 mL) and water (75 mL). The layers were separated and the organic phase was dried over Na2SO4, filtered, and concentrated in vacuo without further purification. 1 H NMR (400 MHz, chloroform-d) δ 8.09–8.06 (m, 1H), 7.38–7.35 (m, 1H), 7.08–7.05 (m, 1H), 6.07 (t, J = 56.2 Hz, 1H), 1.70–1.66 (m, 6H). 19 F NMR (376 MHz, chloroform-d) δ -132.72–-132.96 (m).
[0533] Intermediate I-27: (1,1-difluoro-2-methylpropan-2-yl)carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrole) 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxadiazole 4-pentenyl)methyl ester
[0534]
[0535] To a solution of (3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile (150 mg, 0.453 mmol, 1.0 equiv) and 1,1-difluoro-2-methylpropan-2-yl 1H-imidazole-1-carboxylate (111 mg, 0.543 mmol, 1.2 equiv) in ACN (3.0 mL) was added DBU (0.03 mL, 0.226 mmol, 0.50 equiv). The reaction mixture was stirred at room temperature overnight. The solution was diluted with EtOAc (100 mL) and water (100 mL). The organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered, concentrated in vacuo and purified by silica gel chromatography (0%-100% EtOAc / hexanes) to provide intermediate 1-27. 1HNMR (400MHz, DMSO-d6) δ7.93–7.76(m,3H),6.87(d,J=4.5Hz,1H),6.83(d,J=4.5Hz,1H),6.17(t,J=55.4Hz,1H),5.62(d,J=3.6Hz,1H),5.3 1(dd,J=6.6,3.7Hz,1H),5.10(d,J=6.7Hz,1H),4.50(d,J=11.5Hz,1H),4.38(d,J=11.5Hz,1H),1.64(s,3H),1.48–1.43(m,6H),1.35(s,3H). 19 F NMR(376MHz,DMSO-d6)δ-132.96–-133.25(m). MS m / z[M+1]=467.9.
[0536] Intermediate I-28: ((S)-2-Methylbutyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1- f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-yl methyl ester
[0537]
[0538] To a mixture of intermediate I-2 (100 mg, 0.302 mmol) and (S)-2-methylbutyl chloroformate (0.0545 g, 0.362 mmol) in ACN (2 mL) was added DMAP (74 mg, 0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-28. 1 HNMR (400 MHz, acetonitrile-d3) δ7.91 (s, 1H), 6.80 (d, J = 4.5 Hz, 1H), 6.77 (d, J = 4.5 Hz, 1H), 6.36 (s, 2H), 5.68 (d, J = 3.3 Hz, 1H), 5.32 (dd, J = 6.6, 3.4 Hz, 1H), 5.10 (d, J = 6.6 Hz, 1H), 4.51 (d, J = 11.4 Hz, 1H), 4. 43(d,J=11.3Hz,1H),4.05(ddd,J=10.5,6.0,1.9Hz,1H),3.96(ddd,J=10.5,6.6,2.1Hz,1H),1.84 –1.65(m,4H),1.52–1.34(m,4H),1.29–1.13(m,1H),0.93(d,J=0.7Hz,3H),0.92(d,J=1.1Hz,3H). MS m / z[M+1]=446.0.
[0539] Intermediate I-29: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylbenzyl ester
[0540]
[0541] To a mixture of intermediate I-2 (100 mg, 0.302 mmol) and benzyl chloroformate (61.8 mg, 0.362 mmol) in ACN (2 mL) was added DMAP (74 mg, 0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-29. 1 HNMR (400MHz, acetonitrile-d3) δ7.90(s,1H),7.40(d,J=3.4Hz,5H),6.79(d,J=4.5Hz,1H),6.76(d,J=4.6Hz,1H),6.39(s,2H),5.68(d,J=3.4Hz,1H) ,5.31(dd,J=6.6,3.4Hz,1H),5.18(s,2H),5.10(d,J=6.6Hz,1H),4.54(d,J=11.4Hz,1H),4.47(d,J=11.3Hz,1H),1.72(s,3H),1.38(s,3H). MS m / z[M+1]=465.7.
[0542] Intermediate I-30: (cyclopentylmethyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1, 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0543]
[0544] To a solution of intermediate I-7 (150 mg, 1.40 mmol) in THF (2 mL) was added cyclopentylmethanol (0.15 mL, 1.4 mmol) followed by DBU (0.08 mL, 0.53 mmol). The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo and purified by silica gel chromatography (0% to 5% MeOH / DCM) to give intermediate I-30. 1H NMR (400 MHz, acetonitrile-d3) δ7.91 (s, 1H), 6.80 (d, J = 4.5 Hz, 1H), 6.77 (d, J = 4.5 Hz, 1H), 6.28 (s, 2H), 5.68 (d, J = 3.3 Hz, 1H), 5.32 (dd, J = 6.7, 3.4 Hz, 1H), 5.10 (d, J = 6.6 Hz, 1H ),4.50(d,J=11.4Hz,1H),4.43(d,J=11.3Hz,1H),4.05(d,J=7.2Hz,2H),2.33–2.1 7(m,1H),1.84–1.67(m,5H),1.67–1.53(m,4H),1.40(s,3H),1.36–1.20(m,2H); MS m / z[M+1]=458.0.
[0545] Intermediate I-31: (2-Ethylbutyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1, 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0546]
[0547] To a mixture of intermediate I-2 (100 mg, 0.302 mmol) and 2-ethylbutyl chloroformate (0.058 mL, 0.362 mmol) in ACN (2 mL) was added DMAP (74 mg, 0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-31. 1 HNMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.4Hz,1H ),6.32(s,2H),5.68(d,J=3.3Hz,1H),5.32(dd,J=6.7,3.3Hz,1H),5.10(d,J=6. 6Hz,1H),4.51(d,J=11.4Hz,1H),4.43(d,J=11.4Hz,1H),4.10(d,J=5.8Hz,2H), 1.72(s,3H),1.56(p,J=6.2Hz,1H),1.43–1.30(m,7H),0.91(t,J=7.5Hz,6H);MS m / z[M+1]=460.0.
[0548] Intermediate I-32: (cyclopropylmethyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1, 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ester
[0549]
[0550] To a mixture of intermediate I-2 (100 mg, 0.302 mmol) and cyclopropylmethyl chloroformate (48.7 mg, 0.362 mmol) in ACN (2 mL) was added DMAP (74 mg, 0.604 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-32. 1 HNMR(400MHz, acetonitrile-d3)δ7.92(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.5Hz,1H), 6.29(s,2H),5.68(d,J=3.4Hz,1H),5.32(dd,J=6.6,3.4Hz,1H),5.11(d,J=6.6Hz ,1H),4.49(d,J=11.3Hz,1H),4.44(d,J=11.3Hz,1H),3.98(d,J=7.4Hz,2H),1.72 (s,3H),1.40(s,3H),1.22–1.04(m,1H),0.63–0.54(m,2H),0.38–0.26(m,2H); MS m / z[M+1]=430.0.
[0551] Intermediate I-33A: (S)-tetrahydrofuran-3-yl chloroformate
[0552]
[0553] To a solution of (3S)-tetrahydrofuran-3-ol (0.67 mL, 8.4 mmol) and pyridine (0.68 mL, 8.4 mmol) in DCM (5.0 mL) was added triphosgene (1000 mg, 3.4 mmol) in portions at 0°C (generating gas). The resulting mixture was stirred at room temperature for 15 hours, hexane (50 mL) was added, filtered and concentrated in vacuo at 17°C. The resulting residue was treated with hexane (20 mL), filtered and concentrated in vacuo at 17°C to give intermediate I-33A (approximately 500 mg), which was used in the next reaction without further purification. 1 H NMR (400 MHz, CHLOROFORM-d) δ 5.45-5.39 (m, 1H), 4.04-3.88 (m, 4H), 2.35-2.16 (m, 2H).
[0554] Intermediate I-33: ((S)-tetrahydrofuran-3-yl)carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2, 1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole- 4-aminobenzoic acid methyl ester
[0555]
[0556] To a mixture of intermediate I-2 (200 mg, 0.604 mmol) and DMAP (147 mg, 1.21 mmol) in ACN (4 mL) was added intermediate I-33A (109 mg, 0.724 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-33. 1 H NMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.81(d,J=4.5Hz,1H),6.77(d,J=4.5Hz ,1H),6.27(s,2H),5.68(d,J=3.3Hz,1H),5.33(dd,J=6.6,3.4Hz,1H),5.22 -5.14(m,1H),5.11(d,J=6.7Hz,1H),4.50(d,J=11.3Hz,1H),4.46(d,J=11.3Hz ,1H),3.99–3.63(m,4H),2.124-1.93(m,2H),1.72(s,3H),1.42–1.35(m,3H);MS m / z[M+1]=445.9.
[0557] Intermediate I-34: (2-Propoxyethyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl) Methyl ester
[0558]
[0559] To a mixture of intermediate I-2 (100 mg, 0.604 mmol) and DMAP (74 mg, 0.604 mmol) in ACN (2 mL) was added 2-propoxyethyl chloroformate (60.3 mg, 0.362 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-34. 1HNMR (400 MHz, acetonitrile-d3) δ7.92 (s, 1H), 6.80 (d, J = 4.5 Hz, 1H), 6.77 (dd, J = 4.5, 0.8 Hz, 1H), 6.37 (s, 2H), 5.68 (d, J = 3.3 Hz, 1H), 5.35–5.25 (m, 1H), 5.11 (d, J = 6.6 Hz, 1H), 4.5 0(d,J=11.3Hz,1H),4.46(d,J=11.6Hz,1H),4.29–4.23(m,2H),3.68–3.60(m,2H),3. 44–3.37(m,2H),1.72(s,3H),1.62–1.51(m,2H),1.39(s,3H),0.90(t,J=7.8Hz,3H). MS m / z[M+1]=462.0.
[0560] Intermediate I-35A: 3,3-dimethylbutyl chloroformate
[0561]
[0562] To a solution of 3,3-dimethylbutan-1-ol (1.2 mL, 4.0 mmol) and pyridine (0.81 mL, 10 mmol) in DCM (10 mL) was added triphosgene (1200 mg, 4.0 mmol) in portions at 0 ° C. The resulting mixture was stirred at room temperature for 18 hours, hexane (50 mL) was added, filtered and concentrated in vacuo at 17 ° C. The resulting residue was treated with hexane (20 mL), filtered and concentrated in vacuo at 17 ° C to give intermediate I-35A (995 mg). 1 H NMR (400 MHz, CHLOROFORM-d) δ 4.40 (t, J = 7.5 Hz, 2H), 1.69 (t, J = 7.5 Hz, 2H), 0.98 (s, 9H).
[0563] Intermediate I-35: (3,3-dimethylbutyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1- f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-yl methyl ester
[0564]
[0565] To a mixture of intermediate I-2 (100 mg, 0.604 mmol) and DMAP (147 mg, 1.21 mmol) in ACN (4 mL) was added BQ6784-1 (119 mg, 0.724 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-35. 1H NMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.5Hz ,1H),6.31(s,2H),5.67(d,J=3.3Hz,1H),5.32(dd,J=6.6,3.4Hz,1H),5.10 (d,J=6.6Hz,1H),4.50(d,J=11.4Hz,1H),4.43(d,J=11.4Hz,1H),4.21(t,J =7.5Hz,2H),1.72(s,3H),1.60(t,J=7.5Hz,2H),1.39(s,3H),0.95(s,9H). MS m / z[M+1]=460.0.
[0566] Intermediate I-36: Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7- 2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylspiro[3.3]heptyl- 2-amino ester
[0567]
[0568] To a mixture of intermediate I-2 (100 mg, 0.604 mmol) and DMAP (147 mg, 1.21 mmol) in ACN (4 mL) was added spiro[3.3]hept-2-yl chloroformate (126 mg, 0.724 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-36. 1 HNMR (400MHz, acetonitrile-d3) δ7.91 (s, 1H), 6.80 (d, J = 4.5Hz, 1H), 6.77 (d, J = 4.5Hz, 1H) ,6.31(s,2H),5.67(d,J=3.3Hz,1H),5.32(dd,J=6.6,3.3Hz,1H),5.09(d,J=6.6H z,1H),4.78(p,J=7.2Hz,1H),4.47(d,J=11.4Hz,1H),4.40(d,J=11.3Hz,1H),2. 57–2.30(m,2H),2.10–1.94(m,6H),1.89–1.79(m,2H),1.72(s,3H),1.39(s,3H). MS m / z[M+1]=469.9.
[0569] Intermediate I-37A: 3,3-dimethylcyclobutyl chloroformate
[0570]
[0571] To a solution of 3,3-dimethylcyclobutan-1-ol (0.67 mL, 8.40 mmol) and pyridine (0.68 mL, 8.40 mmol) in DCM (10 mL) was added triphosgene (1000 mg, 3.40 mmol) in portions at 0 ° C. The resulting mixture was stirred at room temperature for 15 hours, hexane (50 mL) was added, filtered, and concentrated in vacuo at 17 ° C. The resulting residue was treated with hexane (20 mL), filtered, and concentrated in vacuo at 17 ° C to give intermediate I-37A (645 mg). 1 H NMR (400 MHz, CHLOROFORM-d) δ 5.14 (p, J = 7.2 Hz, 1H), 2.35–2.28 (m, 2H), 2.09–1.99 (m, 2H), 1.21 (s, 3H), 1.16 (s, 3H).
[0572] Intermediate 37: (3,3-Dimethylcyclobutyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1- f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-yl methyl ester
[0573]
[0574] To a mixture of intermediate I-2 (150 mg, 0.453 mmol) and DMAP (111 mg, 0.905 mmol) in ACN (3 mL) was added intermediate I-37A (88.3 mg, 0.543 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-37. 1 H NMR (400 MHz, acetonitrile-d3) δ7.91 (s, 1H), 6.80 (d, J = 4.5 Hz, 1H), 6.77 (d, J = 4.5 Hz, 1H), 6.29 (s, 2H), 5.67 (d, J = 3.4 Hz, 1H), 5.32 (dd, J = 6.6, 3.4 Hz, 1H), 5.09 (d, J = 6.6 Hz, 1 H),4.93(p,J=7.2Hz,1H),4.48(d,J=11.3Hz,1H),4.41(d,J=11.3Hz,1H),2.30–2. 17(m,2H),1.96–1.84(m,2H),1.72(s,3H),1.39(s,3H),1.17(s,3H),1.14(s,3H). MS m / z[M+1]=458.0.
[0575] Intermediate 38A: (R)-1-methoxyprop-2-yl chloroformate
[0576]
[0577] To a solution of (2R)-1-methoxypropan-2-ol (0.84 mL, 8.4 mmol) and pyridine (0.68 mL, 8.4 mmol) in DCM (10 mL) was added triphosgene (1000 mg, 3.4 mmol) in portions at 0°C (evolving gas). The resulting mixture was stirred at room temperature for 15 hours, hexane (50 mL) was added, filtered, and concentrated in vacuo at 17°C. The resulting residue was treated with hexane (20 mL), filtered, and concentrated in vacuo at 17°C to afford Intermediate I-38A. 1 H NMR (400 MHz, chloroform-d) δ 5.15 (td, J = 6.5, 3.9 Hz, 1H), 3.59–3.46 (m, 2H), 3.41 (s, 3H), 1.38 (d, J = 6.5 Hz, 3H).
[0578] Intermediate 38: ((R)-1-methoxypropan-2-yl)carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2, 1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole- 4-aminobenzoic acid methyl ester
[0579]
[0580] To a mixture of intermediate I-2 (200 mg, 0.604 mmol) and DMAP (147 mg, 1.21 mmol) in ACN (4 mL) was added intermediate I-38A (111.0 mg, 0.724 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-38. 1 H NMR (400MHz, acetonitrile-d3) δ7.92(s,1H),6.81(d,J=4.5Hz,1H),6.77(d,J=4.5Hz,1H) ,6.28(s,2H),5.67(d,J=3.4Hz,1H),5.32(dd,J=6.6,3.4Hz,1H),5.10(d,J=6. 6Hz,1H),4.94–4.81(m,1H),4.49(d,J=11.3Hz,1H),4.44(d,J=11.3Hz,1H),3. 50–3.37(m,2H),3.31(s,3H),1.72(s,3H),1.40(s,3H),1.25(d,J=6.5Hz,3H). MS m / z[M+1]=448.0.
[0581] Intermediate I-39A: (1R,3r,5S)-bicyclo[3.1.0]hex-3-yl chloroformate
[0582]
[0583] To a solution of (1S,5R)-bicyclo[3.1.0]hexan-3-ol (0.67 mL, 8.4 mmol) and pyridine (0.81 mL, 10.00 mmol) in DCM (10 mL) was added triphosgene (1200 mg, 4.0 mmol) in portions at 0 ° C (generating gas). The resulting mixture was stirred at room temperature for 15 hours, hexane (50 mL) was added, filtered, and concentrated in vacuo at 17 ° C. The resulting residue was treated with hexane (20 mL), filtered, and concentrated in vacuo at 17 ° C to give Intermediate I-39A. 1 HNMR (400 MHz, chloroform-d) δ 5.32 (t, J = 6.7 Hz, 1H), 2.31–2.21 (m, 2H), 2.07 (s, 1H), 2.03 (s, 1H), 1.43–1.34 (m, 2H), 0.68–0.53 (m, 1H), 0.44-0.37 (m, 1H).
[0584] Intermediate 39: ((1R,3r,5S)-bicyclo[3.1.0]hexan-3-yl)carbonic acid ((3aS,4R,6S,6aS)-6-(4-amino pyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]diol oxol-4-yl)methyl ester
[0585]
[0586] To a mixture of intermediate I-2 (200 mg, 0.604 mmol) and DMAP (147 mg, 1.21 mmol) in ACN (4 mL) was added intermediate I-39A (116.0 mg, 0.724 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-39. 1 H NMR (400 MHz, acetonitrile-d3) δ7.91 (s, 1H), 6.80 (d, J = 4.5 Hz, 1H), 6.77 (d, J = 4.5 Hz, 1H), 6.28 (s, 2H), 5.67 (d, J = 3.4 Hz, 1H), 5.31 (dd, J = 6.6, 3.4 Hz, 1H), 5.09 (t, J = 7.1 Hz, 2 H),4.47(d,J=11.4Hz,1H),4.38(d,J=11.4Hz,1H),2.29-2.16(m,2H),1.93-1.81 (m,2H),1.72(s,3H),1.42–1.28(m,5H),0.57-0.44(m,1H),0.29(q,J=4.1Hz,1H). MS m / z[M+1]=456.0.
[0587] Intermediate I-40A: (1r,4r)-4-methylcyclohexyl chloroformate
[0588]
[0589] To a solution of trans-4-methylcyclohexanol (1.3 mL, 10 mmol) and pyridine (0.91 mL, 11 mmol) in ACN (10 mL) was added triphosgene (1200 mg, 4.0 mmol) (generating gas) at 0 ° C. The resulting mixture was stirred at room temperature for 2 hours and concentrated in vacuo at 21 ° C. The resulting residue was treated with hexane (50 mL)-DCM (5 mL), filtered, and concentrated in vacuo at 21 ° C. The resulting residue was treated with hexane (5 mL), filtered, and concentrated in vacuo at 21 ° C to give intermediate I-40A. 1 H NMR (400 MHz, chloroform-d) δ 4.82–4.70 (m, 1H), 2.17–1.97 (m, 2H), 1.88–1.70 (m, 2H), 1.65–1.27 (m, 3H), 1.17–0.97 (m, 2H), 0.92 (d, J = 6.5 Hz, 3H).
[0590] Intermediate I-40: ((1r,4R)-4-methylcyclohexyl)carbonate ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo [2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolane 4-Alkenyl)methyl ester
[0591]
[0592] To a mixture of intermediate I-2 (100 mg, 0.302 mmol) and DMAP (74 mg, 0.604 mmol) in ACN (2 mL) was added intermediate I-40A (64.0 mg, 0.362 mmol). The resulting mixture was stirred at room temperature for 1 hour, MeOH was added, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give intermediate I-40. 1 H NMR (400MHz, acetonitrile-d3) δ7.91(s,1H),6.80(d,J=4.5Hz,1H),6.77(d,J=4.5Hz,1H),6.27(s,2H),5.67(d,J=3.4Hz,1H),5.32(dd,J=6.6,3.4Hz,1H ),5.09(d,J=6.6Hz,1H),4.54–4.35(m,3H),2.06-1.85(m,2H),1.80–1. 67(m,5H),1.47–1.27(m,6H),1.15–0.96(m,2H),0.91(d,J=6.6Hz,3H). MS m / z[M+1]=472.0.
[0593] Intermediate I-42B: ((2R,3S,4R,5S)-2-cyano-5-(4-(((Z)-(dimethylamino)methylene)amino)carbonate methyl isopropyl pyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)
[0594]
[0595] To a solution of intermediate I-18A (500 mg, 1.3 mmol) in dichloromethane (15 mL) was added isopropyl chloroformate (1.3 mL, 2.6 mmol), followed by pyridine (0.2 mL, 2 mmol), and stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was diluted with dichloromethane, washed with water and brine, dried and concentrated. The residue was purified by flash chromatography using silica gel column chromatography (0% to 10% MeOH / DCM) to obtain intermediate I-42A. MS m / z[M+1]=473.2.
[0596] To a solution of intermediate I-42A (600 mg, 1.3 mmol) in acetonitrile (10 mL) was added concentrated HCl (0.6 mL, 7.5 mmol) and stirred at room temperature for 30 minutes. After the reaction was complete, it was diluted with ethyl acetate (50 mL), neutralized with aqueous sodium bicarbonate, and the organic layer was separated, washed with water and brine, dried, and concentrated. The residue was purified by flash chromatography using 0%-20% MeOH / DCM as eluent to obtain intermediate I-42B. MS m / z[M+1]=433.2.
[0597] Intermediate I-42: (2R,3S,4S,5S)-2-cyano-5-(4-(((Z)-(dimethylamino)methylene)amino)pyrrole (2,1-f][1,2,4]triazin-7-yl)-2-(((isopropoxycarbonyl)oxy)methyl)tetrahydrofuran-3,4-diyldiisopropyl)- Propyl bis(carbonate)
[0598]
[0599] To a solution of intermediate I-42B (200 mg, 0.32 mmol) in dichloromethane (15 mL) was added isopropyl chloroformate (0.8 mL, 1.6 mmol), followed by pyridine (0.1 mL, 1 mmol), and stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was diluted with dichloromethane, washed with water and brine, dried and concentrated. The residue was purified by flash chromatography using silica gel column chromatography (0% to 10% MeOH / DCM) to obtain intermediate I-42. MS m / z[M+1]=605.2.
[0600] Intermediate I-43B: ((2R,3S,4R,5S)-2-cyano-5-(4-(((Z)-(dimethylamino)methylene)amino)carbonate methyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester
[0601]
[0602] To a solution of intermediate I-18A (400 mg, 1 mmol) in dichloromethane (15 mL) was added methyl chloroformate (1 mL, 2 mmol), followed by pyridine (0.2 mL, 2 mmol), and stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was diluted with dichloromethane, washed with water and brine, dried and concentrated. The residue was purified by flash chromatography using silica gel column chromatography (0% to 10% MeOH / DCM) to obtain intermediate I-43A. MS m / z[M+1]=445.1.
[0603] To a solution of intermediate I-43A (300 mg, 0.7 mmol) in acetonitrile (10 mL) was added concentrated HCl (0.6 mL, 7.5 mmol) and stirred at room temperature for 30 minutes. After the reaction was complete, it was diluted with ethyl acetate (50 mL), neutralized with aqueous sodium bicarbonate, and the organic layer was separated, washed with water and brine, dried, and concentrated. The residue was purified by flash chromatography using 0%-20% MeOH / DCM as eluent to obtain intermediate I-43B. MS m / z[M+1]=405.1.
[0604] Intermediate I-43: (2R,3S,4S,5S)-2-cyano-5-(4-(((Z)-(dimethylamino)methylene)amino)pyrrole 2-(((methoxycarbonyl)oxy)methyl)tetrahydrofuran-3,4-diyldimethyl[2,1-f][1,2,4]triazin-7-yl]-2-(((methoxycarbonyl)oxy)methyl)tetrahydrofuran-3,4-diyldimethyl Bis(carbonate)
[0605]
[0606] To a solution of intermediate I-43B (130 mg, 0.32 mmol) in dichloromethane (15 mL) was added methyl chloroformate (1 mL, 2 mmol), followed by pyridine (0.2 mL, 2 mmol), and stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was diluted with dichloromethane, washed with water and brine, dried and concentrated. The residue was purified by flash chromatography using silica gel column chromatography (0% to 10% MeOH / DCM) to obtain intermediate I-43. MS m / z[M+1]=521.2.
[0607] C. Compounds
[0608] Example 0. Compound 0 (2R, 3S, 4R, 5S)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)- 3,4-Dihydroxy-2-(hydroxymethyl)tetrahydrofuran-2-carbonitrile
[0609]
[0610] Compound 0 was prepared according to WO 2015 / 069939. For example, pages 43-55 of WO 2015 / 069939 provide a method for preparing this compound (identified as Compound 1 in WO 2015 / 069939).
[0611] Example 1: Compound 1 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl cyclopentyl ester
[0612]
[0613] To a solution of intermediate I-14 (0.293 mmol) in ACN (1 mL) was added 25% HCl (0.2 mL) at room temperature. The mixture was stirred for 2 hours, diluted with EtOAc (20 mL), and aqueous NaHCO (10 mL) was slowly added. The mixture was stirred for 10 minutes, each phase was separated, and the aqueous phase was extracted with EtOAc (10 mL × 3). The combined organic phases were dried over sodium sulfate, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give compound 1. 1 HNMR (400MHz, methanol-d4) δ7.82(s,1H),6.87(d,J=4.5Hz,1H),6.74(d,J=4.5Hz,1H),5.53(d,J=4.7Hz,1H),5.09-5.00(m,1 H),4.64–4.56(m,2H),4.49(d,J=5.5Hz,1H),4.41(d,J=11.7Hz,1H),1.94–1.84(m,2H),1.80–1.69(m,4H),1.62(m,2H). MS m / z[M+1]=404.0.
[0614] Example 2: Compound 2 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl neopentyl ester
[0615]
[0616] To a solution of intermediate I-4 (0.33mmol) in ACN (5.0mL) was added concentrated HCl (0.14mL) at room temperature. The reaction mixture was stirred for 1 hour 45 minutes, then quenched with water: saturated NaHCO 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (30mL), washed with Na SO dried, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-20% MeOH / DCM) to obtain compound 2. 1H NMR (400MHz, DMSO-d6) δ7.91–7.64(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.15(d,J=5.9Hz,1H),5.52(d,J=5.5 Hz,1H),5.40(d,J=5.5Hz,1H),4.54(d,J=11.6Hz,1H),4.49–4.42(m,1H),4.37–4.25(m,2H),3.86–3.78(m,2H),0.90(s,9H). MS m / z[M+1]=406.1.
[0617] Example 3: Compound 3 (1-methylcyclopropyl)carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1- f) [1,2,4]triazin-7-yl]-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methyl ester
[0618]
[0619] To the solution of intermediate I-16 (0.19mmol) in CH3CN (4.0mL) at room temperature, concentrated HCl (0.12mL) is added dropwise. The reaction mixture is stirred for 60 minutes, then quenched with water: saturated NaHCO31: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer is separated, and the aqueous layer is extracted once again with EtOAc (30mL). The organic fractions are merged, washed with 1: 1 water: brine (30mL), washed with Na2SO4, dried, filtered and concentrated in vacuo, then purified by silica gel column chromatography (0%-15% MeOH / DCM) to obtain compound 3. 1 H NMR (400MHz, acetonitrile-d3) δ7.90(s,1H),6.77(d,J=4.5Hz,1H),6.74(d,J=4.5H z,1H),6.25(s,2H),5.47(d,J=4.9Hz,1H),4.59(d,J=7.1Hz,1H),4.54(d ,J=11.7Hz,1H),4.47(d,J=4.4Hz,1H),4.36(d,J=11.7Hz,1H),4.24-4.1 6(m,2H),3.99(s,1H),1.52(s,3H),0.95–0.84(m,2H),0.71–0.60(m,2H). MS m / z[M+1]=390.0.
[0620] Example 4: Compound 4 ((S)-sec-butyl)carbonate ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester
[0621]
[0622] To a solution of intermediate I-9 (0.20mmol) in ACN (5.0mL) was added concentrated HCl (0.08mL, 12M) at room temperature. The reaction mixture was stirred for 1 hour and 25 minutes, then quenched with water: saturated NaHCO3 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (40mL), dried over MgSO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-15% MeOH / DCM) to obtain compound 4. 1 H NMR (400MHz, DMSO-d6) δ7.89–7.67(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.50(d,J=5.6Hz,1H),5.3 9(d,J=5.7Hz,1H),4.67–4.56(m,1H),4.55–4.43(m,2H),4.35–4.24(m,2H),1.64–1.46(m,2H),1.19(d,J=6.2Hz,3H),0.88–0.82(m,3H). MS m / z[M+1]=392.1.
[0623] Example 5: Compound 5 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methylphenethyl ester
[0624]
[0625] To a solution of intermediate I-15 (0.257 mmol) in ACN (1 mL) was added 25% HCl (0.2 mL) at room temperature. The mixture was stirred for 2 hours, diluted with EtOAc (20 mL), and aqueous NaHCO (10 mL) was slowly added. The mixture was stirred for 10 minutes, each phase was separated, and the aqueous phase was extracted with EtOAc (10 mL × 3). The combined organic phases were dried over sodium sulfate, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give compound 5. 1HNMR (400MHz, methanol-d4) δ7.81(s,1H),7.31–7.17(m,5H),6.87(d,J=4.5Hz,1H),6.73(d,J=4.5Hz,1H),5.53(d,J=4.8 Hz,1H),4.64–4.53(m,2H),4.48(d,J=5.5Hz,1H),4.42(d,J=11.6Hz,1H),4.38–4.26(m,2H),2.96(t,J=7.0Hz,2H). MS m / z[M+1]=439.9.
[0626] Example 6: Compound 6 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl methyl ester
[0627]
[0628] To a solution of intermediate I-5 (0.28mmol) in ACN (5.0mL) was added concentrated HCl (0.12mL) at room temperature. The reaction mixture was stirred for 3.5 hours, then quenched with water: saturated NaHCO3 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (30mL), dried over Na2SO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-20% MeOH / DCM) to obtain compound 6. 1 H NMR (400MHz, DMSO-d6) δ7.91–7.65(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9H z,1H),5.51(d,J=5.6Hz,1H),5.39(d,J=5.7Hz,1H),4.55–4.43(m,2H),4.38–4.25(m,2H),3.72(s,3H). MS m / z[M+1]=350.0.
[0629] Example 7: Compound 7 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl isopentyl ester
[0630]
[0631] To a solution of intermediate I-13 (0.247 mmol) in ACN (1 mL) was added 25% HCl (0.2 mL) at room temperature. The mixture was stirred for 2 hours, diluted with EtOAc (20 mL), and aqueous NaHCO (10 mL) was slowly added. The mixture was stirred for 10 minutes, each phase was separated, and the aqueous phase was extracted with EtOAc (10 mL × 3). The combined organic phases were dried over sodium sulfate, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give compound 7. 1 HNMR (400MHz, methanol-d4) δ7.82(s,1H),6.87(d,J=4.5Hz,1H),6.75(d,J=4.5Hz,1H),5.53(d,J=4.8Hz,1H),4.66–4.57(m,2H),4.49(d,J=5 .5Hz,1H),4.43(d,J=11.7Hz,1H),4.19(t,J=6.8,2H),1.71(m,1H),1.55(q,J=6.8Hz,2H),0.95(d,J=1.8Hz,3H),0.93(d,J=1.9Hz,3H). MSm / z[M+1]=406.0.
[0632] Example 8: Compound 8 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl isobutyl ester
[0633]
[0634] To a solution of intermediate I-3 (5.9 mmol) in ACN (25.0 mL) was added concentrated HCl (2.4 mL) at room temperature. The reaction mixture was stirred for 1 hour, then cooled in an ice bath and quenched with a 1:1 solution (150 mL) of water and saturated NaHCO. The aqueous layer was extracted with EtOAc (3 × 100 mL). The organic fractions were combined, washed with 1:1 water: brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-20% MeOH / DCM) to give compound 8. 1HNMR (400MHz, DMSO-d6) δ7.91–7.65(m,3H),6.86(d,J=4.5Hz,1H),6.73(d,J=4.5Hz,1H),6.15(d,J=5.9Hz,1H),5.52(d,J=5.6H z,1H),5.40(d,J=5.6Hz,1H),4.57–4.42(m,2H),4.39–4.24(m,2H),3.93–3.84(m,2H),1.96–1.82(m,1H),0.88(d,J=6.8Hz,6H). MS m / z[M+1]=392.1.
[0635] Example 9: Compound 9 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- 7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methylpropyl ester
[0636]
[0637] To a solution of intermediate I-6 (0.34mmol) in ACN (5.0mL) was added concentrated HCl (0.14mL) at room temperature. The reaction mixture was stirred for 4 hours and 25 minutes, then quenched with water: saturated NaHCO 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (30mL), dried over Na SO , filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-20% MeOH / DCM) to obtain compound 9. 1 H NMR (400MHz, DMSO-d6) δ7.88–7.65(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.51(d,J=5.6Hz, 1H), 5.39 (d, J = 5.7Hz, 1H), 4.55–4.43 (m, 2H), 4.36–4.25 (m, 2H), 4.05 (t, J = 6.6Hz, 2H), 1.66–1.54 (m, 2H), 0.87 (t, J = 7.4Hz, 3H). MS m / z[M+1]=378.1.
[0638] Example 10: Compound 10 ((R)-sec-butyl)carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1- f) [1,2,4]triazin-7-yl]-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methyl ester
[0639]
[0640] To a solution of intermediate I-8 (0.24mmol) in ACN (5.0mL) was added concentrated HCl (0.10mL) at room temperature. The reaction mixture was stirred for 50 minutes, then quenched with water: saturated NaHCO3 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (20mL), dried over MgSO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-15% MeOH / DCM) to obtain compound 10. 1 H NMR (400MHz, DMSO-d6) δ7.90–7.67(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.50(d,J=5.6Hz,1H),5.3 9(d,J=5.7Hz,1H),4.65–4.56(m,1H),4.54–4.43(m,2H),4.36–4.23(m,2H),1.61–1.47(m,2H),1.19(d,J=6.2Hz,3H),0.86–0.78(m,3H). MS m / z[M+1]=392.1.
[0641] Example 11: Compound 11 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazolidine) (2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl isopropyl ester
[0642]
[0643] To a solution of intermediate I-11 (0.29mmol) in ACN (5.0mL) was added concentrated HCl (0.12mL) at room temperature. The reaction mixture was stirred for 40 minutes, then quenched with water: saturated NaHCO3 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (40mL), dried over MgSO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-15% MeOH / DCM) to obtain compound 11. 1H NMR (400MHz, DMSO-d6) δ7.90–7.64(m,3H),6.86(d,J=4.4Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.50 (d,J=5.6Hz,1H),5.38(d,J=5.7Hz,1H),4.82–4.71(m,1H),4.55–4.42(m,2H),4.35–4.24(m,2H),1.25–1.19(m,6H). MSm / z[M+1]=378.1.
[0644] Example 12: Compound 12 (tetrahydro-2H-pyran-4-yl)carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrole (2,1-f)(1,2,4]triazin-7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ester
[0645]
[0646] To a solution of intermediate I-17 (0.266 mmol) in ACN (1 mL) was added 25% HCl (0.2 mL) at room temperature. The mixture was stirred for 2 hours, diluted with EtOAc (20 mL), and aqueous NaHCO (10 mL) was slowly added. The mixture was stirred for 10 minutes, each phase was separated, and the aqueous phase was extracted with EtOAc (10 mL × 3). The combined organic phases were dried over sodium sulfate, concentrated in vacuo, and purified by silica gel column chromatography (0% to 5% MeOH / DCM) to give compound 12. 1 HNMR (400MHz, methanol-d4) δ7.82(s,1H),6.87(d,J=4.5Hz,1H),6.75(d,J=4.5Hz,1H),5.53(d,J=4.6Hz,1H),4.80(m,1H), 4.67–4.56(m,2H),4.50(d,J=5.5Hz,1H),4.44(d,J=11.7Hz,1H),3.88(m,2H),3.54(m,2H),1.95(m,2H),1.68(m,2H). MS m / z[M+1]=419.9.
[0647] Example 13: Compound 13 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazolidine) tert-Butyl methyl ester (2-cyano-3,4-dihydroxytetrahydrofuran-2-yl) (oxazin-7-yl)
[0648]
[0649] A 2.0 mL-5.0 mL microwave vial was charged with (2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrofuran-2-carbonitrile hydrochloride (0.25 mmol). A solution of di-tert-butyl dicarbonate (0.39 mmol) in THF (4.0 mL) was transferred to a vial followed by DBU (0.11 mL, 0.76 mmol). The reaction mixture was stirred at room temperature overnight. Additional di-tert-butyl dicarbonate (0.17 mmol) dissolved in THF (1.0 mL) was added and the reaction mixture was stirred at room temperature for an additional 3 hours, then heated to 50 ° C and stirred overnight. The solution was diluted with water (30 mL) and extracted with EtOAc (2×30 mL). The organic fractions were combined, washed with 1:1 brine:water (20 mL), dried over MgSO 4 , filtered, concentrated in vacuo, and purified by silica gel chromatography (0%-20% MeOH / DCM) to provide compound 13. 1 HNMR (400MHz, DMSO-d6) δ7.89–7.68(m,3H),6.86(d,J=4.5Hz,1H),6.73(d,J=4.5Hz,1H),6.13(d,J=5.9 Hz,1H),5.49(d,J=5.7Hz,1H),5.38(d,J=5.8Hz,1H),4.51–4.41(m,2H),4.29–4.20(m,2H),1.40(s,9H). MS m / z[M+1]=392.1.
[0650] Example 14: Compound 14 Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazolidine) (oxazin-7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methylpentan-3-yl ester
[0651]
[0652] To a solution of intermediate I-10 (0.17mmol) in ACN (5.0mL) was added concentrated HCl acid (0.07mL, 12M) at room temperature. The reaction mixture was stirred for 3 hours, then quenched with water: saturated NaHCO3 1: 1 solution (30mL), and diluted with EtOAc (30mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1: 1 water: brine (20mL), dried over MgSO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-15% MeOH / DCM) to obtain compound 14. 1H NMR (400MHz, DMSO-d6) δ7.90–7.63(m,3H),6.86(d,J=4.4Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.50 (d,J=5.6Hz,1H),5.39(d,J=5.7Hz,1H),4.57–4.44(m,3H),4.36–4.23(m,2H),1.66–1.43(m,4H),0.88–0.76(m,6H). MS m / z[M+1]=406.1.
[0653] Example 15: Compound 15 Carbonic acid ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazolidine) isobutyl methyl ester (2-oxotetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-4-cyano[7-oxo-4-oxo-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)
[0654]
[0655] To a solution of compound 8 (0.13 mmol) in ACN (7.5 mL) was added CDI (0.27 mmol). The reaction mixture was stirred at room temperature for 55 minutes and then quenched with water (30 mL). The solution was stirred for 25 minutes and then extracted with EtOAc (2 × 30 mL). The organic fractions were combined, washed with 1: 1 brine: water (40 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude residue was subjected to silica gel chromatography (0%-100% EtOAc / hexane) purification to obtain compound 15. 1 HNMR(400MHz,DMSO-d6)δ8.06–7.78(m,3H),6.90–6.86(m,2H),5.85–5.79(m,2H),5.77–5.71(m,1H),4.7 0(d,J=11.6Hz,1H),4.56(d,J=11.6Hz,1H),3.94–3.87(m,2H),1.97–1.82(m,1H),0.87(d,J=6.7Hz,6H). MS m / z[M+1]=418.1.
[0656] Example 16: Compound 16 (7-((2S,3R,4S,5R)-5-cyano-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran Isobutyl pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]carbamate
[0657]
[0658] To a solution of intermediate I-12 (0.11mmol) in ACN (5.0mL) was added concentrated HCl acid (0.05mL) at room temperature. The reaction mixture was stirred for 3.5 hours, then quenched with water: saturated NaHCO3 1: 1 solution (20mL), and diluted with EtOAc (20mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (20mL). The organic fractions were merged, washed with 1: 1 water: brine (20mL), dried over MgSO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-20% MeOH / DCM) to obtain compound 16. 1 H NMR (400MHz, DMSO-d6) δ10.76(s,1H),8.29(s,1H),7.26(d,J=4.7Hz,1H),7.00(d,J=4.7Hz,1H),5.98–5.93(m,1H),5.68–5.62(m,1H),5.46–5.39 (m,2H),4.48–4.40(m,1H),4.25–4.18(m,1H),4.01–3.93(m,2H),3.74–3 .65(m,1H),3.64–3.55(m,1H),2.05–1.90(m,1H),0.96(d,J=6.7Hz,6H). MS m / z[M+1]=392.1.
[0659] Example 17: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-Cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl cyclobutyl ester
[0660]
[0661] To the solution of intermediate I-18 (250mg, 0.58mmol) in ACN (4.0mL) at room temperature, concentrated HCl (0.24mL) was added dropwise. The reaction mixture was stirred for 1 hour, then quenched with 1:1 saturated NaHCO solution (10mL) and EtOAc (10mL). Each layer was separated, and the aqueous layer was extracted once again with EtOAc (30mL). The organic fractions were merged, washed with 1:1 water: brine (40mL), dried over Na2SO4, filtered and concentrated in vacuo, then purified by silica gel chromatography (0%-20% MeOH / DCM) to obtain compound 17. 1H NMR (400MHz, DMSO-d6) δ7.86(s,1H),7.78(s,2H),6.87(d,J=4.5Hz,1H),6.73(d,J=4.5Hz,1H),6.16(d,J=5.9Hz,1H),5.52(d,J=5.6Hz,1H ),5.39(d,J=5.7Hz,1H),4.95–4.74(m,1H),4.55–4.40(m,2H),4.38–4.16(m,2H),2.36–2.17(m,2H),2.11–1.89(m,2H),1.85–1.44(m,2H). MS m / z[M+1]=389.97.
[0662] Example 18: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-Cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl cyclooctyl ester
[0663]
[0664] To the solution of intermediate I-19 (200mg, 0.37mmol) in acetonitrile (10mL) add concentrated HCl (0.6mL, 7.5mmol) and stir at room temperature for 2 hours.After the reaction is completed, dilute with ethyl acetate (50mL), neutralize with aqueous sodium bicarbonate, separate the organic layer, wash with water, salt water, dry and concentrate.By flash chromatography, use 0%-20% MeOH / DCM as eluent to purify residue, obtain compound 18. 1 H NMR (400MHz, methanol-d4) δ7.82(s,1H),6.87(d,J=4.5Hz,1H),6.74(d,J=4.5Hz,1H),5.52(d,J=4.7Hz,1H),4.77(tt,J=8.2,4.0Hz,1H),4.66–4.5 7(m,2H),4.50(d,J=5.5Hz,1H),4.40(d,J=11.7Hz,1H),1.94–1.65(m, 4H), 1.63–1.44 (m, 8H), 1.31 (dt, J=3.9, 2.4Hz, 1H), 0.96–0.85 (m, 1H). MS m / z[M+1]=446.1.
[0665] Example 19: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-Cyano-3,4-dihydroxytetrahydrofuran-2-yl)methylhexyl ester
[0666]
[0667] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylhexyl carbonate (79 mg, 0.17 mmol, 1.0 equiv) in ACN (5.0 mL) was added concentrated HCl acid (0.07 mL, 12 M, 5.0 equiv) at room temperature. The reaction mixture was stirred for 3 hours before being quenched with a 1:1 solution of water:saturated NaHCO 3 (30 mL) and diluted with EtOAc (30 mL). The layers were separated and the aqueous layer was extracted once more with EtOAc (30 mL). The organic fractions were combined, washed with 1:1 water:brine (40 mL), dried over MgSO 4 , filtered and concentrated in vacuo before purification by silica gel chromatography (0%-15% MeOH / DCM) to afford the title compound 19. 1 H NMR (400MHz, DMSO-d6) δ7.89–7.67(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.51(d,J=5.6Hz,1H),5 .39(d,J=5.7Hz,1H),4.54–4.42(m,2H),4.37–4.24(m,2H),4.12–4.05(m,2H),1.63–1.52(m,2H),1.35–1.18(m,6H),0.89–0.81(m,3H). MS m / z[M+1]=420.1.
[0668] Example 20: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-Cyano-3,4-dihydroxytetrahydrofuran-2-yl)methylpentyl ester
[0669]
[0670] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylpentyl carbonate (161 mg, 0.36 mmol, 1.0 equiv) in ACN (5.0 mL) was added concentrated HCl acid (0.15 mL, 12 M, 5.0 equiv) at room temperature. The reaction mixture was stirred for 4 h 35 min before being quenched with a 1:1 solution of water:saturated NaHCO 3 (30 mL) and diluted with EtOAc (30 mL). The layers were separated, and the aqueous layer was extracted once more with EtOAc (30 mL). The organic fractions were combined, washed with 1:1 water:brine (30 mL), dried over MgSO 4 , filtered and concentrated in vacuo before purification by silica gel chromatography (0%-15% MeOH / DCM) to afford the title compound 20. 1 H NMR (400MHz, DMSO-d6) δ7.97–7.70(m,3H),6.88(d,J=4.5Hz,1H),6.73(d,J=4.4Hz,1H),6.20–6.09(m,1H),5.51(s,1H),5.39(d, J=5.7Hz,1H),4.56–4.42(m,2H),4.36–4.23(m,2H),4.12–4.05(m,2H),1.65–1.52(m,2H),1.34–1.21(m,4H),0.90–0.81(m,3H). MS m / z[M+1]=406.1.
[0671] Example 21: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-Cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl cyclohexyl ester
[0672]
[0673] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylcyclohexyl carbonate (108 mg, 0.24 mmol, 1.0 equiv) in ACN (5.0 mL) was added concentrated HCl acid (0.10 mL, 12 M, 5.0 equiv) at room temperature. The reaction mixture was stirred for 3 hours and 45 minutes before being filtered and washed with minimal ACN. The filtrate was filtered once more and the two filter cakes were combined. The filter cake was dissolved in methanol and concentrated in vacuo before being lyophilized to afford the final compound 21 as an HCl salt. 1H NMR (400MHz, DMSO-d6) δ9.79(s,1H),9.10(s,1H),8.17(s,1H),7.41(d,J=4.6Hz,1H),6.92(d,J=4.6Hz,1H),5.39(d,J=5.5Hz,1H),4.59 –4.48(m,2H),4.47–4.41(m,1H),4.34(d,J=11.7Hz,1H),4.25(d,J=5.1Hz,1H),1.89–1.76(m,2H),1.70–1.59(m,2H),1.53–1.15(m,6H). MS m / z[M+1]=418.1.
[0674] Example 22: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ethyl ester
[0675]
[0676] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl ethyl carbonate (193 mg, 0.48 mmol, 1.0 equiv) in ACN (5.0 mL) was added concentrated HCl acid (0.20 mL, 12 M, 5.0 equiv) at room temperature. The reaction mixture was stirred for 2 h 50 min before being diluted with EtOAc (50 mL) and quenched with a 1:1 solution of water:saturated NaHCO 3 (50 mL). The layers were separated and the aqueous layer was extracted once more with EtOAc (50 mL). The organic fractions were combined, washed with 1:1 water:brine (40 mL), dried over MgSO 4 , filtered and concentrated in vacuo before purification by silica gel chromatography (0%-15% MeOH / DCM) to afford the title compound 22. 1 H NMR (400MHz, DMSO-d6) δ7.95–7.62(m,3H),6.86(d,J=4.5Hz,1H),6.72(d,J=4.5Hz,1H),6.14(d,J=5.9Hz,1H),5.51(d, J=5.6Hz,1H),5.39(d,J=5.7Hz,1H),4.56–4.42(m,2H),4.38–4.23(m,2H),4.14(q,J=7.1Hz,2H),1.21(t,J=7.1Hz,3H). MS m / z[M+1]=364.1.
[0677] Example 23: Carbonic acid ((2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 2-Cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl cyclopropyl ester
[0678]
[0679] To a solution of ((3aS,4R,6S,6aS)-6-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-4-cyano-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methylcyclopropyl carbonate (44 mg, 0.11 mmol, 1.0 equiv) in ACN (5.0 mL) was added concentrated HCl acid (0.04 mL, 12 M, 5.0 equiv) at room temperature. The reaction mixture was stirred for 4 h 45 min before being neutralized with triethylamine ...
Claims
1. A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R 1 OH、OC(O)R 4 OC(O)OR 4 ,and R 2 OH、OC(O)R 5 OC(O)OR 5 ;or R 1 and R 2 Combined to form -OC(O)O- or -OCHR 6 O-, where R 6 is H, C1-C6 alkyl, C1-C6 alkoxy or C6-C 10 Aryl; R 3 is H or C(O)OR 7 ,or R 1 and R 3 together to form -OC(O)-; R 4 , R 5 and R 7 Each is independently C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 carbocyclyl, C6-C 10 aryl, 4- to 6-membered heterocyclyl containing 1, 2 or 3 O atoms, or 5- to 6-membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O and S; Where R 4 , R 5 and R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are each independently optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclyl and phenyl optionally substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl; and Each R 8 are independently H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; Each R 9 are independently H, C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; Each R 10 are independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl; and The base is in R 11 Is OP(O)(OH)2 or OC(O)R 12 Substituted C1-C6 alkyl; R 12 is C1-C8 alkyl or C1-C8 alkoxy; and R 13 Is OP(O)(OH)2 or OC(O)R 12 Substituted C1-C6 alkyl; wherein the compound is not 2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula II 3. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 is OH, and R 2 is OH, or R 1 and R 2 together to form -OC(O)O-; R 3 is H or C(O)OR 7 ; R 7 is a C1-C8 alkyl group, a C3-C8 carbocyclic group, or a 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms; Where R 7 The alkyl, carbocyclic or heterocyclic group is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-C8 alkyl and phenyl; and The base is in R 12 It is a C1-C8 alkoxy group.
4. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 is OH, and R 2 is OH, or R 1 and R 2 together to form -OC(O)O-; R 3 is H or C(O)OR 7 ,and R 7 is methyl, ethyl substituted with phenyl, propyl, butyl, pentyl, cyclopropyl substituted with methyl, cyclopentyl, or tetrahydropyran; and The base is in R 12 It is a C1-C6 alkoxy group.
5. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 It's OH.
6. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 It is OC(O)R 4 .
7. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 It is OC(O)OR 4 .
8. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 2 It's OH.
9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 2 It is OC(O)R 5 .
10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 2 It is OC(O)OR 5 .
11. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Combined to form -OC(O)O-.
12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Put together to form -OCHR 6 O-.
13. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 3 It's H.
14. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 3 It is C(O)OR 7 .
15. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 3 yes 16. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 3 together to form -OC(O)-.
17. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a C1-C6 alkyl group.
18. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a C1-C3 alkyl group.
19. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a C2-C8 alkenyl group.
20. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a C2-C8 alkynyl group.
21. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a C3-C8 carbocyclic group.
22. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is C6-C 10 Aryl.
23. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms.
24. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 It is a 4- to 6-membered heterocyclic group containing one O.
25. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 is a 5- to 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O and S.
26. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by three groups independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group or phenyl substituent.
27. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by two groups independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group or phenyl substituent.
28. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl group is replaced by one independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group or phenyl substituent.
29. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from halo, oxo, cyano and N3.
30. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one, two or three independently selected from -OR 8 substituted by a substituent.
31. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from C1-C8 alkyl groups.
32. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one, two or three independently selected from -NR 9 R 10 substituted by a substituent.
33. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one or two substituents independently selected from C3-C8 carbocyclyl groups.
34. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one or two phenyl groups.
35. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from phenyl groups optionally substituted with one, two or three substituents.
36. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from phenyl substituted with one, two or three substituents.
37. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 4 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl group is substituted by one, two or three substituents independently selected from phenyl substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl.
38. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a C1-C6 alkyl group.
39. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a C1-C3 alkyl group.
40. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a C2-C8 alkenyl group.
41. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a C2-C8 alkynyl group.
42. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a C3-C8 carbocyclic group.
43. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is C6-C 10 Aryl.
44. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms.
45. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 It is a 4- to 6-membered heterocyclic group containing one O.
46. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 is a 5- to 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O and S.
47. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by three groups independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group and phenyl substituents.
48. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by two groups independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group and phenyl substituents.
49. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl group is replaced by one independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group and phenyl substituents.
50. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from halo, oxo, cyano and N3.
51. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one, two or three independently selected from -OR 8 substituted by a substituent.
52. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from C1-C8 alkyl groups.
53. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one, two or three independently selected from -NR 9 R 10 substituted by a substituent.
54. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one or two substituents independently selected from C3-C8 carbocyclyl groups.
55. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one or two phenyl groups.
56. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from phenyl groups optionally substituted with one, two or three substituents.
57. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from phenyl substituted with one, two or three substituents.
58. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 5 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl group is substituted by one, two or three substituents independently selected from phenyl substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl.
59. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 6 It's H.
60. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 6 It is a C1-C6 alkyl group.
61. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 6 It is a C1-C6 alkoxy group.
62. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 6 It is C6-C 10 Aryl.
63. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a C1-C6 alkyl group.
64. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a C1-C3 alkyl group.
65. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a C2-C8 alkenyl group.
66. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a C2-C8 alkynyl group.
67. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a C3-C8 carbocyclic group.
68. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is C6-C 10 Aryl.
69. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a 4- to 6-membered heterocyclic group containing 1, 2 or 3 O atoms.
70. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a 4- to 6-membered heterocyclic group containing one O.
71. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 is a 5- to 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O and S.
72. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by three groups independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group or phenyl substituent.
73. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by two groups independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group or phenyl substituent.
74. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl group is replaced by one independently selected from halo, fluorine, oxo, cyano, N3, OR 8 、C1-C8 alkyl、NR 9 R 10 , C3-C8 carbocyclic group or phenyl substituent.
75. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from halo, oxo, cyano and N3.
76. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one, two or three independently selected from -OR 8 substituted by a substituent.
77. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from C1-C8 alkyl groups.
78. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one, two or three independently selected from -NR 9 R 10 substituted by a substituent.
79. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted by one or two substituents independently selected from C3-C8 carbocyclyl groups.
80. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one or two substituents independently selected from phenyl.
81. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from phenyl groups optionally substituted with one, two or three substituents.
82. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups are substituted with one, two or three substituents independently selected from phenyl substituted with one, two or three substituents.
83. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 The alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl or heteroaryl group is substituted by one, two or three substituents independently selected from phenyl substituted by one, two or three substituents independently selected from halo, cyano and C1-C6 alkyl.
84. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 8 It's H.
85. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 8 It is a C1-C6 alkyl group.
86. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 8 It is a C1-C6 haloalkyl group.
87. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 8 It is a C3-C6 cycloalkyl group.
88. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 9 It's H.
89. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 9 It is a C1-C6 alkyl group.
90. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 9 It is a C1-C6 haloalkyl group.
91. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 9 It is a C3-C6 cycloalkyl group.
92. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 10 It's H.
93. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 10 It is a C1-C6 alkyl group.
94. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 10 It is a C1-C6 haloalkyl group.
95. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein at least one R 10 It is a C3-C6 cycloalkyl group.
96. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the base is 97. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the base is 98. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the base is 99. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the base is 100. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the base is 101. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 11 It is a C1-C6 alkyl group substituted by OP(O)(OH)2.
102. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 11 Is OC(O)R 12 Substituted C1-C6 alkyl.
103. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 12 It is a C1-C8 alkyl group.
104. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 12 It is a C1-C6 alkyl group.
105. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 13 It is a C1-C6 alkyl group substituted by OP(O)(OH)2.
106. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 13 Is OC(O)R 12 Substituted C1-C6 alkyl.
107. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Table 1.
108. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is 109. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is 110. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is 111. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is 112. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is 113. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
114. A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is for subcutaneous administration.
115. A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is for intravenous administration.
116. A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is for oral administration.
117. A pharmaceutical composition according to any one of the preceding claims, wherein the pharmaceutical composition is for administration by inhalation.
118. A method of treating or preventing a viral infection in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition according to any one of the preceding claims.
119. The method of any of the preceding claims, wherein the pharmaceutical composition is administered to the subject via oral, intravenous, subcutaneous, or inhalation administration.
120. The method of any of the preceding claims, wherein the method comprises administering to the subject at least one additional therapeutic or prophylactic agent.
121. A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a therapeutically effective amount of a pharmaceutical composition according to any one of the preceding claims.
122. The method of any of the preceding claims, wherein the pharmaceutical composition is administered to the human via oral, intravenous, subcutaneous, or inhalation administration.
123. The method of any of the preceding claims, wherein the method comprises administering to the human at least one additional therapeutic or prophylactic agent.
124. The method of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an influenza A therapeutic agent.
125. The method of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an influenza B therapeutic agent.
126. The method of any of the preceding claims, wherein the at least one additional therapeutic agent comprises oseltamivir phosphate.
127. The method of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an agent for treating a coronavirus.
128. The method of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an agent for treating COVID-19.
129. The method of any of the preceding claims, wherein the viral infection is a Pneumoviridae viral infection.
130. The method of any one of the preceding claims, wherein the Pneumoviridae viral infection is a respiratory syncytial virus infection.
131. The method of any of the preceding claims, wherein the Pneumoviridae viral infection is a human metapneumovirus infection.
132. The method of any of the preceding claims, wherein the viral infection is a Picornaviridae viral infection.
133. The method of any of the preceding claims, wherein the Picornaviridae viral infection is a human rhinovirus infection.
134. The method of any of the preceding claims, wherein the viral infection is a Flaviviridae viral infection.
135. The method of any of the preceding claims, wherein the Flaviviridae virus infection is a dengue virus infection, a yellow fever virus infection, a West Nile virus infection, tick-borne encephalitis, Kunjin Japanese encephalitis, St. Louis encephalitis, Murray Valley encephalitis, Omsk hemorrhagic fever, bovine viral diarrhea, a Zika virus infection, or an HCV infection.
136. The method of any of the preceding claims, wherein the viral infection is a Filoviridae viral infection.
137. The method of any one of the preceding claims, wherein the Filoviridae viral infection is an Ebola virus infection or a Marburg virus infection.
138. The method of any one of the preceding claims, wherein the viral infection is a Paramyxoviridae viral infection.
139. The method of any one of the preceding claims, wherein the viral infection is human parainfluenza virus, Nipah virus, Hendra virus, measles, or mumps infection.
140. A method of treating a subject exhibiting symptoms of coronavirus, influenza and / or RSV infection, wherein the method comprises administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt according to any one of the preceding claims, a therapeutically effective amount of an agent for treating coronavirus, a therapeutically effective amount of an agent for treating influenza, or a combination thereof.
141. The method of the preceding claim, wherein symptoms of coronavirus, influenza, and / or RSV include fever, chills, cough, sneezing, nasal congestion, runny nose, fatigue, headache, body aches, sore throat, vomiting, diarrhea, conjunctivitis, loss of taste, loss of smell, rash, discoloration of fingers, discoloration of toes, difficulty breathing, shortness of breath, chest pain, intrathoracic pressure, wheezing, shortness of breath, loss of speech, loss of movement, or a combination thereof.
142. A method of treating a patient suffering from coronavirus and RSV, wherein the method comprises administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt according to any one of the preceding claims and a therapeutically effective amount of an agent for treating coronavirus.
143. A method of treating a patient with COVID-19 and RSV, wherein the method comprises administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt according to any one of the preceding claims and a therapeutically effective amount of an agent for treating COVID-19.
144. A method for preparing a medicament for treating or preventing a viral infection in a person in need thereof, characterized in that Use of a compound according to any one of the preceding claims or a pharmaceutically acceptable salt thereof.
145. Use of a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing a viral infection in a human in need thereof.
146. The use according to any one of the preceding claims, wherein the medicament is used together with at least one additional therapeutic agent.
147. The use of any one of the preceding claims, wherein the at least one additional therapeutic agent comprises an influenza A therapeutic agent.
148. The use of any one of the preceding claims, wherein the at least one additional therapeutic agent comprises an influenza B therapeutic agent.
149. The use of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an agent for treating a coronavirus.
150. The use of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an agent for treating COVID-19.
151. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a viral infection in a human in need thereof.
152. A compound according to any of the preceding claims, wherein the compound is used with at least one additional therapeutic agent.
153. The compound of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an influenza A therapeutic agent.
154. The compound of any of the preceding claims, wherein the at least one additional therapeutic agent comprises an influenza B therapeutic agent.
155. A compound according to any of the preceding claims, wherein the at least one additional therapeutic agent comprises an agent for treating a coronavirus.
156. A compound according to any of the preceding claims, wherein the at least one additional therapeutic agent comprises an agent for treating COVID-19.
